| 1 |
Tian Y, Fan Z, Xu L, Cao Y, Chen S, Pan Z, Gao Y, Li H, Zheng S, Ma Y, Duan Z, Zhang X, Ren F. CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients. Emerg Microbes Infect 2023;12:e2177088. [PMID: 36735916 DOI: 10.1080/22221751.2023.2177088] [Reference Citation Analysis]
|
| 2 |
Liu R, Yang L, Jiang T, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hao H, Hu L, Gao Y, Xu M, Chen X, Yi W, Li M, Xie Y. Hepatitis B core-related antigen serum levels may be a predictor of acute flare of chronic hepatitis B among pregnant women in the immune-tolerant phase of chronic HBV infection after short-course antiviral therapy. Virulence 2023;14:2186335. [PMID: 36864005 DOI: 10.1080/21505594.2023.2186335] [Reference Citation Analysis]
|
| 3 |
Bian D, Zhao J, Liao H, Wang Y, Ren Y, Jiang Y, Liu S, Chen X, Hu Z, Duan Z, Lu F, Zheng S. Serum HBV RNA is associated with liver fibrosis regression in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues. J Viral Hepat 2023;30:303-9. [PMID: 36533536 DOI: 10.1111/jvh.13790] [Reference Citation Analysis]
|
| 4 |
Karakus N, Yigit S, Kocak M, Bozkurt N, Duygu F. Impact of methylene-tetrahydrofolate reductase gene C677T and A1298C polymorphisms as a risk factor for hepatitis B virus infection. Nucleosides Nucleotides Nucleic Acids 2023;:1-13. [PMID: 36919686 DOI: 10.1080/15257770.2023.2187061] [Reference Citation Analysis]
|
| 5 |
Hui KY, Fung J, Cheung KS, Mak LY, Seto WK, Yuen MF. Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B. Gut Liver 2023;17:280-7. [PMID: 36317514 DOI: 10.5009/gnl220122] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Conners EE, Panagiotakopoulos L, Hofmeister MG, Spradling PR, Hagan LM, Harris AM, Rogers-Brown JS, Wester C, Nelson NP; Contributors. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023. MMWR Recomm Rep 2023;72:1-25. [PMID: 36893044 DOI: 10.15585/mmwr.rr7201a1] [Reference Citation Analysis]
|
| 7 |
Pham TTH, Maria N, Cheng V, Nguyen B, Toy M, Hutton D, Conners EE, Nelson NP, Salomon JA, So S. Gaps in Prenatal Hepatitis B Screening and Management of HBsAg Positive Pregnant Persons in the U.S., 2015-2020. Am J Prev Med 2023:S0749-3797(23)00056-9. [PMID: 36906494 DOI: 10.1016/j.amepre.2023.01.041] [Reference Citation Analysis]
|
| 8 |
Ablikim D, Zeng X, Xu C, Zhao M, Yang X, Feng X, Liu J. The Multiple Facets and Disorders of B Cell Functions in Hepatitis B Virus Infection. J Clin Med 2023;12. [PMID: 36902786 DOI: 10.3390/jcm12052000] [Reference Citation Analysis]
|
| 9 |
Luo J, Liang X, Xin J, Li J, Li P, Zhou Q, Hao S, Zhang H, Lu Y, Wu T, Yang L, Li J, Li T, Ren K, Guo B, Zhou X, Chen J, He L, Yang H, Hu W, You S, Xin S, Jiang J, Shi D, Chen X, Li J; Chinese Group on the Study of Severe Hepatitis B (COSSH). Predicting the Onset of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol 2023;21:681-93. [PMID: 35337983 DOI: 10.1016/j.cgh.2022.03.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Hou Y, Yu H, Zhang Q, Yang Y, Liu X, Wang X, Jiang Y. Machine learning-based model for predicting the esophagogastric variceal bleeding risk in liver cirrhosis patients. Diagn Pathol 2023;18:29. [PMID: 36823660 DOI: 10.1186/s13000-023-01293-0] [Reference Citation Analysis]
|
| 11 |
Zhao Y, Gong C, Xu J, Chen D, Yang B, Chen Z, Wei L. Research Progress of Fecal Microbiota Transplantation in Liver Diseases. J Clin Med 2023;12. [PMID: 36836218 DOI: 10.3390/jcm12041683] [Reference Citation Analysis]
|
| 12 |
Kim D, Choi Y, Rhu J, Hwang S, You YK, Kim D, Nah YW, Kim B, Cho JY, Kang KJ, Yang JD, Choi D, Joo DJ, Kim MS, Ryu JH, Lee JG. Entecavir versus tenofovir on recurrence of hepatitis B virus–related hepatocellular carcinoma in liver transplantation.. [DOI: 10.21203/rs.3.rs-2568480/v1] [Reference Citation Analysis]
|
| 13 |
Liu J, Kam LY, Huang DQ, Henry L, Cheung R, Nguyen MH. Racial and Ethnic Disparities in Characteristics and Care Patterns of Chronic Hepatitis B Patients in the United States. Clin Gastroenterol Hepatol 2023:S1542-3565(23)00102-7. [PMID: 36781005 DOI: 10.1016/j.cgh.2023.01.035] [Reference Citation Analysis]
|
| 14 |
Al Mahtab M, Akbar SMF, Aguilar JC, Yoshida O, Khan S, Gerardo GN, Hiasa Y. Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment. Front Med (Lausanne) 2023;10:1032531. [PMID: 36844221 DOI: 10.3389/fmed.2023.1032531] [Reference Citation Analysis]
|
| 15 |
Ma GX, Zhu L, Tan Y, Zhai S, Ma X, Ogunwobi OO, Yang WJ, Ting T, Kim S, Wang MQ. A Comparative Trial of Improving Care for Underserved Asian Americans Infected with Hepatitis B Virus. Dig Dis Sci 2023. [PMID: 36749506 DOI: 10.1007/s10620-023-07840-5] [Reference Citation Analysis]
|
| 16 |
Liblik K, Lam J, Pham A, Byun J, Farina JM, Baranchuk A. Sexually Transmitted Infections & the Heart. Curr Probl Cardiol 2023;48:101629. [PMID: 36740205 DOI: 10.1016/j.cpcardiol.2023.101629] [Reference Citation Analysis]
|
| 17 |
Cheng TW, Yang JF, Chen YY, Wu KT, Lee MS, Kuo HJ, Lin TC, Wang CL, Hsieh MH, Lin CY, Batsaikhan B, Ho CK, Dai CY. Epidemiology of Chronic Hepatitis B Infection in the Cohort of College Students with Vaccination in Taiwan. Vaccines (Basel) 2023;11. [PMID: 36851225 DOI: 10.3390/vaccines11020348] [Reference Citation Analysis]
|
| 18 |
Li M, Sun F, Bi X, Lin Y, Yang L, Jiang T, Deng W, Lu Y, Zhang L, Yi W, Xie Y. Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection. Hepatol Int 2023;17:42-51. [PMID: 36109430 DOI: 10.1007/s12072-022-10412-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Reutemann B, Gordon FD. Evaluation of the Patient with Markedly Abnormal Liver Enzymes. Clin Liver Dis 2023;27:1-16. [PMID: 36400459 DOI: 10.1016/j.cld.2022.08.007] [Reference Citation Analysis]
|
| 20 |
Blaney H, Khalid M, Heller T, Koh C. Epidemiology, presentation, and therapeutic approaches for hepatitis D infections. Expert Rev Anti Infect Ther 2023;21:127-42. [PMID: 36519386 DOI: 10.1080/14787210.2023.2159379] [Reference Citation Analysis]
|
| 21 |
Jabeen K, Javed A, Waris A, Shahzad S. Restoration of IL-11 and IL-15 cytokine production post calcium modulators and ROS treatment can assist viral clearance both in vitro and in vivo. Iran J Basic Med Sci 2023;26:176-82. [PMID: 36742132 DOI: 10.22038/IJBMS.2022.65983.14536] [Reference Citation Analysis]
|
| 22 |
Jindal A, Sarin SK. Hepatitis B: "Treat all" or "Treat select". Hepatol Int 2023;17:38-41. [PMID: 36316600 DOI: 10.1007/s12072-022-10441-5] [Reference Citation Analysis]
|
| 23 |
Tan BG, Tang Z, Ou J, Zhou HY, Li R, Chen TW, Zhang XM, Li HJ, Hu J. A novel model based on liver/spleen volumes and portal vein diameter on MRI to predict variceal bleeding in HBV cirrhosis. Eur Radiol 2023;33:1378-87. [PMID: 36048206 DOI: 10.1007/s00330-022-09107-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 24 |
Ma N, Sun Y, Kong Y, Jin Y, Yu F, Liu L, Yang L, Liu W, Gao X, Liu D, Zhang X, Li L. Comprehensive investigating of mismatch repair genes (MMR) polymorphisms in participants with chronic hepatitis B virus infection. Front Genet 2023;14:1077297. [PMID: 36816025 DOI: 10.3389/fgene.2023.1077297] [Reference Citation Analysis]
|
| 25 |
Zhang Y, Han J, Zhang X, Li F, Guo Y, He J, Mao R, Zhu H, Yu J, Huang Y, Yang F, Zhang J. Lower frequency of MDSCs was significantly related to functional cure in CHB patients treated with peginterferon. Liver Int 2023;43:329-39. [PMID: 36453086 DOI: 10.1111/liv.15489] [Reference Citation Analysis]
|
| 26 |
Robinson A, Wong R, Gish RG. Chronic Hepatitis B Virus and Hepatitis D Virus: New Developments. Clin Liver Dis 2023;27:17-25. [PMID: 36400464 DOI: 10.1016/j.cld.2022.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
McCulloch K, Romero N, Allard N, MacLachlan JH, Cowie BC. Modelling jurisdictional disparities in the cascade of care for chronic hepatitis B in Australia: impact of treatment uptake on mortality. Aust N Z J Public Health 2023;47:100011. [PMID: 36638581 DOI: 10.1016/j.anzjph.2022.100011] [Reference Citation Analysis]
|
| 28 |
Lazarevic I, Banko A, Miljanovic D, Cupic M. Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas. Viruses 2023;15. [PMID: 36851587 DOI: 10.3390/v15020373] [Reference Citation Analysis]
|
| 29 |
Stephan AS, Kosinska AD, Mück-Häusl M, Muschaweckh A, Jäger C, Röder N, Heikenwälder M, Dembek C, Protzer U. Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice. Vaccines (Basel) 2023;11. [PMID: 36851121 DOI: 10.3390/vaccines11020245] [Reference Citation Analysis]
|
| 30 |
Kumar M, Pahuja S, Khare P, Kumar A. Current Challenges and Future Perspectives of Diagnosis of Hepatitis B Virus. Diagnostics (Basel) 2023;13. [PMID: 36766473 DOI: 10.3390/diagnostics13030368] [Reference Citation Analysis]
|
| 31 |
Kuznetsov NI, Moiseeva IE. Modern principles of etiotropic therapy for chronic hepatitis B and C. Russian Family Doctor 2023;26:7-15. [DOI: 10.17816/rfd112383] [Reference Citation Analysis]
|
| 32 |
Teng J, Du Y, Visalath P, Zhou T, Du B, Zhang Q, Cai W. A noninvasive model discriminating significant histological changes in treatment-naive chronic hepatitis B patients with normal ALT. Virol J 2023;20:7. [PMID: 36631824 DOI: 10.1186/s12985-023-01963-x] [Reference Citation Analysis]
|
| 33 |
Inoue T, Tanaka Y. Noninvasive assessments of liver disease severity based on biomarkers. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00009-4] [Reference Citation Analysis]
|
| 34 |
Indolfi G, Nicastro E. Hepatitis during childhood. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00031-8] [Reference Citation Analysis]
|
| 35 |
Harris AM, Schillie S. Hepatitis B and Hepatitis D Viruses. Principles and Practice of Pediatric Infectious Diseases 2023. [DOI: 10.1016/b978-0-323-75608-2.00213-5] [Reference Citation Analysis]
|
| 36 |
Yan R, Cai D, Zong Y, Guo L, Zhou Y, Tang A, Li L, Huang Q, Colonno R, Walker MA. Preclinical characterization of ABI-H2158, an HBV core inhibitor with dual mechanisms of action. Antiviral Res 2023;209:105485. [PMID: 36509208 DOI: 10.1016/j.antiviral.2022.105485] [Reference Citation Analysis]
|
| 37 |
Ito T, Nguyen MH. Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes. J Hepatocell Carcinoma 2023;10:413-28. [PMID: 36926055 DOI: 10.2147/JHC.S347959] [Reference Citation Analysis]
|
| 38 |
Guo Y, Han J, Zhang Y, Jin C, Zhang Y, He J, Chen S, Guo Y, Lin Y, Li F, Yang F, Shen Z, Mao R, Zhu H, Zhang J. End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation. Front Cell Infect Microbiol 2023;13:1120300. [PMID: 36909726 DOI: 10.3389/fcimb.2023.1120300] [Reference Citation Analysis]
|
| 39 |
van der Spek DPC, Katwaroe WK, van Kleef LA, Brakenhoff S, de Man RA, de Knegt RJ, van der Meer AJ, Sonneveld MJ. Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980-2020. Eur J Intern Med 2023;107:86-92. [PMID: 36396524 DOI: 10.1016/j.ejim.2022.11.012] [Reference Citation Analysis]
|
| 40 |
Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study. Eur J Intern Med 2023;107:66-72. [PMID: 36347739 DOI: 10.1016/j.ejim.2022.10.026] [Reference Citation Analysis]
|
| 41 |
Dieterich D, Graham C, Wang S, Kwo P, Lim Y, Liu C, Agarwal K, Sulkowski M. It Is Time for a Simplified Approach to Hepatitis B Elimination. Gastro Hep Advances 2023;2:209-218. [DOI: 10.1016/j.gastha.2022.10.004] [Reference Citation Analysis]
|
| 42 |
Shi K, Li P, Zhang Q, Zhang Y, Bi Y, Zeng X, Wang X. Development of a nomogram to predict the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis on antivirals. Front Oncol 2023;13:1128062. [PMID: 36874109 DOI: 10.3389/fonc.2023.1128062] [Reference Citation Analysis]
|
| 43 |
Gillespie IA, Chan KA, Liu Y, Hsieh SF, Schindler C, Cheng W, Chang R, Kap E, Morais E, Duh MS, Park S, Ketz M, Jenner S, Boxall N, Kendrick S, Theodore D. Characteristics, Treatment Patterns, and Clinical Outcomes of Chronic Hepatitis B Across 3 Continents: Retrospective Database Study. Adv Ther 2023;40:425-44. [PMID: 36350533 DOI: 10.1007/s12325-022-02284-1] [Reference Citation Analysis]
|
| 44 |
Tkach S, Dorofeyev A, Kuzenko I, Boyko N, Falalyeyeva T, Kobyliak N. Fecal Microbiota Transplantation in Diseases Not Associated with Clostridium difficile: Current Status and Future Therapeutic Option. Microbiome in 3P Medicine Strategies 2023. [DOI: 10.1007/978-3-031-19564-8_10] [Reference Citation Analysis]
|
| 45 |
Chen DY, Chen HH, Chang SH, Chen YM, Huang PH, Hsieh CW, Lan JL, Tang KT. The Impact of b/tsDMARD Dose Reduction on Chronic Hepatitis B in Rheumatoid Arthritis Patients: A Two-Center Long-Term Safety Analysis. J Clin Med 2022;12. [PMID: 36614890 DOI: 10.3390/jcm12010086] [Reference Citation Analysis]
|
| 46 |
Dey D, Pal S, Chakraborty BC, Baidya A, Bhadra S, Ghosh R, Banerjee S, Ahammed SKM, Chowdhury A, Datta S. Multifaceted Defects in Monocytes in Different Phases of Chronic Hepatitis B Virus Infection: Lack of Restoration after Antiviral Therapy. Microbiol Spectr 2022;10:e0193922. [PMID: 36445121 DOI: 10.1128/spectrum.01939-22] [Reference Citation Analysis]
|
| 47 |
Lee JS, Lim TS, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Lee HW, Lee JI, Kim JK, Min IK, Kim BK. Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis. Diagnostics (Basel) 2022;13. [PMID: 36611295 DOI: 10.3390/diagnostics13010003] [Reference Citation Analysis]
|
| 48 |
Da BL, He AR, Shetty K, Suchman KI, Yu H, Lau L, Wong LL, Rabiee A, Amdur RL, Crawford JM, Fox SS, Grimaldi GM, Shah PK, Weinstein J, Bernstein D, Satapathy SK, Chambwe N, Xiang X, Mishra L. Pathogenesis to management of hepatocellular carcinoma. Genes Cancer 2022;13:72-87. [DOI: 10.18632/genesandcancer.226] [Reference Citation Analysis]
|
| 49 |
Akgul F, Arslan Y, Celik M, Karasahin O, Celen MK. The Effects of the COVID-19 Pandemic on Clinical and Laboratory Follow-up of Patients Diagnosed With Chronic Hepatitis B: A Multicenter, Prospective, Observational Study. Hepat Mon 2022;22. [DOI: 10.5812/hepatmon-132174] [Reference Citation Analysis]
|
| 50 |
Kam LY, Huang DQ, Tobias AF, Poon K, Henry L, Kwo P, Cheung R, Nguyen MH. Impact of advanced practice providers on characteristics and quality of care of patients with chronic hepatitis B. Aliment Pharmacol Ther 2022;56:1591-601. [PMID: 36266768 DOI: 10.1111/apt.17254] [Reference Citation Analysis]
|
| 51 |
Ohlendorf V, Wübbolding M, Gineste P, Höner Zu Siederdissen C, Bremer B, Wedemeyer H, Cornberg M, Maasoumy B. Low anti-HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen-negative patients. Liver Int 2022;42:2674-82. [PMID: 36152268 DOI: 10.1111/liv.15433] [Reference Citation Analysis]
|
| 52 |
Xiao Y, van Gemert C, Howell J, Wallace J, Richmond J, Adamson E, Thompson A, Hellard M. A survey of knowledge, attitudes, barriers and support needs in providing hepatitis B care among GPs practising in Australia. BMC Prim Care 2022;23:137. [DOI: 10.1186/s12875-022-01754-3] [Reference Citation Analysis]
|
| 53 |
Li Q, Sun B, Zhuo Y, Jiang Z, Li R, Lin C, Jin Y, Gao Y, Wang D. Interferon and interferon-stimulated genes in HBV treatment. Front Immunol 2022;13:1034968. [PMID: 36531993 DOI: 10.3389/fimmu.2022.1034968] [Reference Citation Analysis]
|
| 54 |
Chang KC, Lin MT, Wang JH, Hung CH, Chen CH, Chiu SY, Hu TH. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral. Viruses 2022;14. [PMID: 36560675 DOI: 10.3390/v14122671] [Reference Citation Analysis]
|
| 55 |
Scarponi CFO, Pedrosa MAF, Mol MPG, Greco DB. Noncompliance with Therapeutic Guidelines for Chronic Hepatitis B Patients in Minas Gerais, Brazil. Infect Dis Rep 2022;14:955-66. [PMID: 36547240 DOI: 10.3390/idr14060094] [Reference Citation Analysis]
|
| 56 |
Yao H, Li P, Xin J, Liang X, Jiang J, Shi D, Li J, Hassan HM, Chen X, Li J. MiRNA/mRNA network topology in hepatitis virus B-related liver cirrhosis reveals miR-20a-5p/340-5p as hubs initiating fibrosis. BMC Med Genomics 2022;15:240. [DOI: 10.1186/s12920-022-01390-x] [Reference Citation Analysis]
|
| 57 |
Nakanishi A, Okumura H, Hashita T, Yamashita A, Nishimura Y, Watanabe C, Kamimura S, Hayashi S, Murakami S, Ito K, Iwao T, Ikeda A, Hirose T, Sunazuka T, Tanaka Y, Matsunaga T. Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2. Viruses 2022;14. [PMID: 36366568 DOI: 10.3390/v14112468] [Reference Citation Analysis]
|
| 58 |
Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Yuen MF. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. J Hepatol 2022;77:1265-75. [PMID: 35697332 DOI: 10.1016/j.jhep.2022.05.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 59 |
Diao YK, Kong QY, Yang T. HBsAg seroclearance and reduction in late recurrence of HBV-related HCC: Causality or co-existence? J Hepatol 2022;77:1468-9. [PMID: 35732214 DOI: 10.1016/j.jhep.2022.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 60 |
Moorthy V, Tan KG. Bilateral Atraumatic Neck of Femur Fractures Secondary to Tenofovir-Induced Fanconi Syndrome. Journal of Orthopaedic Reports 2022. [DOI: 10.1016/j.jorep.2022.100123] [Reference Citation Analysis]
|
| 61 |
Liaw YF. Perspectives on current controversial issues in the management of chronic HBV infection. J Gastroenterol 2022;57:828-37. [PMID: 36053366 DOI: 10.1007/s00535-022-01918-z] [Reference Citation Analysis]
|
| 62 |
Spearman CW, Dusheiko G, Jonas E, Abdo A, Afihene M, Cunha L, Desalegn H, Kassianides C, Katsidzira L, Kramvis A, Lam P, Lesi OA, Micah EA, Musabeyezu E, Ndow G, Nnabuchi CV, Ocama P, Okeke E, Rwegasha J, Shewaye AB, Some FF, Tzeuton C, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2022;7:1036-48. [PMID: 35810766 DOI: 10.1016/S2468-1253(22)00041-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 63 |
Meng CY, Sun S, Liang Y, Xu H, Zhang C, Zhang M, Wang FS, Fu YX, Peng H. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut 2022:gutjnl-2022-327059. [PMID: 36316098 DOI: 10.1136/gutjnl-2022-327059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 64 |
Wu W, Yuan X, Zhang W, Zhou H, Kong X, He Z, Fu T, Zhang W, Jia W, Liang C, Tang H, Wang F, Ye Y, Shao Z, Ji Z. Clinical significance of novel biomarkers to predict the natural course of hepatitis B infection. Front Public Health 2022;10:1037508. [PMID: 36388269 DOI: 10.3389/fpubh.2022.1037508] [Reference Citation Analysis]
|
| 65 |
Wang X, Song A, Lin X, Lu J, Zheng S, Ma L, Ren S, Zheng Y, Chen X. Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases. Front Immunol 2022;13:1031291. [DOI: 10.3389/fimmu.2022.1031291] [Reference Citation Analysis]
|
| 66 |
Katwaroe WK, Brakenhoff SM, van der Spek DPC, de Knegt RJ, van Kleef LA, de Man RA, van der Meer AJP, Sonneveld MJ, The Icarus Study Group. Assessment of Adherence to Clinical Guidelines in Patients with Chronic Hepatitis B. Viruses 2022;14. [PMID: 36298784 DOI: 10.3390/v14102229] [Reference Citation Analysis]
|
| 67 |
Ma GX, Zhu L, Lu W, Handorf E, Tan Y, Yeh MC, Johnson C, Guerrier G, Nguyen MT. Improving Long-Term Adherence to Monitoring/Treatment in Underserved Asian Americans with Chronic Hepatitis B (CHB) through a Multicomponent Culturally Tailored Intervention: A Randomized Controlled Trial. Healthcare (Basel) 2022;10:1944. [PMID: 36292391 DOI: 10.3390/healthcare10101944] [Reference Citation Analysis]
|
| 68 |
Yuen MF, Berliba E, Sukeepaisarnjaroen W, Ahn SH, Tanwandee T, Lim YS, Kim YJ, Poovorawan K, Tangkijvanich P, Schwabe C, Eley T, Brown J, Lee ACH, Thi EP, Paratala B, Mani N, Sofia MJ, Picchio G, Sims KD, Gane EJ. Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B. Hepatol Commun 2022;6:3457-72. [PMID: 36194181 DOI: 10.1002/hep4.2095] [Reference Citation Analysis]
|
| 69 |
Mak LY, Beasley I, Kennedy PTF. Chronic Viral Hepatitis in Elite Athletes: Approaches to Risk Assessment, Prevention and Management. Sports Med Open 2022;8:123. [PMID: 36192563 DOI: 10.1186/s40798-022-00517-9] [Reference Citation Analysis]
|
| 70 |
Yoo S, Kim JY, Lim YS, Han S, Choi J. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. J Hepatol 2022;77:939-46. [PMID: 35643206 DOI: 10.1016/j.jhep.2022.05.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 71 |
Shata MTM, Hetta HF, Sharma Y, Sherman KE. Viral hepatitis in pregnancy. J Viral Hepat 2022;29:844-61. [PMID: 35748741 DOI: 10.1111/jvh.13725] [Reference Citation Analysis]
|
| 72 |
Akbar SMF, Mahtab MA, Khan S, Yoshida O, Hiasa Y. Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection. Vaccines (Basel) 2022;10. [PMID: 36298512 DOI: 10.3390/vaccines10101644] [Reference Citation Analysis]
|
| 73 |
Shang H, Hu Y, Guo H, Lai R, Fu Y, Xu S, Zeng Y, Xun Z, Liu C, Wu W, Guo J, Ou Q, Chen T. Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon-α monotherapy. J Clin Lab Anal 2022;:e24667. [PMID: 36181316 DOI: 10.1002/jcla.24667] [Reference Citation Analysis]
|
| 74 |
Ho Lee D, Young Lee J, Ihn Choi B. Evaluation of Liver Fibrosis Using Shear Wave Elastography: An Overview. Elastography - Applications in Clinical Medicine 2022. [DOI: 10.5772/intechopen.102853] [Reference Citation Analysis]
|
| 75 |
Tan BG, Yang LQ, Wu YP, Lu FL, Ou J, Chen TW, Zhang XM, Li R, Li HJ. Combinations of liver lobe and spleen volumes obtained on magnetic resonance imaging to predict esophagogastric variceal bleeding in hepatitis B-related cirrhotic patients: A prospective cohort study. Medicine (Baltimore) 2022;101:e30616. [PMID: 36197258 DOI: 10.1097/MD.0000000000030616] [Reference Citation Analysis]
|
| 76 |
Cheng R, Xu X. Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis. J Hepatocell Carcinoma 2022;9:987-97. [PMID: 36117526 DOI: 10.2147/JHC.S377435] [Reference Citation Analysis]
|
| 77 |
Li M, Gao Y, Yang L, Lin Y, Deng W, Jiang T, Bi X, Lu Y, Zhang L, Shen G, Liu R, Wu S, Chang M, Xu M, Hu L, Song R, Jiang Y, Yi W, Xie Y. Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B. Front Immunol 2022;13:1024333. [DOI: 10.3389/fimmu.2022.1024333] [Reference Citation Analysis]
|
| 78 |
Tony SM, Shaaban MEA, Mohamed AIM, Abdelrahim MEA. Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis. Beni-Suef Univ J Basic Appl Sci 2022;11. [DOI: 10.1186/s43088-022-00294-0] [Reference Citation Analysis]
|
| 79 |
Yim HJ, Kim JH, Cho YK, Kweon YO, Cho HC, Hwang JS, Lee C, Koh MS, Baek Y, Park Y, Lee J, Kim SU, Kang M, Park NH, Lee JS, Chon YE, Cheon GJ, Chae HB, Sohn JH, Lim Y. Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients. DDDT 2022;Volume 16:3263-3274. [DOI: 10.2147/dddt.s376821] [Reference Citation Analysis]
|
| 80 |
Ding C, Hong Y, Che Y, He T, Wang Y, Zhang S, Wu J, Xu W, Hou J, Hao H, Cao L. Bile acid restrained T cell activation explains cholestasis aggravated hepatitis B virus infection. FASEB J 2022;36:e22468. [PMID: 35913801 DOI: 10.1096/fj.202200332R] [Reference Citation Analysis]
|
| 81 |
Howell J, Hellard M. Making child's play of tolerance: Defining the immune-viral interplay during combination entecavir and pegylated interferon therapy for immune-tolerant hepatitis B infection. Hepatology 2022;76:554-7. [PMID: 35262950 DOI: 10.1002/hep.32450] [Reference Citation Analysis]
|
| 82 |
Upadhyay P, Lal BB, Sood V, Khanna R, Gupta E, Rastogi A, Alam S. Incidence and Predictors of Relapse After Stopping Antiviral Therapy in Pediatric Chronic Hepatitis B. Pediatr Infect Dis J 2022;41:714-9. [PMID: 35703278 DOI: 10.1097/INF.0000000000003602] [Reference Citation Analysis]
|
| 83 |
Hwang JP, Artz AS, Shah P, Symington B, Feld JJ, Hammond SP, Ludwig E, Pai A, Ramsey SD, Schlam I, Suga JM, Wang SH, Somerfield MR. Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer. JCO Oncology Practice 2022;18:636-644. [DOI: 10.1200/op.22.00074] [Reference Citation Analysis]
|
| 84 |
Alshuwaykh O, Daugherty T, Cheung A, Goel A, Dhanasekaran R, Ghaziani TT, Ahmed A, Dronamraju D, Kumari R, Kwong A, Nguyen M, Kim WR, Kwo PY. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy. Hepatol Commun 2022;6:3052-61. [PMID: 36004713 DOI: 10.1002/hep4.2064] [Reference Citation Analysis]
|
| 85 |
Wang H, Yin YP, Wang ZL, Qian Y, Fan YC, Liu HH, Wang K. Hypermethylation of thymosin β4 predicts a poor prognosis for patients with acute-on-chronic hepatitis B liver failure. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00191-6. [PMID: 36041971 DOI: 10.1016/j.hbpd.2022.08.005] [Reference Citation Analysis]
|
| 86 |
Chen D, Tan X, Chen W, Liu Y, Li C, Wu J, Zheng J, Shen HC, Zhang M, Wu W, Wang L, Xiong J, Dai J, Sun K, Zhang JD, Xiang K, Li B, Ni X, Zhu Q, Gao L, Wang L, Feng S. Discovery of Novel cccDNA Reducers toward the Cure of Hepatitis B Virus Infection. J Med Chem 2022. [PMID: 35973101 DOI: 10.1021/acs.jmedchem.1c02215] [Reference Citation Analysis]
|
| 87 |
Da BL. Clinical trials in hepatitis D virus: Measuring success. Hepatology 2022. [PMID: 35969089 DOI: 10.1002/hep.32732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 88 |
Huang DQ, Li X, Le MH, Le AK, Yeo YH, Trinh HN, Zhang J, Li J, Wong C, Wong C, Cheung RC, Yang HI, Nguyen MH. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. Clin Gastroenterol Hepatol 2022;20:1803-1812.e5. [PMID: 33465482 DOI: 10.1016/j.cgh.2021.01.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 89 |
Li S, Li N, Yang S, Deng H, Li Y, Wang Y, Yang J, Lv J, Dong L, Yu G, Hou X, Wang G. The study of immune checkpoint inhibitors in chronic hepatitis B virus infection. International Immunopharmacology 2022;109:108842. [DOI: 10.1016/j.intimp.2022.108842] [Reference Citation Analysis]
|
| 90 |
Kim DS, Kim BK, Seo YS, Kim BS, Jang BK, Kim SG, Suk KT, Lee JW, Jeong SW, Kim SU; Korean Transient Elastography Study Group. Fibrotic burden during antiviral therapy for chronic hepatitis B, not ALT level, independently predicts liver cancer risk. Liver Int 2022;42:1902-6. [PMID: 35474279 DOI: 10.1111/liv.15282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 91 |
Maslac O, Wagner J, Sozzi V, Mason H, Svarovskaia J, Tan S, Gaggar A, Locarnini S, Yuen L, Littlejohn M, Revill PA. Secreted hepatitis B virus splice variants differ by HBV genotype and across phases of chronic hepatitis B infection. J Viral Hepat 2022;29:604-15. [PMID: 35582878 DOI: 10.1111/jvh.13702] [Reference Citation Analysis]
|
| 92 |
Pan CQ, Afdhal NH, Ankoma-Sey V, Bae H, Curry MP, Dieterich D, Frazier L, Frick A, Hann HW, Kim WR, Kwo P, Milligan S, Tong MJ, Reddy KR. First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide. Hepatol Commun 2022;6:1881-94. [PMID: 35445803 DOI: 10.1002/hep4.1964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 93 |
Mohareb AM, Larmarange J, Kim AY, Coffie PA, Kouamé MG, Boyd A, Freedberg KA, Hyle EP. Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. The Lancet HIV 2022;9:e585-94. [DOI: 10.1016/s2352-3018(22)00123-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 94 |
Jindal A. Severity of Hepatitis B Relapse After Cessation of Nucleos(t)ide Analog: Need a Closer Look! Clin Gastroenterol Hepatol 2022;20:1885-6. [PMID: 34508869 DOI: 10.1016/j.cgh.2021.09.004] [Reference Citation Analysis]
|
| 95 |
Segeral O, Dim B, Durier C, Nhoueng S, Chhim K, Sovann S, Yom S, Vong C, Yin S, Ros B, Ky V, Pech S, Nem B, Hout K, Guillebaud J, Ear E, Caroupaye-caroupin L, Rekacewicz C, Fernandez L, Laurent D, Yay C, Kim R, Meyer L, Chhun S, Keang C, Khan O, Nang B, Sreng VL, In S, Sun S, Sov L, Nor B, Hing B, Seng S, Soum S, Say L, Ay SS, Thol D, Chhouk C, Piola P, Nouhin J, Roque Afonso A, Duclos Vallee JC, Sann C, Kruy LS, Lemoine M, Mandelbrot L, Blanche S, Diallo A, Paul C, Tiv S, Sar P, Nov L, Vann D, Chea T, Touch B, Neav K, Kong E, Chea R, Ouk C, Meak L, Krouch R, Chhan N, Seang S, Nuon V, Meng L, Tharith SL, Hang S, Som V, Som R, Seng P, Lim M, Srey K, Uch SR, Hou P, Bo S, Ieang E, Korn K, Noun CR, Soy S, Khim T, Sou V, Pol S, Nget S, Sun M, Uon P, Ya KT, Lean K, Eang KE, Ung S, Rith R, Mom C, Keang C, Sam S, Chuong S, Nam C, Khuon S, Cheang S, Lean S, Tarantola A, Fournier I, Rouveau N, Calvo cortez M. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial. The Lancet Infectious Diseases 2022;22:1181-1190. [DOI: 10.1016/s1473-3099(22)00206-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 96 |
Lee MH. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. Aliment Pharmacol Ther 2022;56:546-7. [PMID: 35804473 DOI: 10.1111/apt.17079] [Reference Citation Analysis]
|
| 97 |
Sun H, Liu Y, Zhang Y, Jie Y, Wu Y, Li Z, Wei X, Li X, Niu B. Finite versus Indefinite Nucleos(t)ide Analogue Therapy of Patients with Chronic Hepatitis B Exhibiting Negative HBsAg Levels after Treatment. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/6069781] [Reference Citation Analysis]
|
| 98 |
Liao H, Li L, Zheng WV, Zou J, Yu G, Si L, Ge F, Zhou T, Ji D, Chen X, Xu D, Cheng G, Liu Y, Chen J, Colangelo L. Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients. Disease Markers 2022;2022:1-13. [DOI: 10.1155/2022/4133283] [Reference Citation Analysis]
|
| 99 |
Sagnelli C, Sica A, Creta M, Calogero A, Ciccozzi M, Sagnelli E. Epidemiological and clinical aspects of hepatitis B virus infection in Italy over the last 50 years. World J Gastroenterol 2022; 28(26): 3081-3091 [DOI: 10.3748/wjg.v28.i26.3081] [Reference Citation Analysis]
|
| 100 |
Karakoese Z, Schwerdtfeger M, Karsten CB, Esser S, Dittmer U, Sutter K. Distinct Type I Interferon Subtypes Differentially Stimulate T Cell Responses in HIV-1-Infected Individuals. Front Immunol 2022;13:936918. [DOI: 10.3389/fimmu.2022.936918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 101 |
Dai Y, Zhao Z, Liu C. Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. Front Pharmacol 2022;13:942841. [DOI: 10.3389/fphar.2022.942841] [Reference Citation Analysis]
|
| 102 |
Quan M, Liu X, Liu C, Li W, Xing H, Pan JS. Antiviral Therapy for Prevention of Perinatal Hepatitis B Virus Transmission Reduces the Incidence of Postpartum Hepatitis Flare. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/7046955] [Reference Citation Analysis]
|
| 103 |
Mu Y, Ren XH, Han D, Guan YY, Liu PL, Cheng SX, Liu H. Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity. Pharmaceutics 2022;14:1439. [PMID: 35890334 DOI: 10.3390/pharmaceutics14071439] [Reference Citation Analysis]
|
| 104 |
Liu Y, Park D, Cafiero TR, Bram Y, Chandar V, Tseng A, Gertje HP, Crossland NA, Su L, Schwartz RE, Ploss A. Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses. JHEP Rep 2022;4:100535. [PMID: 36035359 DOI: 10.1016/j.jhepr.2022.100535] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 105 |
Shiue SJ, Cheng CL, Shiue HS, Chen CN, Cheng SW, Wu LW, Jargalsaikhan G, Chan TS, Lin HY, Wu MS. Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile. Nutrients 2022;14:2790. [PMID: 35889747 DOI: 10.3390/nu14142790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 106 |
He F, Xia Z, Wang H, Zhu J, Hu L. Clinical Efficacy and Safety of Tenofovir in the Treatment of Patients with Chronic Hepatitis B. Evid Based Complement Alternat Med 2022;2022:1673453. [PMID: 35774746 DOI: 10.1155/2022/1673453] [Reference Citation Analysis]
|
| 107 |
Umemura M, Ogawa K, Morikawa K, Kubo A, Tokuchi Y, Yamada R, Kitagataya T, Shigesawa T, Shimazaki T, Kimura M, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Suda G, Natsuizaka M, Ono K, Murata K, Sugiyama M, Mizokami M, Sakamoto N. Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients. Hepatol Res 2022;52:586-96. [PMID: 35352445 DOI: 10.1111/hepr.13768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 108 |
You J, Wu W, Lu M, Xie Y, Miao R, Gu M, Xi D, Yan W, Wu D, Wang X, Chen T, Ning Q, Han M. Hepatic exosomes with declined MiR-27b-3p trigger RIG-I/TBK1 signal pathway in macrophages. Liver Int 2022;42:1676-91. [PMID: 35460174 DOI: 10.1111/liv.15281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 109 |
Yoon EL, Jun DW. Precision medicine in the era of potent antiviral therapy for chronic hepatitis B. J Gastroenterol Hepatol 2022;37:1191-6. [PMID: 35430754 DOI: 10.1111/jgh.15856] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 110 |
Watanabe T, Hayashi S, Tanaka Y. Drug Discovery Study Aimed at a Functional Cure for HBV. Viruses 2022;14:1393. [DOI: 10.3390/v14071393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Jia N, Gao W, Fan X, Gao H, Li X, Mi B, Yang J. Clinical Efficacy of PEG-IFNα-2a and PEG-IFNα-2b in the Treatment of Hepatitis B e Antigen-Positive Hepatitis B and Their Value in Improving Inflammatory Factors and Hemodynamics in Patients: A Comparative Study. Oxid Med Cell Longev 2022;2022:3185320. [PMID: 35726331 DOI: 10.1155/2022/3185320] [Reference Citation Analysis]
|
| 112 |
Wang F, Zhou J, Li L, Wang M, Tao Y, Wang Y, Zhang D, Chen E. Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B. Front Microbiol 2022;13:901233. [DOI: 10.3389/fmicb.2022.901233] [Reference Citation Analysis]
|
| 113 |
Feng M, Lei L, Xu J, Shi Y, Yang W. Platelet-to-Portal Vein Width Ratio and Platelet-to-Spleen Thickness Ratio Can Be Used to Predict Progressive Liver Fibrosis Among Patients With HBV Infection With HBeAg-Negativity and a Normal ALT Level. Front Med 2022;9:837898. [DOI: 10.3389/fmed.2022.837898] [Reference Citation Analysis]
|
| 114 |
Stella L, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. World J Gastroenterol 2022; 28(21): 2251-2281 [DOI: 10.3748/wjg.v28.i21.2251] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 115 |
Tacke F, Klinker H, Boeker KHW, Merle U, Link R, Buggisch P, Hüppe D, Cornberg M, Sarrazin C, Wedemeyer H, Berg T, Mauss S; DHC-R. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry. Hepatol Commun 2022. [PMID: 35666055 DOI: 10.1002/hep4.2015] [Reference Citation Analysis]
|
| 116 |
Bernstein DE, Trinh HN, Schiff ER, Smith CI, Mospan AR, Zink RC, Fried MW, Lok AS. Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. Dig Dis Sci 2022;67:2637-45. [PMID: 34059991 DOI: 10.1007/s10620-021-07033-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 117 |
Lin MH, Li HQ, Zhu L, Su HY, Peng LS, Wang CY, He CP, Liang XE, Wang Y. Liver Fibrosis in the Natural Course of Chronic Hepatitis B Viral Infection: A Systematic Review with Meta-Analysis. Dig Dis Sci 2022;67:2608-26. [PMID: 34008117 DOI: 10.1007/s10620-021-07009-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 118 |
Wang Y, Che Y, Wang S, Wang J, Liu X, Kou B, Guan Y, Chen D, Shi Y. ASPP2 reduction attenuates HBV induced chronic liver damage: A hybrid mouse model study. Biochemical and Biophysical Research Communications 2022;610:61-9. [DOI: 10.1016/j.bbrc.2022.03.109] [Reference Citation Analysis]
|
| 119 |
Huang J, Liu Y, Liu Y. Antiviral therapy in hepatitis B virus-infected with immune-tolerant: A meta-analysis. Gastroenterología y Hepatología 2022. [DOI: 10.1016/j.gastrohep.2022.05.014] [Reference Citation Analysis]
|
| 120 |
Chen Y, Gao WK, Shu YY, Ye J. Clinical treatment of chronic hepatitis B virus infection in indeterminate phase: Current status and future prospects. Shijie Huaren Xiaohua Zazhi 2022; 30(10): 436-443 [DOI: 10.11569/wcjd.v30.i10.436] [Reference Citation Analysis]
|
| 121 |
Murai K, Kodama T, Hikita H, Shimoda A, Fukuoka M, Fukutomi K, Shigeno S, Shiode Y, Motooka D, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Tahata Y, Makino Y, Yamada R, Sakamori R, Tatsumi T, Takehara T. Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy. Hepatol Commun 2022. [PMID: 35608131 DOI: 10.1002/hep4.2014] [Reference Citation Analysis]
|
| 122 |
Zhang L, Yang S, Yu Y, Wang S, Yu Y, Jin Y, Zhao A, Mao Y, Lu L. Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus. Hepatol Commun 2022. [PMID: 35593183 DOI: 10.1002/hep4.1994] [Reference Citation Analysis]
|
| 123 |
Song J, Yin H, Huang J, Wu Z, Wei C, Qiu T, Luo Y. Deep learning for assessing liver fibrosis based on acoustic nonlinearity maps: an in vivo study of rabbits. Comput Assist Surg (Abingdon) 2022;27:15-26. [PMID: 35559651 DOI: 10.1080/24699322.2022.2063760] [Reference Citation Analysis]
|
| 124 |
McCain JD, Chascsa DM. Special Considerations in the Management of HIV and Viral Hepatitis Coinfections in Liver Transplantation. Hepat Med 2022;14:27-36. [PMID: 35514530 DOI: 10.2147/HMER.S282662] [Reference Citation Analysis]
|
| 125 |
Nikogosova AD, Umrik DV, Tsirulnikova OM. Post-liver transplant HBV infection (Review). RJTAO 2022;24:31-38. [DOI: 10.15825/1995-1191-2022-2-31-38] [Reference Citation Analysis]
|
| 126 |
Feng R, Liu Y, Zhu XL, Zhai WY, He Y, Fu HX, Jiang Q, Jiang H, Lu J, Liu H, Wang JW, Wang H, Xie YD, Ma H, Huang XJ, Zhang XH. Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B-related cirrhosis: Multicentre real-world observational study. J Viral Hepat 2022;29:306-16. [PMID: 35152507 DOI: 10.1111/jvh.13655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 127 |
Pan CQ. The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B. Antiviral Therapy 2022;27:135965352210766. [DOI: 10.1177/13596535221076640] [Reference Citation Analysis]
|
| 128 |
Scarponi CFO, Pedrosa MAF, Mol MPG, Hardman MJM, Greco DB. Low eligibility for hepatitis B treatment in the Brazilian public health system. Rev Soc Bras Med Trop 2022;55:e02972021. [PMID: 35416869 DOI: 10.1590/0037-8682-0297-2021] [Reference Citation Analysis]
|
| 129 |
Coste M, Badji MA, Diallo A, Mora M, Boyer S, Prah JJ. Applying the health capability profile to empirically study chronic hepatitis B in rural Senegal: a social justice mixed-methods study protocol. BMJ Open 2022;12:e055957. [PMID: 35410929 DOI: 10.1136/bmjopen-2021-055957] [Reference Citation Analysis]
|
| 130 |
Pollicino T. The Impact of Nucleos(t)ide Analogs on Hepatitis B Virus DNA Integration: Hype or Reality? Gastroenterology 2022;162:1030-3. [PMID: 35120915 DOI: 10.1053/j.gastro.2022.01.039] [Reference Citation Analysis]
|
| 131 |
Hsu YC, Suri V, Nguyen MH, Huang YT, Chen CY, Chang IW, Tseng CH, Wu CY, Lin JT, Pan DZ, Gaggar A, Podlaha O. Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation. Gastroenterology 2022;162:1160-1170.e1. [PMID: 34995536 DOI: 10.1053/j.gastro.2021.12.286] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 132 |
Liao G, Liu Z, Xia M, Chen H, Wu H, Li B, Yu T, Cai S, Zhang X, Peng J. Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued. IDR 2022;Volume 15:2347-57. [DOI: 10.2147/idr.s360202] [Reference Citation Analysis]
|
| 133 |
Yıldız İE, Bahçeci İ, Ilgar T, Beyazal M, Kostakoğlu U, Ertürk A. Is Liver Biopsy Necessary in Patients with Chronic Hepatitis B with Normal Alanine Aminotransferase Level? vhd 2022;28:1-6. [DOI: 10.4274/vhd.galenos.2021.2021-7-1] [Reference Citation Analysis]
|
| 134 |
Pan CQ, Dai E, Duan Z, Han G, Zhao W, Wang Y, Zhang H, Zhu B, Jiang H, Zhang S, Zhang X, Zou H, Chen X, Chen Y. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China. Gut 2022;71:798-806. [PMID: 33789963 DOI: 10.1136/gutjnl-2020-322719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 135 |
Nagra N, Kozarek RA, Burman BE. Therapeutic Advances in Viral Hepatitis A-E. Adv Ther 2022;39:1524-52. [PMID: 35220557 DOI: 10.1007/s12325-022-02070-z] [Reference Citation Analysis]
|
| 136 |
Gülseren YD, Kılıç F, Esenkaya Taşbent F. A Study of the Hepatitis B Frequency and Its Possible Adverse Outcomes on Pregnancy at a University Hospital. vhd 2022;28:14-17. [DOI: 10.4274/vhd.galenos.2021.2020-12-9] [Reference Citation Analysis]
|
| 137 |
Malik GF, Zakaria N, Majeed MI, Ismail FW. Viral Hepatitis - The Road Traveled and the Journey Remaining. Hepat Med 2022;14:13-26. [PMID: 35300491 DOI: 10.2147/HMER.S352568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 138 |
Durmashkina E, Zeuzem S, Sarrazin C. [Treatment of parenterally transmittable viral hepatitis]. Internist (Berl) 2022. [PMID: 35303130 DOI: 10.1007/s00108-022-01287-y] [Reference Citation Analysis]
|
| 139 |
Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong G, Brakenhoff SM, Chien RN, Feld J, Sonneveld MJ, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng WJ, Janssen HLA; RETRACT-B Study Group. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology 2022;162:757-771.e4. [PMID: 34762906 DOI: 10.1053/j.gastro.2021.11.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 140 |
Nagura Y, Matsuura K, Iio E, Fujita K, Inoue T, Matsumoto A, Tanaka E, Nishiguchi S, Kang JH, Matsui T, Enomoto M, Ikeda H, Watanabe T, Okuse C, Tsuge M, Atsukawa M, Tateyama M, Kataoka H, Tanaka Y. Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B. PLoS One 2022;17:e0263844. [PMID: 35157730 DOI: 10.1371/journal.pone.0263844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 141 |
Prabhu M, Susich MK, Packer CH, Hersh AR, Riley LE, Caughey AB. Universal Hepatitis B Antibody Screening and Vaccination in Pregnancy: A Cost-Effectiveness Analysis. Obstet Gynecol 2022;139:357-67. [PMID: 35115449 DOI: 10.1097/AOG.0000000000004652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 142 |
Li C, Li H, Gong M, Wei J. Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate. Clin Case Rep 2022;10:e05641. [PMID: 35356169 DOI: 10.1002/ccr3.5641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 143 |
Li B, Li Y, Li S, Li H, Liu L, Xu Y. Inhibition of Protease Activated Receptor 2 Attenuates HBx-Induced Inflammation and Mitochondria Oxidative Stress. IDR 2022;Volume 15:961-73. [DOI: 10.2147/idr.s343864] [Reference Citation Analysis]
|
| 144 |
Shi Z, Zheng H, Han M, Hu J, Hu Y, Li X, Zhu W, He X, Deng H, Long Q, Huang A. Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.03.003] [Reference Citation Analysis]
|
| 145 |
Dionne-Odom J, Cozzi GD, Franco RA, Njei B, Tita ATN. Treatment and prevention of viral hepatitis in pregnancy. Am J Obstet Gynecol 2022;226:335-46. [PMID: 34516961 DOI: 10.1016/j.ajog.2021.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 146 |
Kaur SP, Talat A, Karimi-Sari H, Grees A, Chen HW, Lau DTY, Catana AM. Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg). J Clin Med 2022;11:1126. [PMID: 35207397 DOI: 10.3390/jcm11041126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 147 |
Kim SH, Cho EJ, Jang BO, Lee K, Choi JK, Choi GH, Lee JH, Yu SJ, Kim YJ, Lee YB, Yoon JH, Kim JW, Jeong SH, Jang ES. Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. Liver Int 2022;42:320-9. [PMID: 34679254 DOI: 10.1111/liv.15086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 148 |
Byun KS, Choi J, Kim JH, Lee YS, Lee HC, Kim YJ, Yoo BC, Kwon SY, Gwak GY, Lim YS. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. Clin Gastroenterol Hepatol 2022;20:427-437.e5. [PMID: 33962041 DOI: 10.1016/j.cgh.2021.04.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 149 |
Liu Y, Liao W, Xu A, Yin W, Yu J, Fan W, Xue J, Liang X. Early serum HBV RNA combined with HBsAg response can predict HBeAg seroconversation in patients on Entecavir therapy (ClinicalTrials.gov (NCT03909191)). J Infect 2022:S0163-4453(22)00053-6. [PMID: 35120973 DOI: 10.1016/j.jinf.2022.01.035] [Reference Citation Analysis]
|
| 150 |
Corcuera A, Donald A, Urban A. Direct‐Acting Antivirals for the Treatment of Chronic Hepatitis B Virus (HBV) Infection. New Drug Development for Known and Emerging Viruses 2022. [DOI: 10.1002/9783527810697.ch9] [Reference Citation Analysis]
|
| 151 |
Lee JS, Lee HW, Lim TS, Min IK, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. Cancers 2022;14:711. [DOI: 10.3390/cancers14030711] [Reference Citation Analysis]
|
| 152 |
Zhang Q, Zhong C, Cai S, Yu T, Xu X, Yin J. Risk Factors Associated With Quality of Life in Patients With Hepatitis B Virus Related Cirrhosis. Front Psychol 2021;12:770415. [PMID: 35069349 DOI: 10.3389/fpsyg.2021.770415] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 153 |
Vasconcelos J, Domingos J, Bastos L, Baptista T, Mansinho K. Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection. Case Rep Infect Dis 2022;2022:3890309. [PMID: 35036013 DOI: 10.1155/2022/3890309] [Reference Citation Analysis]
|
| 154 |
Akbar SMF, Al Mahtab M, Yoshida O, Hiasa Y. Cellular and Molecular Mechanisms Underlying Scope and Limitation of Ongoing and Innovative Therapies for Treating Chronic Hepatitis B. Livers 2022;2:1-14. [DOI: 10.3390/livers2010001] [Reference Citation Analysis]
|
| 155 |
Tkach S, Dorofeyev A, Kuzenko I, Boyko N, Falalyeyeva T, Boccuto L, Scarpellini E, Kobyliak N, Abenavoli L. Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation. Medicina (Kaunas) 2022;58:84. [PMID: 35056392 DOI: 10.3390/medicina58010084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 156 |
Passos MRL, Junior JE, Kreitchmann R, Miranda AE. Congenital Infection 1 (Syphilis, AIDS, and Viral Hepatitis). Perinatology 2022. [DOI: 10.1007/978-3-030-83434-0_44] [Reference Citation Analysis]
|
| 157 |
Toy M, Hutton D, McCulloch K, Romero N, Revill PA, Penicaud MC, So S, Cowie BC. The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia. Liver Int 2022;42:16-25. [PMID: 34328697 DOI: 10.1111/liv.15027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 158 |
Akbar SMF, Yoshida O, Hiasa Y. Immune therapies against chronic hepatitis B. J Gastroenterol 2022;57:517-28. [PMID: 35708793 DOI: 10.1007/s00535-022-01890-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 159 |
Vittal A, Sharma D, Hu A, Majeed NA, Terry N, Auh S, Ghany MG. Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. Aliment Pharmacol Ther 2022;55:8-25. [PMID: 34850415 DOI: 10.1111/apt.16659] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 160 |
Premkumar M, Chawla YK. Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia. J Clin Exp Hepatol 2022;12:144-54. [PMID: 35068795 DOI: 10.1016/j.jceh.2021.08.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 161 |
Puiu MM, Grama A, Benţa G, Lorinţiu P, Larionesi F, Simu C, Pop TL. Virusul hepatitei B – un agent patogen silenţios cu mai multe feţe ale infecţiei cronice. Prezentare de caz. Pediatru ro 2022;2:36. [DOI: 10.26416/pedi.66.2.2022.6621] [Reference Citation Analysis]
|
| 162 |
Bergasa NV. Chronic Hepatitis B. Clinical Cases in Hepatology 2022. [DOI: 10.1007/978-1-4471-4715-2_7] [Reference Citation Analysis]
|
| 163 |
Koc ÖM, Verbeek J, Koek GH, Bielen R, Busschots D, Gamil M, Robaeys G, Nevens F. A long-term study of liver-related events in Caucasian hepatitis B patients with normal ALT values and high viremia. Acta Gastroenterol Belg 2022;85:56-61. [PMID: 35304994 DOI: 10.51821/85.1.9160] [Reference Citation Analysis]
|
| 164 |
Ye Q, Kam LY, Yeo YH, Dang N, Huang DQ, Cheung R, Nguyen MH. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J Hepatol 2022;76:63-74. [PMID: 34474097 DOI: 10.1016/j.jhep.2021.08.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 165 |
Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Khan S, Penton E, Gerardo GN, Hiasa Y. The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial. Vaccines (Basel) 2021;10:45. [PMID: 35062707 DOI: 10.3390/vaccines10010045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 166 |
Kushner T, Da BL, Chan A, Dieterich D, Sigel K, Saberi B. Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era. Transplant Direct 2022;8:e1253. [PMID: 34957333 DOI: 10.1097/TXD.0000000000001253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 167 |
Filippidis P, Vionnet J, Manuel O, Mombelli M. Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34854329 DOI: 10.1080/14787210.2022.2013808] [Reference Citation Analysis]
|
| 168 |
González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 169 |
Nkongolo S, Mahamed D, Kuipery A, Sanchez Vasquez JD, Kim SC, Mehrotra A, Patel A, Hu C, Mcgilvray I, Feld JJ, Fung S, Chen D, Wallin JJ, Gaggar A, Janssen HLA, Gehring AJ. Pathogenic CD8 T cells defined by longitudinal liver sampling in chronic hepatitis B patients starting antiviral therapy.. [DOI: 10.1101/2021.12.16.21267870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 170 |
Kim H, Ko C, Lee JY, Kim M. Current Progress in the Development of Hepatitis B Virus Capsid Assembly Modulators: Chemical Structure, Mode-of-Action and Efficacy. Molecules 2021;26:7420. [PMID: 34946502 DOI: 10.3390/molecules26247420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 171 |
Wang C, Ma C, Gong L, Dai S, Li Y. Preventive and therapeutic role of betaine in liver disease: A review on molecular mechanisms. Eur J Pharmacol 2021;912:174604. [PMID: 34743980 DOI: 10.1016/j.ejphar.2021.174604] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 172 |
Dokmak A, Trivedi HD, Bonder A, Wolf J. Pregnancy in Chronic Liver Disease: Before and After Transplantation. Ann Hepatol 2021;26:100557. [PMID: 34656772 DOI: 10.1016/j.aohep.2021.100557] [Reference Citation Analysis]
|
| 173 |
Kwo PY. Emerging Biomarkers for HBV Cure: HBsAg and Beyond. Curr Hepatology Rep 2021;20:151-157. [DOI: 10.1007/s11901-021-00573-x] [Reference Citation Analysis]
|
| 174 |
Lee CK, Jonas MM. Viral Hepatitis B—Management in Children. Curr Hepatology Rep 2021;20:137-143. [DOI: 10.1007/s11901-021-00570-0] [Reference Citation Analysis]
|
| 175 |
Ouzan D, Mosnier A, Penaranda G, Daviaud I, Joly H, Muntlak M, Cohen JM. Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease. Eur J Gastroenterol Hepatol 2021;33:e986-91. [PMID: 34966134 DOI: 10.1097/MEG.0000000000002340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 176 |
Chang Y, Kim SG, Jeong SW, Jang JY, Yoo JJ, Lee SH, Kim YS, Kim HS, Lee HW, Park S. Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study. J Clin Med 2021;10:5628. [PMID: 34884330 DOI: 10.3390/jcm10235628] [Reference Citation Analysis]
|
| 177 |
Lempp FA, Roggenbach I, Nkongolo S, Sakin V, Schlund F, Schnitzler P, Wedemeyer H, Le Gal F, Gordien E, Yurdaydin C, Urban S. A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. Viruses 2021;13:2371. [PMID: 34960640 DOI: 10.3390/v13122371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 178 |
Xu HQ, Wang CG, Zhou Q, Gao YH. Effects of alcohol consumption on viral hepatitis B and C. World J Clin Cases 2021; 9(33): 10052-10063 [PMID: 34904075 DOI: 10.12998/wjcc.v9.i33.10052] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 179 |
Lee JS, Lee HW, Lim TS, Shin HJ, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. Cancers (Basel) 2021;13:5892. [PMID: 34885000 DOI: 10.3390/cancers13235892] [Reference Citation Analysis]
|
| 180 |
Song A, Lin X, Lu J, Ren S, Cao Z, Zheng S, Hu Z, Li H, Shen C, Chen X. Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis. Front Immunol 2021;12:779347. [PMID: 34804072 DOI: 10.3389/fimmu.2021.779347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 181 |
Wang CR, Zhong GC, Chen ZW, Hu P. A Nomogram for Predicting Non-Rebound in HBV-Infected Pregnant Women With Mother-to-Child Transmission Prevention. Front Med (Lausanne) 2021;8:746759. [PMID: 34805216 DOI: 10.3389/fmed.2021.746759] [Reference Citation Analysis]
|
| 182 |
Chon HY, Ahn SH, Kim YJ, Yoon JH, Lee JH, Sinn DH, Kim SU. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. Hepatol Int 2021;15:1328-36. [PMID: 34799838 DOI: 10.1007/s12072-021-10262-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 183 |
Fang Y, Xu X, Hou F, Jia W. A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients. Antiviral Therapy 2021;26:126-33. [DOI: 10.1177/13596535211059895] [Reference Citation Analysis]
|
| 184 |
Lou B, Ma G, Lv F, Yuan Q, Xu F, Dong Y, Lin S, Tan Y, Zhang J, Chen Y. Baseline Quantitative Hepatitis B Core Antibody Titer Is a Predictor for Hepatitis B Virus Infection Recurrence After Orthotopic Liver Transplantation. Front Immunol 2021;12:710528. [PMID: 34777339 DOI: 10.3389/fimmu.2021.710528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 185 |
Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C, Kendrick S. Health-related quality of life for adults living with hepatitis B in the United States: a qualitative assessment. J Patient Rep Outcomes 2021;5:121. [PMID: 34757456 DOI: 10.1186/s41687-021-00398-8] [Reference Citation Analysis]
|
| 186 |
Jiragraivutidej C, Tangkijvanich P, Chaithongwongwatthana S. Use of Hepatitis B-e Antigen to Identify Pregnant Women With Hepatitis B Virus Infection Who Need Antiviral Therapy for Prevention of Mother-to-child Transmission. Cureus 2021;13:e18430. [PMID: 34737899 DOI: 10.7759/cureus.18430] [Reference Citation Analysis]
|
| 187 |
Zhu B, Lv X, Zhao Z, Chen L, Chen X, Li C, Li S, Dai E. Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus. Medicine (Baltimore) 2021;100:e27695. [PMID: 34871254 DOI: 10.1097/MD.0000000000027695] [Reference Citation Analysis]
|
| 188 |
Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial. Pathogens 2021;10:1440. [PMID: 34832596 DOI: 10.3390/pathogens10111440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 189 |
Fischer MG, Newman W, Hammer K, Rohrich M, Lo TS. Comparison of Renal Function Between Tenofovir Disoproxil Fumarate and Other Nucleos(t)ide Reverse Transcriptase Inhibitors in Patients With Hepatitis B Virus Infection. Fed Pract 2021;38:363-7. [PMID: 34733088 DOI: 10.12788/fp.0169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 190 |
Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C. Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment. J Viral Hepat 2021;28:1539-44. [PMID: 34363715 DOI: 10.1111/jvh.13592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 191 |
Tsai HJ, Chuang YW, Yang SS, Chang YZ, Chang HR, Lee TY. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease. J Viral Hepat 2021;28:1579-86. [PMID: 34464999 DOI: 10.1111/jvh.13603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 192 |
Wang L, Zhao J, Liu J, Zhen C, Zhang M, Dong Y, Gan Y, Xu Z, Li Y, Zhu S, Wang FS. Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B. J Viral Hepat 2021;28:1554-62. [PMID: 34448324 DOI: 10.1111/jvh.13598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 193 |
Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 194 |
Zhang YR, Wang H, Zhou N, Zhang YD, Lin Y, Wu LY, Wei SF, Ma YY, Wang CX. A Multidisciplinary Team Approach to the Treatment of Liver Cirrhosis. J Inflamm Res 2021;14:5443-50. [PMID: 34712056 DOI: 10.2147/JIR.S328334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 195 |
Cui D, Li W, Jiang D, Wu J, Xie J, Wu Y. Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:754709. [PMID: 34660653 DOI: 10.3389/fmed.2021.754709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 196 |
Chen Y, Xiang X, Qi R, Wang Y, Huang Y, You M, Xian Y, Wu Y, Fu R, Kang C, Tang J, Yu H, Zhang T, Yuan Q, Luo W, Xia N. Novel monkey mAbs induced by a therapeutic vaccine targeting the hepatitis B surface antigen effectively suppress hepatitis B virus in mice. Antib Ther 2021;4:197-207. [PMID: 34646979 DOI: 10.1093/abt/tbab020] [Reference Citation Analysis]
|
| 197 |
Premkumar M, Kumar Chawla Y. Chronic Hepatitis B: Challenges and Successes in India. Clin Liver Dis (Hoboken) 2021;18:111-6. [PMID: 34691396 DOI: 10.1002/cld.1125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 198 |
Ding R, Lu W, Zhou X, Huang D, Wang Y, Li X, Yan L, Lin W, Song S, Zhang Z, Chen L. A Novel Non-invasive Model Based on GPR for the Prediction of Liver Fibrosis in Patients With Chronic Hepatitis B. Front Med (Lausanne) 2021;8:727706. [PMID: 34631748 DOI: 10.3389/fmed.2021.727706] [Reference Citation Analysis]
|
| 199 |
Xiang Y, Yang Y, Chen P, Lai X, Shi S, Li S, You W. Analysis of serum hepatitis B virus RNA levels among HBsAg and HBsAb copositive patients and its correlation with HBV DNA. Medicine (Baltimore) 2021;100:e27433. [PMID: 34622857 DOI: 10.1097/MD.0000000000027433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 200 |
B. Oti V. Traveler’s Infections: Overview of Hepatitis B Virus Infection. Tourism 2021. [DOI: 10.5772/intechopen.92174] [Reference Citation Analysis]
|
| 201 |
Sayre W, Thompson P. Prevention of Vertical Transmission of Hepatitis B Within a North Carolina Hospital System. Clin Ther 2021;43:1786-91. [PMID: 34593255 DOI: 10.1016/j.clinthera.2021.08.012] [Reference Citation Analysis]
|
| 202 |
Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
|
| 203 |
Lim JH, Yu JH, Suh YJ, Lee JW, Jin YJ. Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir. Medicine (Baltimore) 2021;100:e27417. [PMID: 34596169 DOI: 10.1097/MD.0000000000027417] [Reference Citation Analysis]
|
| 204 |
Ferrando-Martinez S, Snell Bennett A, Lino E, Gehring AJ, Feld J, Janssen HLA, Robbins SH. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection. Front Immunol 2021;12:648420. [PMID: 34589081 DOI: 10.3389/fimmu.2021.648420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 205 |
Jeng WJ, Lok AS. Should Treatment Indications for Chronic Hepatitis B Be Expanded? Clin Gastroenterol Hepatol 2021;19:2006-14. [PMID: 32434068 DOI: 10.1016/j.cgh.2020.04.091] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 206 |
Gane EJ, Kim HJ, Visvanathan K, Kim YJ, Nguyen AH, Wallin JJ, Chen DY, McDonald C, Arora P, Tan SK, Gaggar A, Roberts SK, Lim YS. Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B. Hepatology 2021;74:1737-49. [PMID: 33704806 DOI: 10.1002/hep.31795] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 207 |
Jeong S, Cho Y, Park SM, Kim W. Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:e77-86. [PMID: 33883516 DOI: 10.1097/MCG.0000000000001548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 208 |
Yu X, Xin L, Rongyong M, Aibing W, Jianzhong C. Clinical efficacy and safety of TCM prescriptions combined with nucleoside (acid) analogues in treating chronic hepatitis B: a meta-analysis. Digital Chinese Medicine 2021;4:170-9. [DOI: 10.1016/j.dcmed.2021.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 209 |
Liu Y, He S, Yin S, Zhong Q, Zhong J, Zhang X, Fan R, Hou J. Prevalence of Dual-Positivity for Both Hepatitis B e Antigen and Hepatitis B e Antibody Among Hospitalized Patients with Chronic Hepatitis B Virus Infection. Int J Gen Med 2021;14:5759-70. [PMID: 34557028 DOI: 10.2147/IJGM.S328714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 210 |
Park MK, Lee YB. [Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis]. Korean J Gastroenterol 2021;78:152-60. [PMID: 34565784 DOI: 10.4166/kjg.2021.113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 211 |
Yuan Q, Haque O, Hong S, Ortiz A, Bethea ED, Sise ME, Markmann JF, Elias N. Influence of donor and recipient hepatitis B virus infection on long-term outcomes after kidney transplantation. Clin Transplant 2021;:e14466. [PMID: 34545965 DOI: 10.1111/ctr.14466] [Reference Citation Analysis]
|
| 212 |
Roggenbach I, Chi X, Lempp FA, Qu B, Walter L, Wu R, Gao X, Schnitzler P, Ding Y, Urban S, Niu J. HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection. Viruses 2021;13:1799. [PMID: 34578380 DOI: 10.3390/v13091799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 213 |
Xu X, Wu C, Jiang L, Peng C, Pan L, Zhang X, Shen W, Chen L, Lou Z, Xu K, Li L, Dong Y, Ruan B. Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049. Int J Health Policy Manag 2021;11:2115-23. [PMID: 34664496 DOI: 10.34172/ijhpm.2021.126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 214 |
Liao G, Ding X, Xia M, Wu Y, Chen H, Fan R, Zhang X, Cai S, Peng J. Hepatitis B Core-Related Antigen is a Biomarker for off-Treatment Relapse After Long-Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B. Int J Gen Med 2021;14:4967-76. [PMID: 34483685 DOI: 10.2147/IJGM.S321253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 215 |
Sandmann L, Cornberg M. Towards eradication of HBV: Treatment approaches and status of clinical trials. Curr Opin Pharmacol 2021;60:232-40. [PMID: 34474210 DOI: 10.1016/j.coph.2021.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 216 |
Duvoux C, Belli LS, Fung J, Angelico M, Buti M, Coilly A, Cortesi P, Durand F, Féray C, Fondevila C, Lebray P, Martini S, Nevens F, Polak WG, Rizzetto M, Volpes R, Zoulim F, Samuel D, Berenguer M. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. Aliment Pharmacol Ther 2021;54:583-605. [PMID: 34287994 DOI: 10.1111/apt.16374] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 217 |
Tran S, Jeong D, Henry L, Cheung RC, Nguyen MH. Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. Am J Gastroenterol 2021;116:1885-95. [PMID: 33927125 DOI: 10.14309/ajg.0000000000001271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 218 |
Choi HSJ, van Campenhout MJH, van Vuuren AJ, Krassenburg LAP, Sonneveld MJ, de Knegt RJ, Hansen BE, Janssen HLA. Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2021;19:1933-1940.e1. [PMID: 32890755 DOI: 10.1016/j.cgh.2020.09.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 219 |
Chen Z, Jiang H, Wang Y, Liang R, Xu L, Lai J, Shen J, Li J, Li D, Li S, Lei K, Zhou Q, Peng B, Peng H, Peng S, Kuang M. Three-day postoperative antibiotics reduces post-hepatectomy infection rate in hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2021;36:2531-9. [PMID: 33948991 DOI: 10.1111/jgh.15528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 220 |
Thompson P, Morgan CE, Ngimbi P, Mwandagalirwa K, Ravelomanana NLR, Tabala M, Fathy M, Kawende B, Muwonga J, Misingi P, Mbendi C, Luhata C, Jhaveri R, Cloherty G, Kaba D, Yotebieng M, Parr JB. Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study. Lancet Glob Health 2021;9:e1600-9. [PMID: 34416175 DOI: 10.1016/S2214-109X(21)00304-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 221 |
Zhang H, Shi X, Wang L, Zeng Y, Kang X, Huang L. Performance of noninvasive tools for identification of minimal liver fibrosis in patients with hepatitis B virus infection. J Clin Lab Anal 2021;35:e23960. [PMID: 34403524 DOI: 10.1002/jcla.23960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 222 |
Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099 [PMID: 34497437 DOI: 10.3748/wjg.v27.i30.5088] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 223 |
Ren P, Li H, Huang Y, Jiang J, Guo S, Cao Z, Zhang C, Zhou T, Gan Q, Zhao S, Chen L, Guo Q, Cai W, Wang H, Hu P, Xie Q. A simple-to-use tool for predicting response to peginterferon in HBV DNA suppressed chronic hepatitis B patients in China. Antiviral Res 2021;194:105163. [PMID: 34389410 DOI: 10.1016/j.antiviral.2021.105163] [Reference Citation Analysis]
|
| 224 |
Lakoh S, Firima E, Jiba DF, Kamara MN, Gashau W, Deen GF, Adekanmbi O, Yendewa GA. Prevalence of sero-markers and non-invasive assessment of liver cirrhosis in patients with Hepatitis B virus infection in Freetown, Sierra Leone: a cross-sectional study. BMC Gastroenterol 2021;21:320. [PMID: 34372775 DOI: 10.1186/s12876-021-01892-5] [Reference Citation Analysis]
|
| 225 |
Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
|
| 226 |
Chak E, Vu F, Dang J, Smith U, Stewart S, Tam K, Beste-Fong A, Phelps B, Johnson I, Suarez M, Pat Pauly M, Chen MS Jr. Enhancing Electronic Health Systems to End Transmission of Chronic Hepatitis B During COVID-19: A Collaborative Approach. Clin Liver Dis (Hoboken) 2021;17:424-8. [PMID: 34386208 DOI: 10.1002/cld.1144] [Reference Citation Analysis]
|
| 227 |
Vargas JI, Jensen D, Martínez F, Sarmiento V, Peirano F, Acuña P, Provoste F, Bustos V, Cornejo F, Fuster A, Acuña M, Fuster F, Soto S, Estay D, Jensen W, Ahumada R, Arab JP, Soza A, Fuster F. Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients With HIV: A Randomized Clinical Trial. JAMA Netw Open 2021;4:e2120929. [PMID: 34424307 DOI: 10.1001/jamanetworkopen.2021.20929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 228 |
Toyoda H, Leong J, Landis C, Atsukawa M, Watanabe T, Huang DQ, Liu J, Quek SXZ, Ishikawa T, Arai T, Yokohama K, Chuma M, Takaguchi K, Uojima H, Senoo T, Dang H, Maeda M, Hoang J, Le RH, Yasuda S, Thin KN, Tran S, Chien N, Henry L, Asai A, Fukunishi S, Cheung R, Lim SG, Trinh HN, Nguyen MH. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. Hepatology 2021;74:656-66. [PMID: 33706421 DOI: 10.1002/hep.31793] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 229 |
Xiao L, Tang S, Zhang L, Ma S, Zhao Y, Zhang F, Xie Z, Li L. Serum CXCL1 Is a Prognostic Factor for Patients With Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. Front Med (Lausanne) 2021;8:657076. [PMID: 34395462 DOI: 10.3389/fmed.2021.657076] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 230 |
Gu Y, Bi Y, Wei H, Li J, Huang Z, Liao C, Liao W, Huang Y. Expression and clinical significance of inhibitory receptor Leukocyte-associated immunoglobulin-like receptor-1 on peripheral blood T cells of chronic hepatitis B patients: A cross-sectional study. Medicine (Baltimore) 2021;100:e26667. [PMID: 34398030 DOI: 10.1097/MD.0000000000026667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 231 |
Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 232 |
Pinon M, Giugliano L, Nicastro E, Kakaa O, Coscia A, Carbonara C, D'Antiga L, Calvo PL. Timely Birth Dose Vaccine to Prevent Vertical Transmission of Hepatitis B: A Single Center Experience on the Road to the WHO Elimination Goals in Italy. Vaccines (Basel) 2021;9:801. [PMID: 34358216 DOI: 10.3390/vaccines9070801] [Reference Citation Analysis]
|
| 233 |
Scheller L, Hilgard G, Anastasiou O, Dittmer U, Kahraman A, Wedemeyer H, Deterding K. Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients. Medicine (Baltimore) 2021;100:e26571. [PMID: 34260535 DOI: 10.1097/MD.0000000000026571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 234 |
Cheng R, Xu J, Tan N, Luo H, Pan J, Xu X. Predictive Nomograms for Clinical Outcomes in Hepatitis B-Related Cirrhosis Patients Receiving Antiviral Therapy. Infect Drug Resist 2021;14:2707-19. [PMID: 34290509 DOI: 10.2147/IDR.S316026] [Reference Citation Analysis]
|
| 235 |
Sun WC, Tang PL, Chen WC, Tsay FW, Wang HM, Tsai TJ, Kao SS, Cheng JS, Tsai WL. Hepatitis B Virus Screening Before Cancer Chemotherapy in Taiwan: A Nationwide Population-Based Study. Front Med (Lausanne) 2021;8:657109. [PMID: 34336877 DOI: 10.3389/fmed.2021.657109] [Reference Citation Analysis]
|
| 236 |
Akar M. Real-life data of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in the patients with chronic hepatitis B: a single-center experience. Anatolian Current Medical Journal 2021;3:239-245. [DOI: 10.38053/acmj.951923] [Reference Citation Analysis]
|
| 237 |
Sandmann L, Petersen J, Cornberg M. Die wichtigsten Änderungen der S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion im Überblick. Z Gastroenterol 2021;59:641-3. [PMID: 34255314 DOI: 10.1055/a-1498-2680] [Reference Citation Analysis]
|
| 238 |
Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 239 |
Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. WJGPT 2021;12:56-78. [DOI: 10.4292/wjg.v12.i4.56] [Reference Citation Analysis]
|
| 240 |
Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. World J Gastrointest Pharmacol Ther 2021; 12(4): 56-78 [PMID: 34316384 DOI: 10.4292/wjgpt.v12.i4.56] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 241 |
Ahn SB, Choi J, Jun DW, Oh H, Yoon EL, Kim HS, Jeong SW, Kim SE, Shim JJ, Cho YK, Lee HY, Han SW, Nguyen MH; SAINT cohort. Twelve-month post-treatment parameters are superior in predicting hepatocellular carcinoma in patients with chronic hepatitis B. Liver Int 2021;41:1652-61. [PMID: 33550661 DOI: 10.1111/liv.14820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 242 |
Hagiwara S, Nishida N, Ueshima K, Yoshida A, Minami Y, Kudo M. Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long-term effects from a prospective study. Hepatol Res 2021;51:767-74. [PMID: 33900663 DOI: 10.1111/hepr.13650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 243 |
Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, Wu W, Liu Y, Chen Y, Zhang Z, Li J, Huang R, Wu C. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat 2021;28:1025-33. [PMID: 33797145 DOI: 10.1111/jvh.13511] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 244 |
Pan CQ, Li MH, Yi W, Zhang L, Lu Y, Hao HX, Wan G, Cao WH, Wang XY, Ran CP, Shen G, Wu SL, Chang M, Gao YJ, Xie Y. Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. Liver Int 2021;41:1498-508. [PMID: 33486874 DOI: 10.1111/liv.14801] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 245 |
Haraguchi M, Miuma S, Yamamoto K, Nakao Y, Ichikawa T, Kanda Y, Sasaki R, Fukushima M, Akazawa Y, Miyaaki H, Nakao K. Geranylgeranylacetone decreases the production of hepatitis B virus-related antigen by comprehensive downregulation of mRNA transcription activity. J Gastroenterol Hepatol 2021;36:1979-87. [PMID: 33393671 DOI: 10.1111/jgh.15394] [Reference Citation Analysis]
|
| 246 |
Feng J, Tang YN, Zhou LX, Pan JS. Standardized Nursing Procedures for Fecal Microbiota Transplantation via Upper Endoscopy. Gastroenterol Nurs 2021;44:227-32. [PMID: 34176888 DOI: 10.1097/SGA.0000000000000577] [Reference Citation Analysis]
|
| 247 |
Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: Immunological Response, Natural Course and Pregnancy Outcomes. J Clin Med 2021;10:2926. [PMID: 34210105 DOI: 10.3390/jcm10132926] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 248 |
Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: An Update on Evidence-Based Management. Obstet Gynecol Surv. 2020;75:557-565. [PMID: 32997148 DOI: 10.1097/ogx.0000000000000831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 249 |
Zhang X, An X, Shi L, Yang X, Chen Y, Liu X, Li J, Ye F, Lin S. Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years. Sci Rep 2021;11:13389. [PMID: 34183689 DOI: 10.1038/s41598-021-92757-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 250 |
Chen XF, Fan YN, Si CW, Yu YY, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Xu JH. Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks. World J Clin Cases 2021; 9(18): 4690-4699 [PMID: 34222435 DOI: 10.12998/wjcc.v9.i18.4690] [Reference Citation Analysis]
|
| 251 |
Yan K, Feng J, Liu X, Wang H, Li Q, Li J, Xu T, Sajid M, Ullah H, Zhou L, Zhou L, Chen Y. Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters. Front Microbiol 2021;12:665184. [PMID: 34254007 DOI: 10.3389/fmicb.2021.665184] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 252 |
Na JH, Kim JH, Choe WH, Kwon SY, Yoo BC. Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients. Korean J Gastroenterol 2021;77:285-93. [PMID: 34158448 DOI: 10.4166/kjg.2021.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 253 |
Azeem HA, Alkabeer AM, Mohammed AS, Hussein AA. Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs). Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00121-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 254 |
Gu S, Fu X, Ye G, Chen C, Li X, Zhong S, Tang L, Chen H, Jiang D, Hou J, Li Y. High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection. Front Immunol 2021;12:649197. [PMID: 34234772 DOI: 10.3389/fimmu.2021.649197] [Reference Citation Analysis]
|
| 255 |
Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 256 |
Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 257 |
Zheng S, Li M, Pan X, Huang X. Association of IL-32 rs28372698 polymorphism with active chronic HBV infection. J Med Virol 2021. [PMID: 34138488 DOI: 10.1002/jmv.27140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 258 |
Li J, Hu C, Chen Y, Zhang R, Fu S, Zhou M, Gao Z, Fu M, Yan T, Yang Y, Li J, Liu J, Chen T, Zhao Y, He Y. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis 2021;21:567. [PMID: 34126939 DOI: 10.1186/s12879-021-06237-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 259 |
Yi W, Cao X, Zeng Z, Cao W, Zhang Y, Sun F, Wang Y, Wan G, Li M, Xie Y. Developmental consequences of children born from mothers with telbivudine treatment during late pregnancy: A prospective study with 3-year follow-up. Virulence 2021;12:1527-37. [PMID: 34120564 DOI: 10.1080/21505594.2021.1936769] [Reference Citation Analysis]
|
| 260 |
Ahmed B, Konje JC. Screening for infections in pregnancy - An overview of where we are today. Eur J Obstet Gynecol Reprod Biol 2021;263:85-93. [PMID: 34171635 DOI: 10.1016/j.ejogrb.2021.06.002] [Reference Citation Analysis]
|
| 261 |
Auriti C, De Rose DU, Santisi A, Martini L, Piersigilli F, Bersani I, Ronchetti MP, Caforio L. Pregnancy and viral infections: Mechanisms of fetal damage, diagnosis and prevention of neonatal adverse outcomes from cytomegalovirus to SARS-CoV-2 and Zika virus. Biochim Biophys Acta Mol Basis Dis 2021;1867:166198. [PMID: 34118406 DOI: 10.1016/j.bbadis.2021.166198] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 262 |
Giang J, Harrison DS, Hansen BK, Fried MW, Darling JM. Killing Two Birds With No Stone. Clin Liver Dis (Hoboken) 2021;17:371-4. [PMID: 34136144 DOI: 10.1002/cld.1064] [Reference Citation Analysis]
|
| 263 |
Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J 2021;18:114. [PMID: 34082765 DOI: 10.1186/s12985-021-01589-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 264 |
Zhao P, Qian X, Su C, Yang X, Bai X. Lamivudine vs placebo or no treatment in preventing the transmission of hepatitis B virus during pregnancy: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg 2020;114:121-30. [PMID: 31703121 DOI: 10.1093/trstmh/trz078] [Reference Citation Analysis]
|
| 265 |
Choi J, Yoo S, Lim YS. Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance. Hepatology 2021;73:2155-66. [PMID: 33131063 DOI: 10.1002/hep.31610] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 266 |
Li T, Liang Y, Zhang M, Liu F, Zhang L, Yang B, Wang L. Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatol Res 2021;51:633-40. [PMID: 33772988 DOI: 10.1111/hepr.13641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 267 |
Ji JH, Park SY, Son WJ, Shin HJ, Lee H, Lee HW, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. J Viral Hepat 2021;28:951-8. [PMID: 33763928 DOI: 10.1111/jvh.13506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 268 |
Nguyen MH, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh HN, Arai T, Fukunishi S, Ogawa E, Hsu YC, Maeda M, Dang H, Tseng CH, Takahashi H, Jun DW, Watanabe T, Chuma M, Nozaki A, Kawada N, Cheung R, Enomoto M, Takaguchi K, Toyoda H. Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. Am J Gastroenterol 2021;116:1264-73. [PMID: 34074829 DOI: 10.14309/ajg.0000000000001157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 269 |
Freeland C, Farrell S, Kumar P, Kamischke M, Jackson M, Bodor S, Block TM, Frasso R, Cohen C. Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study. BMC Public Health 2021;21:1004. [PMID: 34044808 DOI: 10.1186/s12889-021-11093-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 270 |
Lee YS, Bang SM, Lee YS. Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B. J Clin Med 2021;10:2320. [PMID: 34073357 DOI: 10.3390/jcm10112320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 271 |
Dzobo K. The Role of Viruses in Carcinogenesis and Molecular Targeting: From Infection to Being a Component of the Tumor Microenvironment. OMICS 2021;25:358-71. [PMID: 34037476 DOI: 10.1089/omi.2021.0052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 272 |
Linye H, Zijing X, Wei P, Chao H, Chuan L, Tianfu W. Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis. Medicine (Baltimore) 2021;100:e25749. [PMID: 34011034 DOI: 10.1097/MD.0000000000025749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 273 |
Lee HW, Kim EH, Lee J, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. Clin Transl Gastroenterol 2020;11:e00140. [PMID: 32352711 DOI: 10.14309/ctg.0000000000000140] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 274 |
Toy M, Hutton D, Harris AM, Nelson N, Salomon JA, So S. Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. Clin Infect Dis 2021:ciab405. [PMID: 33956937 DOI: 10.1093/cid/ciab405] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 275 |
Shimakawa Y, Vernoux L, Gabassi A, Mercier-Delarue S, Vincent JP, Simon F, Maylin S. Analytical validation of hepatitis B core-related antigen (HBcrAg) using dried blood spots (DBS). J Viral Hepat 2021;28:837-43. [PMID: 33599049 DOI: 10.1111/jvh.13489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 276 |
Hamida ME, Raja SM, Seyoum Y, Elkhidir IM, Tekle F. Prevalence of chronic hepatitis B phases in Eritrean patients: a laboratory-based cross-sectional study. BMC Gastroenterol 2021;21:198. [PMID: 33933017 DOI: 10.1186/s12876-021-01789-3] [Reference Citation Analysis]
|
| 277 |
Wang M, Chen L, Dong M, Li J, Zhu B, Yang Z, Gong Q, Han Y, Yu D, Zhang D, Zoulim F, Zhang J, Zhang X. Viral quasispecies quantitative analysis: a novel approach for appraising the immune tolerant phase of chronic hepatitis B virus infection. Emerg Microbes Infect 2021;10:842-51. [PMID: 33870846 DOI: 10.1080/22221751.2021.1919033] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 278 |
Liu Y, Zhu P, Wang W, Tan X, Liu C, Chen Y, Pei R, Cheng X, Wu M, Guo Q, Liang H, Liang Z, Liu J, Xu Y, Wu X, Weng X. Mucosal-Associated Invariant T Cell Dysregulation Correlates With Conjugated Bilirubin Level in Chronic HBV Infection. Hepatology 2021;73:1671-87. [PMID: 33080074 DOI: 10.1002/hep.31602] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 279 |
Zhang YR, Wang H, Zhang YD, Lin Y, Wu LY, Wei SF, Ma YY, Wang CX. Highly sensitive nucleic acid detection and transaminase level in treatment decisions for Chinese patients with cirrhosis caused by hepatitis. J Int Med Res 2020;48:300060520959217. [PMID: 33050759 DOI: 10.1177/0300060520959217] [Reference Citation Analysis]
|
| 280 |
Yıldız Kaya S, Mete B, Kaya A, Balkan II, Saltoglu N, Tabak ÖF. The role of quantitative HBsAg in patients with HBV DNA between 2000-20,000 IU/ml. Wien Klin Wochenschr 2021;133:647-53. [PMID: 33914152 DOI: 10.1007/s00508-021-01854-7] [Reference Citation Analysis]
|
| 281 |
Liu Y, Maya S, Ploss A. Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions. Viruses 2021;13:777. [PMID: 33924793 DOI: 10.3390/v13050777] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 282 |
Farag MS, van Campenhout MJH, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Ferenci P, Feld JJ, Berg T, Hansen BE, van Bömmel F, Janssen HLA. Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. Clin Infect Dis 2021;72:202-11. [PMID: 31912157 DOI: 10.1093/cid/ciaa013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 283 |
Segeral O, Dim B, Durier C, Prak S, Chhim K, Vong C, Pech S, Tiv S, Nem B, Hout K, Nouhin J, Chhun S, Borand L. Hepatitis B e Antigen (HBeAg) Rapid Test and Alanine Aminotransferase Level-Based Algorithm to Identify Pregnant Women at Risk of HBV Mother-to-Child Transmission: The ANRS 12345 TA PROHM Study. Clin Infect Dis 2020;71:e587-93. [PMID: 32188982 DOI: 10.1093/cid/ciaa282] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 284 |
Fagan O, Armstrong P, Merwe KVD, Crosnoi D, Steele C, Sopena-Falco J, Parihar V. Viral hepatitis: A brief introduction, review of management, advances and challenges. World J Meta-Anal 2021; 9(2): 139-152 [DOI: 10.13105/wjma.v9.i2.139] [Reference Citation Analysis]
|
| 285 |
Alay H, Yilmaz S, Parlak M, Kesmez Can F, Pür N. The relationship between health-related quality of life and demographic characteristics in patients with chronic hepatitis B. Anatolian Current Medical Journal 2021;3:130-135. [DOI: 10.38053/acmj.864261] [Reference Citation Analysis]
|
| 286 |
Boudewijns R, Ma J, Neyts J, Dallmeier K. A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice. JHEP Rep 2021;3:100295. [PMID: 34159304 DOI: 10.1016/j.jhepr.2021.100295] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 287 |
Qin C, Gao Y, Li J, Huang C, He S. Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma. Oncol Lett 2021;21:487. [PMID: 33968203 DOI: 10.3892/ol.2021.12748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 288 |
Shen Z, Gao Z, Gu C, Wu J, Wang J, Zhang J, Xie Y, Liu J. Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence. Antiviral Res 2021;190:105076. [PMID: 33865876 DOI: 10.1016/j.antiviral.2021.105076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 289 |
Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 290 |
Liu Y, Luo Y, Zhu T, Jiang M, Tian Z, Tang G, Liang X. Regulatory B Cells Dysregulated T Cell Function in an IL-35-Dependent Way in Patients With Chronic Hepatitis B. Front Immunol 2021;12:653198. [PMID: 33912178 DOI: 10.3389/fimmu.2021.653198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 291 |
Han XZ, Zhang SF, Yi JY, Wang B, Sun HQ. Effect of FibroScan test in antiviral therapy for HBV-infected patients with ALT <2 upper limit of normal. Open Life Sci 2020;15:418-22. [PMID: 33817230 DOI: 10.1515/biol-2020-0044] [Reference Citation Analysis]
|
| 292 |
Song A, Wang X, Lu J, Jin Y, Ma L, Hu Z, Zheng Y, Shen C, Chen X. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis. J Viral Hepat 2021;28:601-12. [PMID: 33455067 DOI: 10.1111/jvh.13471] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 293 |
Safadi R, Khoury T, Saed N, Hakim M, Jamalia J, Nijim Y, Farah N, Nuser T, Natur N, Mahamid M, Amer J, Roppert PL, Gerlich WH, Glebe D. Efficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac. Vaccines (Basel) 2021;9:331. [PMID: 33915943 DOI: 10.3390/vaccines9040331] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 294 |
Alkhouri N, Reddy GK, Lawitz E. Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases. Hepatology 2021;73:1581-93. [PMID: 32978989 DOI: 10.1002/hep.31569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 295 |
Suzuki F, Sezaki H, Hosaka T, Suzuki Y, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir. Hepatol Res 2021;51:503-8. [PMID: 33462964 DOI: 10.1111/hepr.13618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 296 |
Garcia-Garcia S, Cortese MF, Rodríguez-Algarra F, Tabernero D, Rando-Segura A, Quer J, Buti M, Rodríguez-Frías F. Next-generation sequencing for the diagnosis of hepatitis B: current status and future prospects. Expert Rev Mol Diagn 2021;21:381-96. [PMID: 33880971 DOI: 10.1080/14737159.2021.1913055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 297 |
Lakoh S, García-Tardón N, Adekanmbi O, van der Valk M, Smith SJ, Grobusch MP. Prevalence of viral hepatitis B and C in Sierra Leone-current knowledge and knowledge gaps: a narrative review. Trans R Soc Trop Med Hyg 2021:trab054. [PMID: 33772308 DOI: 10.1093/trstmh/trab054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 298 |
Yang S, Shen Z, Kang Y, Sun L, Viswanathan U, Guo H, Zhou T, Dai X, Chang J, Zhang J, Guo JT. A putative amphipathic alpha helix in hepatitis B virus small envelope protein plays a critical role in the morphogenesis of subviral particles. J Virol 2021;95:JVI. [PMID: 33536177 DOI: 10.1128/JVI.02399-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 299 |
Umoke M, Sage P, Bjoernsen T, Umoke PCI, Ezeugworie C, Ejiofor D, Agha O, Nwalieji CA, Onwe RN, Nwafor IE, Chukwu OJ. Co-infection and Risk Factors Associated with STIs among Pregnant Women in Rural Health Facilities in Nigeria: A Retrospective Study. Inquiry 2021;58:46958021992912. [PMID: 33736517 DOI: 10.1177/0046958021992912] [Reference Citation Analysis]
|
| 300 |
Thompson P, Morgan CE, Ngimbi P, Mwandagalirwa K, Ravelomanana N, Tabala M, Fathy M, Kawende B, Muwonga J, Misingi P, Mbendi C, Luhata C, Jhaveri R, Cloherty G, Kaba D, Yotebieng M, Parr JB. Arresting Vertical Transmission of Hepatitis B Virus (AVERT-HBV) in the Democratic Republic of the Congo.. [DOI: 10.1101/2021.03.19.21253929] [Reference Citation Analysis]
|
| 301 |
Liang J, Liang X, Ma H, Nie L, Tian Y, Chen G, Wang Y. Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR. J Clin Transl Hepatol 2021;9:143-8. [PMID: 34007795 DOI: 10.14218/JCTH.2020.00118] [Reference Citation Analysis]
|
| 302 |
Lu Y, Song Y, Zhai X, Zhu F, Liu J, Chang Z, Li Y, Xiao Y, Li L, Liu M, Liu J, Duan Z, Zou H, Zhuang H, Wang J, Li J. Maternal hepatitis B e antigen can be an indicator for antiviral prophylaxis of perinatal transmission of hepatitis B virus. Emerg Microbes Infect 2021;10:555-64. [PMID: 33682609 DOI: 10.1080/22221751.2021.1899055] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 303 |
Faure-Bardon V, Ville Y. Maternal infections: revisiting the need for screening in pregnancy. BJOG 2021;128:304-15. [PMID: 32937015 DOI: 10.1111/1471-0528.16509] [Reference Citation Analysis]
|
| 304 |
Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, Donaldson E, Westman G, Buchholz S, Miller V, Hansen BE. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:463-72. [PMID: 32473348 DOI: 10.1016/j.cgh.2020.05.041] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 19.5] [Reference Citation Analysis]
|
| 305 |
Yin GQ, Li J, Zhong B, Yang YF, Wang MR. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. World J Gastroenterol 2021; 27(8): 666-676 [PMID: 33716446 DOI: 10.3748/wjg.v27.i8.666] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 306 |
Sagnelli C, Sagnelli E, Russo A, Pisaturo M, Occhiello L, Coppola N. HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges. Life (Basel) 2021;11:169. [PMID: 33671730 DOI: 10.3390/life11020169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 307 |
Boglione L, Caccia C, Civra A, Cusato J, D'Avolio A, Biasi F, Lembo D, Di Perri G, Poli G, Leoni V. Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers. J Steroid Biochem Mol Biol 2021;210:105854. [PMID: 33631373 DOI: 10.1016/j.jsbmb.2021.105854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 308 |
Miao J, Yang X, Shang X, Gao Z, Li Q, Hong Y, Wu J, Meng T, Yuan H, Hu F. Hepatocyte-targeting and microenvironmentally responsive glycolipid-like polymer micelles for gene therapy of hepatitis B. Mol Ther Nucleic Acids 2021;24:127-39. [PMID: 33738144 DOI: 10.1016/j.omtn.2021.02.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 309 |
Chen VL, Du X, Chen Y, Kuppa A, Handelman SK, Vohnoutka RB, Peyser PA, Palmer ND, Bielak LF, Halligan B, Speliotes EK. Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology. Nat Commun 2021;12:816. [PMID: 33547301 DOI: 10.1038/s41467-020-20870-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 310 |
Cho YY, Chang Y, Nam JY, Cho H, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. Gut Liver 2020;14:225-31. [PMID: 31060115 DOI: 10.5009/gnl18474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 311 |
Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yang Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver. 2019;. [PMID: 31158948 DOI: 10.5009/gnl18546.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 312 |
Tsai MC, Chang KC, Yen YH, Wu CK, Lin MT, Hu TH. Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites. Eur J Gastroenterol Hepatol 2021;32:208-13. [PMID: 32371826 DOI: 10.1097/MEG.0000000000001711] [Reference Citation Analysis]
|
| 313 |
Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C, Gerlich WH, Glebe D, Wat C, Pavlovic V, Heyne R, Berg T, van Bömmel F. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2021;74:283-92. [PMID: 32931877 DOI: 10.1016/j.jhep.2020.08.039] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 314 |
Su F, Berry K, Ioannou GN. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut 2021;70:370-8. [PMID: 32229544 DOI: 10.1136/gutjnl-2019-319867] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 315 |
Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yan Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver 2020;14:232-47. [PMID: 31158948 DOI: 10.5009/gnl18546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 316 |
Lee J, Cho S, Kim HJ, Lee H, Ko MJ, Lim YS. High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: A nationwide cohort study. J Viral Hepat 2021;28:353-63. [PMID: 33051945 DOI: 10.1111/jvh.13418] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 317 |
Chan HL. Debate settled for elevated alanine aminotransferase in hepatitis B? Lancet Infect Dis 2021;21:750-1. [PMID: 33524313 DOI: 10.1016/S1473-3099(20)30682-4] [Reference Citation Analysis]
|
| 318 |
Choi J, Lim YS. Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies. Kaohsiung J Med Sci 2021;37:262-7. [PMID: 33502828 DOI: 10.1002/kjm2.12364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 319 |
Wang T, Liu Y, Letran D, Dang JHT, Harris AM, Li CS, Chen MS, Bowlus CL, Chak E. Healthcare Disparities Identified Between Hmong and Other Asian Origin Groups Living with Chronic Hepatitis B Infection in Sacramento County 2014-2017. J Community Health 2020;45:412-8. [PMID: 31612369 DOI: 10.1007/s10900-019-00763-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 320 |
Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Yang JM, Kim KH, Han KH, Um SH. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. Clin Mol Hepatol 2021;27:346-59. [PMID: 33493393 DOI: 10.3350/cmh.2020.0307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 321 |
Lin M, Guo R, Ma C, Zeng D, Su Z. Manganese Breaks the Immune Tolerance of HBs-Ag. Open Forum Infect Dis 2021;8:ofab028. [PMID: 33614817 DOI: 10.1093/ofid/ofab028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 322 |
Huang CZ, Zhang J, Zhang L, Yu CH, Mo Y, Mo LY. Serum vitamin D and vitamin-D-binding protein levels in children with chronic hepatitis B. World J Gastroenterol 2021; 27(3): 255-266 [PMID: 33519140 DOI: 10.3748/wjg.v27.i3.255] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 323 |
Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 324 |
Chen S, Huang H, Huang W. A noninvasive model to predict liver histology for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase < 2 upper limit of normal. BMC Gastroenterol 2021;21:4. [PMID: 33407146 DOI: 10.1186/s12876-020-01576-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 325 |
King H, Xing J, Dean HD, Holtzman D. Trends in Prevalence of Protective Levels of Hepatitis B Surface Antibody Among Adults Aged 18-49 Years With Risk Factors for Hepatitis B Virus Infection-United States, 2003-2014. Clin Infect Dis 2020;70:1907-15. [PMID: 31228240 DOI: 10.1093/cid/ciz537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 326 |
El-Khayat H, Yakoot M, El-Shabrawi M, Fouad Y, Attia D, Kamal EM. Treatment of Chronic Hepatitis C in Adolescent Patients With Positive HBsAg or With Occult Hepatitis B: Is the Risk of Hepatitis B Reactivation Significant? Pediatr Infect Dis J 2021;40:11-5. [PMID: 32925546 DOI: 10.1097/INF.0000000000002894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 327 |
Peeters LLH, de Leeuw PW, Post Uiterweer ED. Preexistent chronic disorders, often indirectly affecting pregnancy. Pathophysiology of pregnancy complications 2021. [DOI: 10.1007/978-90-368-2571-9_4] [Reference Citation Analysis]
|
| 328 |
Warner S, Kelly DA. Liver Failure. Pediatric Gastrointestinal and Liver Disease 2021. [DOI: 10.1016/b978-0-323-67293-1.00077-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 329 |
Dave S, Park S, Murad MH, Barnard A, Prokop L, Adams LA, Singh S, Loomba R. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Hepatology 2021;73:68-78. [PMID: 32277491 DOI: 10.1002/hep.31267] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 330 |
Choi J, Lim Y. Nucleos(t)ide Therapy and Long-Term Outcomes. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_13] [Reference Citation Analysis]
|
| 331 |
Lim SG, Phyo WW, Ling JZJ, Cloherty G, Butler EK, Kuhns MC, McNamara AL, Holzmayer V, Gersch J, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lee YM, Lee GH, Tan PS, Huang DQ, Khine HTW, Lee C, Tay A, Chan E. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg). Aliment Pharmacol Ther 2021;53:172-82. [PMID: 33159496 DOI: 10.1111/apt.16149] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 332 |
Lai M, Chen H, Chang M. Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_16] [Reference Citation Analysis]
|
| 333 |
Wu D, Ning Q. Combination Therapy. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_14] [Reference Citation Analysis]
|
| 334 |
Yang H, Su T. Viral and Host Factors Affecting Disease Progression of Hepatitis B Virus Infection. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_9] [Reference Citation Analysis]
|
| 335 |
Liem KS, Wong DK, Fung S, Zahirieh A, Yim C, Zanjir WR, Feld JJ, Hansen BE, Janssen HLA. Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients. J Viral Hepat 2021;28:51-60. [PMID: 32896948 DOI: 10.1111/jvh.13401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 336 |
Ye Q, Kam LY, Yeo YH, Dang N, Huang DQ, Cheung R, Nguyen M. Substantial Gaps in Evaluation and Treatment of Hepatitis B Patients in the US: A Nationwide Study of 14,693 Patients. SSRN Journal. [DOI: 10.2139/ssrn.3759709] [Reference Citation Analysis]
|
| 337 |
Liaqat A, Chughtai MFJ, Khaliq A, Mehmood T, Ahsan S, Saeed K, Rahman SJU, Sameed N, Aziz S, Iqba R, Ahmad W, Rahman SU. Drugs Resistance Against Viral Diseases. Biochemistry of Drug Resistance 2021. [DOI: 10.1007/978-3-030-76320-6_3] [Reference Citation Analysis]
|
| 338 |
Sonneveld MJ, van Meer S. Management of Patients With Chronic Hepatitis B (Hepadnaviridae) and Chronic Hepatitis D Infection (Deltavirus). Encyclopedia of Virology 2021. [DOI: 10.1016/b978-0-12-814515-9.00104-1] [Reference Citation Analysis]
|
| 339 |
Kumada T, Toyoda H, Yasuda S, Miyake N, Tada T, Ito T, Tanaka J. Serial changes in FIB‐4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy. GastroHep 2021;3:37-49. [DOI: 10.1002/ygh2.434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 340 |
Younas U, Tehseen S, Khan F, Niaz K. Hepatitis B. Influence of Nutrients, Bioactive Compounds, and Plant Extracts in Liver Diseases 2021. [DOI: 10.1016/b978-0-12-816488-4.00012-7] [Reference Citation Analysis]
|
| 341 |
Chen VL, Hawa F, Berinstein JA, Reddy CA, Kassab I, Platt KD, Hsu CY, Steiner CA, Louissaint J, Gunaratnam NT, Sharma P. Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19. Dig Dis Sci 2021;66:3192-8. [PMID: 32980956 DOI: 10.1007/s10620-020-06618-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 342 |
Ding R, Zheng J, Huang D, Wang Y, Li X, Zhou X, Yan L, Lu W, Yang Z, Zhang Z. INR-to-platelet ratio (INPR) as a novel noninvasive index for predicting liver fibrosis in chronic hepatitis B. Int J Med Sci 2021;18:1159-66. [PMID: 33526976 DOI: 10.7150/ijms.51799] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 343 |
Zhou K, Terrault NA. Treatment of HCV, HDV, or HIV Coinfections. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_15] [Reference Citation Analysis]
|
| 344 |
Wu D, Zhang S, Xie Z, Chen E, Rao Q, Liu X, Huang K, Yang J, Xiao L, Ji F, Jiang Z, Zhao Y, Ouyang X, Zhu D, Dai X, Hou Z, Liu B, Deng B, Zhou N, Gao H, Sun Z, Li L. Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. J Clin Invest 2020;130:2069-80. [PMID: 32175919 DOI: 10.1172/JCI130197] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 345 |
Woldemedihn GM, Rueegg CS, Desalegn H, Aberra H, Berhe N, Johannessen A. Validity of a point-of-care viral load test for hepatitis B in a low-income setting. J Virol Methods 2021;289:114057. [PMID: 33359613 DOI: 10.1016/j.jviromet.2020.114057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 346 |
Gu Y, Li X, Gu L, Lian Y, Wang K, Chen Y, Lai J, Mei Y, Liu J, Huang Z, Zhang M, Chen L, Huang Y. An Immuno-Clinic score model for evaluating T cell immunity and predicting early antiviral therapy effectiveness in chronic hepatitis B. Aging (Albany NY) 2020;12:26063-79. [PMID: 33401245 DOI: 10.18632/aging.202274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 347 |
Lee IC, Su CW, Lan KH, Wang YJ, Lee KC, Lin HC, Hou MC, Huang YH. Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. J Formos Med Assoc 2021;120:1676-85. [PMID: 33339708 DOI: 10.1016/j.jfma.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 348 |
Myers A, Oxner A, Sinnott J, Brechot C. Hepatitis in Pregnancy. Protocols for High‐Risk Pregnancies 2020. [DOI: 10.1002/9781119635307.ch24] [Reference Citation Analysis]
|
| 349 |
Wu X, Cai B, Lu W, Fu Y, Wei B, Niu Q, Su Z, Li Y, Wang L. HBV upregulated triggering receptor expressed on myeloid cells-1 (TREM-1) expression on monocytes participated in disease progression through NF-Kb pathway. Clin Immunol 2021;223:108650. [PMID: 33316373 DOI: 10.1016/j.clim.2020.108650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 350 |
Xu N, Xie Q, Li J, Gao Y, Li X. Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease. J Int Med Res 2020;48:300060520903667. [PMID: 32070159 DOI: 10.1177/0300060520903667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 351 |
Talla C, Itanyi IU, Tsuyuki K, Stadnick N, Ogidi AG, Olakunde BO, Patel D, Oko JO, Aarons G, Onoka CA, Ezeanolue EE. Hepatitis B infection and risk factors among pregnant women and their male partners in the Baby Shower Programme in Nigeria: a cross-sectional study. Trop Med Int Health 2021;26:316-26. [PMID: 33247862 DOI: 10.1111/tmi.13531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 352 |
Saffo S, Lim JK. Waking Up the Sleeping Giant: Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy. Clin Liver Dis (Hoboken) 2020;16:198-203. [PMID: 33318788 DOI: 10.1002/cld.975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 353 |
Zhang L, Li MH, Yi W, Lu Y, Wu S, Hao H, Gao Y, Lu H, Chen Q, Shen G, Chang M, Hu L, Liu R, Sun L, Wan G, Xie Y. AST and HBeAg Level Can Help to Distinguish Non-Minimal Liver Inflammation in Persistently Normal Alanine Aminotransferase of Chronic HBV Infection. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.99580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 354 |
Lee HW, Chon YE, Kim BK, Yip TC, Tse YK, Wong GL, Wong VW, Chan HL, Ahn SH. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. Eur J Intern Med 2021;84:68-73. [PMID: 33288393 DOI: 10.1016/j.ejim.2020.10.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 355 |
Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N. Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clin Mol Hepatol 2021;27:413-24. [PMID: 33317250 DOI: 10.3350/cmh.2020.0187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 356 |
Xu J, Zhan Q, Fan Y, Yu Y, Zeng Z. Human genetic susceptibility to hepatitis B virus infection. Infect Genet Evol 2021;87:104663. [PMID: 33278635 DOI: 10.1016/j.meegid.2020.104663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 357 |
Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 358 |
Jeon MY, Kim BK, Lee JS, Lee HW, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. Clin Mol Hepatol 2021;27:295-304. [PMID: 33317247 DOI: 10.3350/cmh.2020.0216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 359 |
Kaewdech A, Tangkijvanich P, Sripongpun P, Witeerungrot T, Jandee S, Tanaka Y, Piratvisuth T. Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. Liver Int 2020;40:2961-71. [PMID: 32668074 DOI: 10.1111/liv.14606] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 360 |
Zhang Y, Gao X, Liu T, Gao P, Li H, Liu N, Gao L, Wan G, Zhang Y, Duan X. Association between osteoporosis and hepatitis B cirrhosis: a case-control study. Afr Health Sci 2020;20:1610-6. [PMID: 34394221 DOI: 10.4314/ahs.v20i4.13] [Reference Citation Analysis]
|
| 361 |
Gao X, Duan X, Cai H, Hu Y, Liu M, Kang K, Zhou M, Fu D, Yi W. The safety and efficacy of tenofovir disoproxil fumarate used throughout pregnancy for mothers with chronic hepatitis B. Eur J Gastroenterol Hepatol 2020;32:1533-7. [PMID: 31895914 DOI: 10.1097/MEG.0000000000001662] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 362 |
Li FC, Li YK, Fan YC. Biomarkers for hepatitis B virus replication: an overview and a look to the future. Expert Rev Gastroenterol Hepatol 2020;14:1131-9. [PMID: 32887529 DOI: 10.1080/17474124.2020.1815530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 363 |
Jianfei L, Ling L, Yu Z, Jiming Z, Bin W. Tooth loss associated with the use of tenofovir disoproxil fumarate. J Clin Pharm Ther 2020;45:1478-82. [PMID: 32820829 DOI: 10.1111/jcpt.13219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 364 |
Fidan S, Capkın E, Arıca DA, Durak S, Okatan IE. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy. Int J Rheum Dis 2021;24:254-9. [PMID: 33244900 DOI: 10.1111/1756-185X.14034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 365 |
Cho HJ, Shin SK, Kwon OS, Kim JH, Kim YS. Seroreversion and Acute Decompensation in Chronic Hepatitis B after Discontinuation of Oral Nucleotide Analog in the Patients Achieving HBsAg Loss. Korean J Gastroenterol 2020;76:256-60. [PMID: 33234774 DOI: 10.4166/kjg.2020.111] [Reference Citation Analysis]
|
| 366 |
Zheng Y, Xia S, Ren X, Zhan W, Zheng Z, Chen Z. A study of spleen shear-wave elastography in indirect prediction of liver fibrosis in patients with chronic hepatitis B. Clin Hemorheol Microcirc 2020;76:63-72. [PMID: 32538828 DOI: 10.3233/CH-200869] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 367 |
Peiffer KH, Spengler C, Basic M, Jiang B, Kuhnhenn L, Obermann W, Zahn T, Glitscher M, Loglio A, Facchetti F, Carra G, Kubesch A, Vermehren J, Knop V, Graf C, Dietz J, Finkelmeier F, Herrmann E, Trebicka J, Grünweller A, Zeuzem S, Sarrazin C, Lampertico P, Hildt E. Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. JCI Insight 2020;5:135833. [PMID: 33055418 DOI: 10.1172/jci.insight.135833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 368 |
Tan M, Bhadoria AS, Cui F, Tan A, Van Holten J, Easterbrook P, Ford N, Han Q, Lu Y, Bulterys M, Hutin Y. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:106-19. [PMID: 33197397 DOI: 10.1016/S2468-1253(20)30307-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 369 |
Holt SG, Locarnini S, Sasadeusz J. Hepatitis B related dilemmas in the renal unit. Nephrology (Carlton) 2021;26:287-93. [PMID: 33155307 DOI: 10.1111/nep.13815] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 370 |
Ekouevi DK, Larrouy L, Gbeasor-Komlanvi FA, Mackiewicz V, Tchankoni MK, Bitty-Anderson AM, Gnatou GY, Sadio A, Salou M, Dagnra CA, Descamps D, Coffie PA. Prevalence of hepatitis B among childbearing women and infant born to HBV-positive mothers in Togo. BMC Infect Dis 2020;20:839. [PMID: 33183254 DOI: 10.1186/s12879-020-05574-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 371 |
Chen H, He G, Chen Y, Zhang X. Hepatitis B Virus Might Be Sensed by STING-Dependent DNA Sensors and Attenuates the Response of STING-Dependent DNA Sensing Pathway in Humans with Acute and Chronic Hepatitis B Virus Infection. Viral Immunol 2020;33:642-51. [PMID: 33170089 DOI: 10.1089/vim.2020.0096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 372 |
Liu K, Qin M, Tao K, Liang Z, Cai F, Zhao L, Peng P, Liu S, Zou J, Huang J. Identification and external validation of the optimal FIB-4 and APRI thresholds for ruling in chronic hepatitis B related liver fibrosis in tertiary care settings. J Clin Lab Anal 2021;35:e23640. [PMID: 33146916 DOI: 10.1002/jcla.23640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 373 |
Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 374 |
Wang J, Xia J, Yan X, Yang Y, Wei J, Xiong Y, Wu W, Liu Y, Chen Y, Jia B, Chen Z, Zhang Z, Ding W, Huang R, Wu C. The gamma-glutamyl transpeptidase to platelet ratio predicts liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase. Clin Res Hepatol Gastroenterol 2020;44:913-22. [PMID: 32147439 DOI: 10.1016/j.clinre.2020.01.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 375 |
Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol 2020;73:1037-45. [PMID: 32553667 DOI: 10.1016/j.jhep.2020.06.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 376 |
Lim N, Jackson S, Engler C, Lake JR. The Impact of Tenofovir Disoproxil Fumarate on Reduced Bone Mineral Density and Fractures in Liver Transplant Recipients. Transplant Proc 2021;53:215-20. [PMID: 33139039 DOI: 10.1016/j.transproceed.2020.09.009] [Reference Citation Analysis]
|
| 377 |
Shi K, Liu Y, Wang X, Li Y, Zhang Q, Hu Y, Ran C, Huang Y, Hou J, Wang X. Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis. Evid Based Complement Alternat Med 2020;2020:8826091. [PMID: 33178324 DOI: 10.1155/2020/8826091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 378 |
Abreu RM, Bassit LC, Tao S, Jiang Y, Ferreira AS, Hori PC, Ganova-Raeva LM, Khudyakov Y, Schinazi RF, Carrilho FJ, Ono SK. Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study. Antivir Ther 2019;24:567-79. [PMID: 31799942 DOI: 10.3851/IMP3338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 379 |
Kong LN, Yao Y, Li L, Zhao QH, Wang T, Li YL. Psychological distress and self-management behaviours among patients with chronic hepatitis B receiving oral antiviral therapy. J Adv Nurs 2021;77:266-74. [PMID: 33074555 DOI: 10.1111/jan.14610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 380 |
Leshchuk Y, Danylo Halytsky Lviv National Medical University, Abrahamovych O, Abrahamovych M, Danylo Halytsky Lviv National Medical University, Danylo Halytsky Lviv National Medical University. Modern Principles of Liver Fibrosis Diagnosis in Patients With Chronic Diffuse Liver Lesions: Literature Review and Clinical Case Description. Lʹviv klin visn 2020;3:62-72. [DOI: 10.25040/lkv2020.03.062] [Reference Citation Analysis]
|
| 381 |
Besombes J, Pronier C, Lefevre C, Lagathu G, Maillard A, Grolhier C, Thibault V. Performances of NeuMoDx, a random-access system for HBV-DNA and HCV-RNA quantification.. [DOI: 10.1101/2020.10.14.340398] [Reference Citation Analysis]
|
| 382 |
Deng N, Zhang Q. Towards Dynamic Uncertain Causality Graphs for the Intelligent Diagnosis and Treatment of Hepatitis B. Symmetry 2020;12:1690. [DOI: 10.3390/sym12101690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 383 |
Qi X, Jiang Q, Lv Y, Yang S, Li J, Huang Y, Chen L, Zhang J. Association between Signal Transducer and Activator of Transcription 4 Genetic Polymorphisms and the Spontaneous Clearance of Hepatitis B Surface Antigen: A Large Population Case Control Study in China. J Biomed Res Environ Sci 2020;1:256-262. [DOI: 10.37871/jbres1152] [Reference Citation Analysis]
|
| 384 |
Guingané AN, Bougouma A, Sombié R, King R, Nagot N, Meda N, Van de Perre P, Tuaillon E. Identifying gaps across the cascade of care for the prevention of HBV mother-to-child transmission in Burkina Faso: Findings from the real world. Liver Int 2020;40:2367-76. [PMID: 32633864 DOI: 10.1111/liv.14592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 385 |
Wang J, Wu W, Yan X, Wei J, Yao K, Yang Y, Xiong Y, Xia J, Liu Y, Chen Y, Jia B, Zhang Z, Ding W, Huang R, Wu C. HBeAg Negativity Is Associated With More Advanced Liver Fibrosis in Patients With Chronic Hepatitis B: A Propensity Score-Matching Analysis. J Clin Gastroenterol 2020;54:826-31. [PMID: 31789771 DOI: 10.1097/MCG.0000000000001291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 386 |
Kaplan DE, Medvedeva E, Serper M. Care quality and outcomes among US veterans with chronic hepatitis B in the hepatitis C direct-acting antiviral era. J Viral Hepat 2020;27:1082-92. [PMID: 32484991 DOI: 10.1111/jvh.13340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 387 |
Matsumoto A, Nishiguchi S, Enomoto H, Tanaka Y, Shinkai N, Okuse C, Kang JH, Matsui T, Miyase S, Yatsuhashi H, Nagaoka S, Kanda T, Enomoto M, Yamada R, Hiramatsu N, Saito S, Takaguchi K, Ito K, Masaki T, Morihara D, Tsuge M, Chayama K, Ikeda F, Kagawa T, Kondo Y, Murata K, Tanaka E. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. J Gastroenterol 2020;55:977-89. [PMID: 32666202 DOI: 10.1007/s00535-020-01707-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 388 |
Kale İ, Bayik R, Kavas S. Gebelerde Hepatit B, Hepatit C ve HIV Seroprevalansı; 6 yıllık deneyim. Türk Kadın Sağlığı ve Neonatoloji Dergisi 2020. [DOI: 10.46969/ezh.742307] [Reference Citation Analysis]
|
| 389 |
Ye J, Wu Y, Li M, Gong X, Zhong B. Keratin 8 Mutations Were Associated With Susceptibility to Chronic Hepatitis B and Related Progression. J Infect Dis 2020;221:464-73. [PMID: 31515557 DOI: 10.1093/infdis/jiz467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 390 |
van Gemert C, Dimech W, Stoove M, Guy R, Howell J, Bowden S, Nicholson S, Pendle S, Donovan B, Hellard M; ACCESS collaboration. Tracking the uptake of outcomes of hepatitis B virus testing using laboratory data in Victoria, 2011-16: a population-level cohort study. Sex Health 2019;16:358-66. [PMID: 31256771 DOI: 10.1071/SH18102] [Reference Citation Analysis]
|
| 391 |
Sbarigia U, Vincken T, Wigfield P, Hashim M, Heeg B, Postma M. A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients. J Comp Eff Res 2020;9:1051-65. [PMID: 32945178 DOI: 10.2217/cer-2020-0068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 392 |
Wongjarupong N, Yonli AT, Nagalo BM, Djigma FW, Somda SK, Hassan MA, Mohamed EA, Sorgho AP, Compaore TR, Soubeiga ST, Kiendrebeogo I, Sanou M, Diarra B, Yang HI, Chen CJ, Ouattara AK, Zohoncon TM, Martinson JJ, Buetow K, Chamcheu JC, Antwi SO, Borad MJ, Simpore J, Roberts LR. Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. Hepatol Commun 2020;4:1781-92. [PMID: 33305149 DOI: 10.1002/hep4.1595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 393 |
Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuismink ZMA, Santoro R, Jaroszewicz J, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen HLA; GIANT-B Global Consortium. Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. Clin Infect Dis 2019;69:1969-79. [PMID: 30715261 DOI: 10.1093/cid/ciz084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 394 |
Huang DQ, Yeo YH, Tan E, Takahashi H, Yasuda S, Saruwatari J, Tanaka K, Oniki K, Kam LY, Muthiah MD, Hyogo H, Ono M, Barnett SD, Li J, Zou B, Fung J, Lee TY, Wong VW, Yuen MF, Dan YY, Lim SG, Cheung R, Toyoda H, Eguchi Y, Nguyen MH. ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. Hepatol Commun 2020;4:1624-36. [PMID: 33163833 DOI: 10.1002/hep4.1593] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 395 |
Sylvester-Armstrong KR, Duff P. Evidence for Use of Tenofovir in Pregnancy to Prevent Perinatal Transmission of Hepatitis B Infection. Clin Obstet Gynecol 2019;62:835-45. [PMID: 30921004 DOI: 10.1097/GRF.0000000000000438] [Reference Citation Analysis]
|
| 396 |
Lee H, Park Y, Choi Y. Overview of anti-Hepatitis B virus agents. jbv 2020;50:141-9. [DOI: 10.4167/jbv.2020.50.3.141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 397 |
Jeon MY, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Han KH, Ahn SH, Kim SU. Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. J Viral Hepat 2020;27:932-40. [PMID: 32365240 DOI: 10.1111/jvh.13313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 398 |
Yip TC, Lee HW, Wong VW, Wong GL, Tse YK, Lui GC, Ahn SH, Chan HL. Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. J Gastroenterol Hepatol 2020;35:1610-8. [PMID: 32032974 DOI: 10.1111/jgh.15007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 399 |
Gattani M, Ingle M, Chauhan S, Lad S. Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B. Aliment Pharmacol Ther 2020;52:911-2. [PMID: 32852812 DOI: 10.1111/apt.15966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 400 |
Duan WJ, Wang XZ, Ma AL, Shang J, Nan YM, Gao ZL, Tang H, Fu QC, Xie Q, Mao Q, Niu JQ, Han T, Li J, Han Y, Cao JB, Kong YY, Shi XY, Lv FD, Wang TL, Ma H, You H, Ou XJ, Jia JD. Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. J Dig Dis 2020;21:519-25. [PMID: 32700794 DOI: 10.1111/1751-2980.12924] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 401 |
Liu Y, Xue J, Liao W, Yan H, Liang X. Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy. J Clin Gastroenterol 2020;54:e73-82. [PMID: 32604147 DOI: 10.1097/MCG.0000000000001376] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 402 |
Zhou SN, Zhang N, Liu HH, Xia P, Zhang C, Song JW, Fan X, Shi M, Jin L, Zhang JY, Wang FS. Skewed CD39/CD73/adenosine pathway contributes to B-cell hyperactivation and disease progression in patients with chronic hepatitis B. Gastroenterol Rep (Oxf) 2021;9:49-58. [PMID: 33747526 DOI: 10.1093/gastro/goaa048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 403 |
Sawinski D, Wong T, Goral S. Current state of kidney transplantation in patients with HIV, hepatitis C, and hepatitis B infection. Clin Transplant 2020;34:e14048. [PMID: 32700341 DOI: 10.1111/ctr.14048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 404 |
Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 405 |
Auzin AM, Slavenburg S, Peters C, Boland G, Rahamat-Langendoen J, Melchers WJG, Schuurman R. Rapid, random-access, and quantification of hepatitis B virus using the Cepheid Xpert HBV viral load assay. J Med Virol 2021;93:3999-4003. [PMID: 32761911 DOI: 10.1002/jmv.26392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 406 |
Yu XQ, Wang MJ, Yu DM, Chen PZ, Zhu MY, Huang W, Han Y, Gong QM, Zhang XX. Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients. J Clin Microbiol 2020;58:e00075-20. [PMID: 32554476 DOI: 10.1128/JCM.00075-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 407 |
Wang D, Yan X, Zhang M, Ren C, Wang L, Ma J, Guo L. Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection. Medicine (Baltimore) 2020;99:e21387. [PMID: 32871988 DOI: 10.1097/MD.0000000000021387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 408 |
Xia Z, He L, Xiong L, Wen T. The comparison of different antiviral therapies on the prognosis of hepatitis B virus-related hepatocellular carcinoma after curative treatments: A network meta-analysis. Medicine (Baltimore) 2020;99:e20877. [PMID: 32871973 DOI: 10.1097/MD.0000000000020877] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 409 |
Wu KL, Chen YL, Ko CJ, Lin PY, Chou CT. Comparison of the diagnostic performance of magnetic resonance elastography and Wisteria foribunda agglutinin-positive Mac-2-binding protein in the determination of advanced liver fibrosis stages in patients with chronic liver disease. Exp Ther Med 2020;20:1953-60. [PMID: 32782504 DOI: 10.3892/etm.2020.8922] [Reference Citation Analysis]
|
| 410 |
Yu HC, Lin KH, Tsay FW, Tsai TJ, Wu PC, Chen YH, Chen YH. Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies. PLoS One 2020;15:e0237586. [PMID: 32785260 DOI: 10.1371/journal.pone.0237586] [Reference Citation Analysis]
|
| 411 |
Li X, Zhang L, Qiu M, Huang Y, Xiao H, Lu B, Jiang Y, Long F, Lin H, He J, Wu Q, Zhang M, Wang L, Zhu X, Gong M, Sun X, Sun J, Sun F, Lu W, Xu W, Chen G, Li Z, Gan D, Yang X, Du H, Ye Y. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China. Trials 2020;21:708. [PMID: 32787905 DOI: 10.1186/s13063-020-04417-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 412 |
Pan X, Chen J, Zhou L, Ou X, He F, Liu Y, Zheng S, Wang H, Cao B, Wang Z, Liu H, Liu G, Huang Z, Shen G, Liu S, Chen D. Efficacy and safety of continuous antiviral therapy from preconception to prevent perinatal transmission of hepatitis B virus. Sci Rep 2020;10:13631. [PMID: 32788743 DOI: 10.1038/s41598-020-70644-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 413 |
Fang Z, Yu X, Tong S, Lu C, Huang Y, Chen L, Yuan Z, Zhang Y. Serum ERK1/2 proteins fluctuating with HBV infection report frequency of viral-specific CD8+ T cells and predict IFNα therapeutic effect in chronic hepatitis B patients. Clin Immunol 2020;219:108570. [PMID: 32791312 DOI: 10.1016/j.clim.2020.108570] [Reference Citation Analysis]
|
| 414 |
Lin CL, Chien RN, Chu YD, Liang KH, Huang YH, Ke PY, Lin KH, Lin YH, Yeh CT. Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression. Hepatol Int 2020;14:973-84. [PMID: 32770306 DOI: 10.1007/s12072-020-10079-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 415 |
Huang R, Zhu L, Wang J, Xue L, Liu L, Yan X, Huang S, Li Y, Yan X, Zhang B, Xu T, Li C, Ji F, Ming F, Zhao Y, Cheng J, Wang Y, Zhao H, Hong S, Chen K, Zhao XA, Zou L, Sang D, Shao H, Guan X, Chen X, Chen Y, Wei J, Zhu C, Wu C. Clinical features of COVID-19 patients with non-alcoholic fatty liver disease. Hepatol Commun 2020. [PMID: 32838108 DOI: 10.1002/hep4.1592] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 416 |
Cho H, Chang Y, Lee JH, Cho YY, Nam JY, Lee YB, Lee DH, Cho EJ, Yu SJ, Kim YJ, Lee JM, Yoon JH. Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B. J Clin Gastroenterol 2020;54:633-41. [PMID: 31033805 DOI: 10.1097/MCG.0000000000001217] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 417 |
Jia Q, Yu F, Zhou Q, Chen X, Gu Z, Ma C. Predictive effect of five hepatitis B virus markers on re-vaccination time of hepatitis B vaccine. Exp Ther Med 2020;20:1709-15. [PMID: 32742400 DOI: 10.3892/etm.2020.8859] [Reference Citation Analysis]
|
| 418 |
Zhang PF, Xie D, Li Q. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects. Immunotherapy 2020;12:1021-34. [PMID: 32727249 DOI: 10.2217/imt-2020-0009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 419 |
Tepper JL, Puopolo KM. Update on Prenatal Laboratory Screening: Joint Commission Required Elements. Neoreviews 2019;20:e584-91. [PMID: 31575780 DOI: 10.1542/neo.20-10-e584] [Reference Citation Analysis]
|
| 420 |
Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, Hershman DL, Loehrer AP, Sabichi AL, Symington BE, Terrault N, Wong ML, Somerfield MR, Artz AS. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.J Clin Oncol. 2020;38:3698-3715. [PMID: 32716741 DOI: 10.1200/JCO.20.01757] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 421 |
Cao JM, Yang JQ, Ming ZQ, Wu JL, Yang LQ, Chen TW, Li R, Ou J, Zhang XM, Mu QW, Li HJ, Hu J. A radiomics model of liver CT to predict risk of hepatic encephalopathy secondary to hepatitis B related cirrhosis.Eur J Radiol. 2020;130:109201. [PMID: 32738462 DOI: 10.1016/j.ejrad.2020.109201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 422 |
Mohammed EH, Saud MR, Yemane S, Isam Mohammed E, Freweini T. Serological and virological profile of patients with chronic hepatitis B infection in Eritrea. Int J Clin Virol 2020;4:095-101. [DOI: 10.29328/journal.ijcv.1001022] [Reference Citation Analysis]
|
| 423 |
Lin MT, Chang KC, Yen YH, Tsai MC, Chen CH, Wang JH, Hsiao CC, Chiu YH, Hu TH. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. J Formos Med Assoc 2021;120:621-8. [PMID: 32718890 DOI: 10.1016/j.jfma.2020.07.019] [Reference Citation Analysis]
|
| 424 |
Zaytseva EA, Popova LL, Konstantinov DY. The use of Ingaron® in the treatment of chronic viral hepatitis B. Aspirantskiy Vestnik Povolzhiya 2020;20:63-67. [DOI: 10.17816/2072-2354.2020.20.3.63-67] [Reference Citation Analysis]
|
| 425 |
Gu Y, Lian Y, Zheng Q, Huang Z, Gu L, Bi Y, Li J, Huang Y, Wu Y, Chen L, Huang Y. Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B. BMC Infect Dis 2020;20:509. [PMID: 32664850 DOI: 10.1186/s12879-020-05233-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 426 |
Maasoumy B, Geretti AM, Frontzek A, Austin H, Aretzweiler G, Garcia-Álvarez M, Leuchter S, Simon CO, Marins EG, Canchola JA, Cornberg M, Delgado R, Wedemeyer H. HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination. Hepatol Commun 2020;4:983-97. [PMID: 32626831 DOI: 10.1002/hep4.1520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 427 |
Cheng M, Feng X, Wang L, Yang Y, Ma L, Wang B. Nucleoside analogs assisted with Chinese compound prescription in treating hepatic fibrosis of chronic hepatitis B patients: A protocol of systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21032. [PMID: 32629728 DOI: 10.1097/MD.0000000000021032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 428 |
Lee HW, Park SY, Lee M, Lee EJ, Lee J, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. Liver Int 2020;40:1736-43. [PMID: 32239602 DOI: 10.1111/liv.14451] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 429 |
Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, Nam SW, Bae SH, Choi JY, Yoon SK, Han NI, Jang JW. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut 2020;69:1301-8. [PMID: 31672838 DOI: 10.1136/gutjnl-2019-318947] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 24.7] [Reference Citation Analysis]
|
| 430 |
Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE; GLOBAL PBC Study Group. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. Am J Gastroenterol 2020;115:1066-74. [PMID: 32618657 DOI: 10.14309/ajg.0000000000000557] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 431 |
Lee HA, Lee HW, Kim IH, Park SY, Sinn DH, Yu JH, Seo YS, Um SH, Lee JI, Lee KS, Lee CH, Tak WY, Kweon YO, Kang W, Paik YH, Lee JW, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther 2020;52:196-204. [PMID: 32452564 DOI: 10.1111/apt.15741] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 432 |
Hu Y, Yu H. Prevention strategies of mother-to-child transmission of hepatitis B virus (HBV) infection. Pediatr Investig 2020;4:133-7. [PMID: 32851357 DOI: 10.1002/ped4.12205] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 433 |
Ugwu EO, Eleje GU, Ugwu AO, Nwagha UI, Ikechebelu JI, Umeh UA, Okafor HU. Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus. Cochrane Database of Systematic Reviews 2020. [DOI: 10.1002/14651858.cd013653] [Reference Citation Analysis]
|
| 434 |
Li Z, Yang Y. Detection of immunoglobulin indexes by immunoturbidimetry: patients with chronic hepatitis B. Minerva Med 2020;111:491-7. [PMID: 32567820 DOI: 10.23736/S0026-4806.20.06621-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 435 |
Chen L, Cao Z, Yan L, Ding Y, Shen X, Liu K, Xiang X, Xie Q, Zhu C, Bao S, Wang H. Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome. Front Physiol 2020;11:526. [PMID: 32655398 DOI: 10.3389/fphys.2020.00526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 436 |
Windradi C, Awalia A. Challenging Therapy In Pregnant Woman With Systemic Lupus Erythematosus (SLE) and Chronic Hepatitis B. BHSJ 2020;3:53. [DOI: 10.20473/bhsj.v3i1.19198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 437 |
Lukhwareni A, Gededzha MP, Amponsah-Dacosta E, Blackard JT, Burnett RJ, Selabe SG, Kyaw T, Mphahlele MJ. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans. Viruses 2020;12:E634. [PMID: 32545313 DOI: 10.3390/v12060634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 438 |
Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Zhang RX, Zhao X, Chen ST, Liu S, Li GH, Cao ZM, Xu L, Chen J. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial. Trials 2020;21:482. [PMID: 32503608 DOI: 10.1186/s13063-020-04395-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 439 |
Wang L, Li J, Yang K, Zhang H, Wang Q, Lv X, Guan S. Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels. Medicine (Baltimore) 2020;99:e20548. [PMID: 32502018 DOI: 10.1097/MD.0000000000020548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 440 |
Hsiao B, Khan A, Kang I. Vaccinations and Biologics. Infectious Disease Clinics of North America 2020;34:425-450. [DOI: 10.1016/j.idc.2020.02.012] [Reference Citation Analysis]
|
| 441 |
Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Idilman R, Esteban R, Janssen HLA, Berg T, Lampertico P. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J Hepatol 2020;72:1088-96. [PMID: 31981727 DOI: 10.1016/j.jhep.2020.01.007] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 442 |
Wang J, Xia J, Yan X, Yang Y, Wei J, Xiong Y, Wu W, Liu Y, Chen Y, Jia B, Chen Z, Zhang Z, Ding W, Huang R, Wu C. Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B. J Viral Hepat 2020;27:602-9. [PMID: 31981279 DOI: 10.1111/jvh.13264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 443 |
Kim GA, Lim YS. Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. Authors' reply. Aliment Pharmacol Ther 2020;51:1440-1. [PMID: 32445524 DOI: 10.1111/apt.15794] [Reference Citation Analysis]
|
| 444 |
Howell J, Chan HLY, Feld JJ, Hellard ME, Thompson AJ. Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma? Gastroenterology 2020;158:2028-32. [PMID: 32088205 DOI: 10.1053/j.gastro.2020.02.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 445 |
Lee SB, Jeong J, Park JH, Jung SW, Jeong ID, Bang SJ, Shin JW, Park BR, Park EJ, Park NH. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol 2020;26:364-75. [PMID: 32466635 DOI: 10.3350/cmh.2020.0012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 446 |
Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J Hepatol 2020;12:220-9. [PMID: 32547689 DOI: 10.4254/wjh.v12.i5.220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 447 |
Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. WJH 2020;12:210-9. [DOI: 10.4254/wjh.v12.i5.210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 448 |
Bahrami M, Cheraghpour M, Jafarirad S, Alavinejad P, Asadi F, Hekmatdoost A, Mohammadi M, Yari Z. The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. Complement Ther Med 2020;52:102452. [PMID: 32951715 DOI: 10.1016/j.ctim.2020.102452] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 449 |
Johansson ED, Nunez M. Acute Hepatitis B Surge: Opioid Epidemic Implication and Management Challenges. Open Forum Infect Dis 2020;7:ofaa190. [PMID: 32550238 DOI: 10.1093/ofid/ofaa190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 450 |
Zhang K, Lin S, Wang M, Huang J, Zhu Y. The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment. Biomed Res Int 2020;2020:5728359. [PMID: 32596332 DOI: 10.1155/2020/5728359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 451 |
Sinn DH. [Natural History and Treatment Indications of Chronic Hepatitis B]. Korean J Gastroenterol 2019;74:245-50. [PMID: 31765552 DOI: 10.4166/kjg.2019.74.5.245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 452 |
Luk A, Jiang Q, Glavini K, Triyatni M, Zhao N, Racek T, Zhu Y, Grippo JF. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers. Clin Transl Sci. 2020;13:985-993. [PMID: 32268000 DOI: 10.1111/cts.12791] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 453 |
Lenci I, Milana M, Grassi G, Manzia TM, Gazia C, Tisone G, Angelico R, Baiocchi L. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? World J Gastroenterol 2020; 26(18): 2166-2176 [PMID: 32476783 DOI: 10.3748/wjg.v26.i18.2166] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 454 |
Geng J, Bao H, Chen Y, Shi L, Geng J, Wang Q, Yu H. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti Infect Ther 2020;18:823-34. [PMID: 32329638 DOI: 10.1080/14787210.2020.1760843] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 455 |
Allard NL, MacLachlan JH, Dev A, Dwyer J, Srivatsa G, Spelman T, Thompson AJ, Cowie BC. Adherence in chronic hepatitis B: associations between medication possession ratio and adverse viral outcomes. BMC Gastroenterol 2020;20:140. [PMID: 32381025 DOI: 10.1186/s12876-020-01219-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 456 |
Pierra Rouviere C, Dousson CB, Tavis JE. HBV replication inhibitors. Antiviral Res 2020;179:104815. [PMID: 32380149 DOI: 10.1016/j.antiviral.2020.104815] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 457 |
Xiao Y, Howell J, van Gemert C, Thompson AJ, Seaman CP, McCulloch K, Scott N, Hellard ME. Enhancing the hepatitis B care cascade in Australia: A cost-effectiveness model. J Viral Hepat 2020;27:526-36. [PMID: 31856377 DOI: 10.1111/jvh.13252] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 458 |
Piccinni R, Rodrigues SG, Montani M, Murgia G, Delgado MG, Casu S, Stirnimann G, Semmo N, De Gottardi A, Dufour JF, Berzigotti A. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. Liver Int 2020;40:1151-8. [PMID: 31823449 DOI: 10.1111/liv.14325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 459 |
Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, Peng CY, Chen CH. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatol Int. 2020;14:513-520. [PMID: 32319045 DOI: 10.1007/s12072-020-10031-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 460 |
Sonneveld MJ, Hansen BE, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Chien RN, de Knegt RJ, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Man RA, Janssen HLA; SONIC-B Study group. hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study. J Infect Dis 2020:jiaa192. [PMID: 32318704 DOI: 10.1093/infdis/jiaa192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 461 |
Ko WS, Yang YP, Shen FP, Wu MC, Shih CJ, Lu MC, Yan YH, Chiou YL. The Study of Correlation Between Serum Vitamin D3 Concentrations and HBV DNA Levels and Immune Response in Chronic Hepatitis Patients. Nutrients 2020;12:E1114. [PMID: 32316365 DOI: 10.3390/nu12041114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 462 |
Indolfi G, Abdel-Hady M, Bansal S, Debray D, Smets F, Czubkowski P, van der Woerd W, Samyn M, Jahnel J, Gupte G, Zellos A, Mozer-Glassberg Y, Verkade HJ, Sokal E, Fischler B. Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies. J Pediatr Gastroenterol Nutr 2020;70:527-38. [PMID: 31977956 DOI: 10.1097/MPG.0000000000002628] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 463 |
Wang J, Huang R, Yan X, Li M, Chen Y, Xia J, Liu Y, Jia B, Zhu L, Zhang Z, Zhu C, Wu C. Red blood cell distribution width: A promising index for evaluating the severity and long-term prognosis of hepatitis B virus-related diseases. Dig Liver Dis 2020;52:440-6. [PMID: 32008975 DOI: 10.1016/j.dld.2019.12.144] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 464 |
McCulloch K, Romero N, MacLachlan J, Allard N, Cowie B. Modeling Progress Toward Elimination of Hepatitis B in Australia. Hepatology 2020;71:1170-81. [PMID: 31419332 DOI: 10.1002/hep.30899] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 465 |
Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 466 |
Nayagam S, Shimakawa Y, Lemoine M. Mother-to-child transmission of hepatitis B: What more needs to be done to eliminate it around the world? J Viral Hepat 2020;27:342-9. [PMID: 31698534 DOI: 10.1111/jvh.13231] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 467 |
Jonas MM. Treatment of hepatitis B in children. Clinical Dilemmas in Viral Liver Disease 2020. [DOI: 10.1002/9781119533481.ch29] [Reference Citation Analysis]
|
| 468 |
Sun Y, Zhang Y, Xu Y, Shu M, Bonroy K, Qiu H, Cai W. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B. Epidemiol Infect 2019;147:e193. [PMID: 31364558 DOI: 10.1017/S0950268819000815] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 469 |
Yin J, Liang P, Chen G, Wang F, Cui F, Liang X, Zhuang G. Tenofovir prophylaxis for preventing mother-to-child hepatitis B virus transmission in China: A cost-effectiveness analysis. Int J Infect Dis 2020;95:118-24. [PMID: 32205288 DOI: 10.1016/j.ijid.2020.03.036] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 470 |
Aslam S, Grossi P, Schlendorf KH, Holm AM, Woolley AE, Blumberg E, Mehra MR; working group members. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. J Heart Lung Transplant 2020;39:418-32. [PMID: 32362393 DOI: 10.1016/j.healun.2020.03.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 471 |
Hardtstock F, Sbarigia U, Kocaata Z, Wilke T, Sylvester SV. Preferences of Patients with Chronic Hepatitis B - A Discrete Choice Experiment on the Acceptability of Functional Cure. Patient Prefer Adherence 2020;14:613-24. [PMID: 32256052 DOI: 10.2147/PPA.S238833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 472 |
Ganesan M, Eikenberry A, Poluektova LY, Kharbanda KK, Osna NA. Role of alcohol in pathogenesis of hepatitis B virus infection. World J Gastroenterol 2020; 26(9): 883-903 [PMID: 32206001 DOI: 10.3748/wjg.v26.i9.883] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 473 |
Megahed FAK, Zhou X, Sun P. The Interactions between HBV and the Innate Immunity of Hepatocytes. Viruses 2020;12:E285. [PMID: 32151000 DOI: 10.3390/v12030285] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 474 |
Trivella JP, Martin P, Carrion AF. Novel targeted therapies for the management of liver fibrosis. Expert Opinion on Emerging Drugs 2020;25:59-70. [DOI: 10.1080/14728214.2020.1735350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 475 |
Sbarigia U, Kariburyo F, Sah J, Colasurdo J, Xie L, Katz EG, Sylvester S. Evaluating the Effect of Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the United States Veterans Population. Adv Ther 2020;37:1156-72. [PMID: 32009232 DOI: 10.1007/s12325-020-01240-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 476 |
Kim MN, Lee JH, Chon YE, Ha Y, Hwang SG. Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy. Eur J Gastroenterol Hepatol 2020;32:433-9. [PMID: 31490417 DOI: 10.1097/MEG.0000000000001520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 477 |
Otsuka M, Koike K. Should Level of HBV RNA be Used to Determine When Patients Should Stop Treatment With Nucleos(t)ide Analogues. Clin Gastroenterol Hepatol 2020;18:551-2. [PMID: 31473358 DOI: 10.1016/j.cgh.2019.08.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 478 |
Cornberg M, Lok AS, Terrault NA, Zoulim F, Berg T, Brunetto MR, Buchholz S, Buti M, Chan HL, Chang K, Dandri M, Dusheiko G, Feld JJ, Ferrari C, Ghany M, Janssen HL, Kennedy P, Lampertico P, Liang J, Locarnini S, Maini MK, Mishra P, Papatheodoridis G, Petersen J, Schlottmann S, Wang S, Wedemeyer H. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology 2020;72:539-557. [DOI: 10.1016/j.jhep.2019.11.003] [Cited by in Crossref: 144] [Cited by in F6Publishing: 138] [Article Influence: 48.0] [Reference Citation Analysis]
|
| 479 |
Voulgaris T, Papatheodoridi M, Lampertico P, Papatheodoridis GV. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int 2020;40:484-95. [PMID: 31884726 DOI: 10.1111/liv.14334] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 480 |
Luo H, Tan N, Kang Q, Pan J, Chen H, Xi H, Yu M, Xu X. Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues. J Viral Hepat 2020;27:323-8. [PMID: 31667945 DOI: 10.1111/jvh.13227] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 481 |
Lechner S, Yee M, Limketkai BN, Pham EA. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. Dig Dis Sci 2020;65:897-905. [PMID: 32020359 DOI: 10.1007/s10620-020-06100-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 482 |
Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, Wiegand J, Cornberg M, Lange C, Berg T, Zeuzem S, Mauss S. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver Int 2020;40:539-48. [PMID: 31241820 DOI: 10.1111/liv.14186] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 483 |
Ou Q, Guo J, Zeng Y, Chen H. Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection. J Viral Hepat 2020;27:224-32. [PMID: 31954089 DOI: 10.1111/jvh.13260] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 484 |
Kaya Kiliç E, Altun Demircan Ş, Bulut C, Ataman Hatipoğlu Ç, Arslan K, Kinikli S. Bir eğitim ve araştırma hastanesinde hastanesinde takip edilen Hepatit B ile enfekte gebelerin değerlendirilmesi. Turkish Journal of Clinics and Laboratory 2020. [DOI: 10.18663/tjcl.584867] [Reference Citation Analysis]
|
| 485 |
Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 100] [Cited by in F6Publishing: 106] [Article Influence: 33.3] [Reference Citation Analysis]
|
| 486 |
Attar BM. CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated. Clin Liver Dis (Hoboken) 2020;15:25-30. [PMID: 32104574 DOI: 10.1002/cld.893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 487 |
Nusair M, Rayyan Y, Hammoudeh W, Al-Khatib MA, Mansour E, Snehanshu S, Bassil N, Kozma S, Ghazzawi IA. Hepatitis B care pathway in Jordan: current situation, gaps and recommended actions. J Virus Erad 2020;6:1-6. [PMID: 32175084] [Reference Citation Analysis]
|
| 488 |
Guo X, Chen D, Cai Q, Huang Z, Xu W, Peng L, Chen P. Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line. BMC Mol Cell Biol. 2020;21:6. [PMID: 32070272 DOI: 10.1186/s12860-020-00250-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 489 |
Na HG, Imran A, Kim K, Han HS, Lee YJ, Kim MJ, Yun CS, Jung YS, Lee JY, Han SB. Discovery of a New Sulfonamide Hepatitis B Capsid Assembly Modulator. ACS Med Chem Lett 2020;11:166-71. [PMID: 32071684 DOI: 10.1021/acsmedchemlett.9b00550] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 490 |
Kriss MS, Burton JR, Rosen HR. Biological Principles and Clinical Issues Underlying Liver Transplantation for Viral‐Induced End‐Stage Liver Disease in the Era of Highly Effective Direct‐Acting Antiviral Agents. The Liver 2020. [DOI: 10.1002/9781119436812.ch69] [Reference Citation Analysis]
|
| 491 |
Yan LT, Wang LL, Yao J, Yang YT, Mao XR, Yue W, Mao YW, Zhou W, Chen QF, Chen Y, Duan ZP, Li JF. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection. Medicine (Baltimore) 2020;99:e19248. [PMID: 32080129 DOI: 10.1097/MD.0000000000019248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 492 |
Huang DQ, Lim SG. Hepatitis B: Who to treat? A critical review of international guidelines. Liver Int 2020;40 Suppl 1:5-14. [PMID: 32077616 DOI: 10.1111/liv.14365] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 493 |
Karakus N, Duygu F, Coskun US, Atay A, Yigit S. Influence of PON1 gene polymorphisms (rs662 and rs854560) on the chronicity of HBV infection. Meta Gene 2020;23:100618. [DOI: 10.1016/j.mgene.2019.100618] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 494 |
Zhang TY, Guo XR, Wu YT, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Ge SX, Chen PJ, Zhang J, Yuan Q, Xia NS. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut 2020;69:343-54. [PMID: 30926653 DOI: 10.1136/gutjnl-2018-317725] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 495 |
Rinker F, Bremer CM, Schröder K, Wiegand SB, Bremer B, Manns MP, Kraft AR, Wedemeyer H, Yang L, Pavlovic V, Wat C, Gerlich WH, Glebe D, Cornberg M. Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. Liver Int 2020;40:324-32. [PMID: 31721419 DOI: 10.1111/liv.14298] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 496 |
Lyu J, Wang S, He Q, Pan C, Tang AS. Hep B Moms: A cross-sectional study of mother-to-child transmission risk among pregnant Asian American women with chronic hepatitis B in New York City, 2007-2017. J Viral Hepat 2020;27:168-75. [PMID: 31638292 DOI: 10.1111/jvh.13221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 497 |
Luo Y, Pan M, Ning M, Chenyu X, Liu L, Chen L, Chen T, Biyun X, Yali H, Zhou YH. High mutation prevalence of precore and basal core promoter in pregnant women who underwent spontaneous HBeAg seroconversion within one year postpartum. Dig Liver Dis 2020;52:199-204. [PMID: 31320303 DOI: 10.1016/j.dld.2019.06.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 498 |
Liu Y, Liu H, Hu Z, Ding Y, Pan XB, Zou J, Xi J, Yu G, Huang H, Luo MT, Guo F, Liu S, Sheng Q, Jia J, Zheng YT, Wang J, Chen X, Guo JT, Wei L, Lu F. Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. Hepatology 2020;71:463-76. [PMID: 31278760 DOI: 10.1002/hep.30844] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 499 |
Chen H, Sun J, Zhou B, Peng J, Xie Q, Liang X, Fan R, Conran C, Xu J, Ji Y, Zhang X, Sun L, Jia J, Wang G, Hou J, Jiang DK. A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFNα therapy in Chinese HBeAg-positive chronic hepatitis B patients. Aliment Pharmacol Ther 2020;51:469-78. [PMID: 31943297 DOI: 10.1111/apt.15624] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 500 |
Jing W, Liu J, Liu M. Eliminating mother-to-child transmission of HBV: progress and challenges in China. Front Med 2020;14:21-9. [PMID: 31974872 DOI: 10.1007/s11684-020-0744-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 501 |
Laing N, Tufton H, Ochola E, P'Kingston OG, Maini MK, Easom N. Hepatitis B assessment without hepatitis B virus DNA quantification: a prospective cohort study in Uganda. Trans R Soc Trop Med Hyg 2019;113:11-7. [PMID: 30452730 DOI: 10.1093/trstmh/try117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 502 |
Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 503 |
Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 22.7] [Reference Citation Analysis]
|
| 504 |
Yamauchi R, Takeyama Y, Takata K, Fukunaga A, Sakurai K, Tanaka T, Fukuda H, Fukuda S, Kunimoto H, Umeda K, Morihara D, Yokoyama K, Irie M, Shakado S, Sakisaka S, Hirai F. Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate. Intern Med 2020;59:1163-6. [PMID: 31956202 DOI: 10.2169/internalmedicine.3805-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 505 |
Li XK, Zhang MX, Shao FZ, Zhou DQ, Xue JD, Liu TJ, Chi XL, Lu BJ, Wang XB, Li Q, Li J, Mao DW, Yang HS, Yang HZ, Zhao WX, Li Y, Zhang GL, Zhao YM, Zou JD, Liu MY, Zhang KK, Yang XZ, Gan DN, Li Y, Zhang P, Li ZG, Li S, Ye YA. Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial. Chin J Integr Med 2020;26:330-8. [PMID: 31919749 DOI: 10.1007/s11655-020-3250-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 506 |
Muthiah MD, Tan EY, Chua SHM, Huang DQY, Bonney GK, Kow AWC, Lim SG, Dan YY, Tan PS, Lee GH, Lim BL. Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficacious. Hepatol Int 2020;14:57-69. [PMID: 31919678 DOI: 10.1007/s12072-019-10011-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 507 |
Li M, Lv T, Wu S, Wei W, Wu X, Ou X, Ma H, Chow SC, Kong Y, You H, Jia J. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int. 2020;14:105-114. [PMID: 31898210 DOI: 10.1007/s12072-019-10005-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 508 |
Lee HW, Chan HL. Unresolved issues of immune tolerance in chronic hepatitis B. J Gastroenterol 2020;55:383-9. [PMID: 32016713 DOI: 10.1007/s00535-020-01665-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 509 |
Munir R. Combination therapy against human infections caused by viruses. Combination Therapy Against Multidrug Resistance 2020. [DOI: 10.1016/b978-0-12-820576-1.00010-2] [Reference Citation Analysis]
|
| 510 |
Marzinke MA, Dufour DR. Laboratory diagnosis of liver disease. Contemporary Practice in Clinical Chemistry 2020. [DOI: 10.1016/b978-0-12-815499-1.00031-4] [Reference Citation Analysis]
|
| 511 |
Brouwer WP, Zhao Q, Hansen BE, Lau D, Khalili M, Terrault NA, Di Bisceglie AM, Perrillo RP, Fried MW, Wong D, Feld JJ, Belle SH, Janssen HLA; Hepatitis B Research Network. HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. Clin Gastroenterol Hepatol 2020;18:259-61. [PMID: 30630104 DOI: 10.1016/j.cgh.2018.12.039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 512 |
Benmassaoud A, Sebastiani G. Fibrosis Assessment via Liver Stiffness Measurements: How Many Patients Are Spared from a Liver Biopsy? Liver Elastography 2020. [DOI: 10.1007/978-3-030-40542-7_49] [Reference Citation Analysis]
|
| 513 |
Wang Y, Li XY, Wu LL, Zheng XY, Deng Y, Li MJ, You X, Chong YT, Hao YT. Dynamic prediction of liver cirrhosis risk in chronic hepatitis B patients using longitudinal clinical data. Eur J Gastroenterol Hepatol 2020;32:120-6. [PMID: 31688313 DOI: 10.1097/MEG.0000000000001592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 514 |
Nusair M, Rayyan Y, Hammoudeh W, Al-khatib MA, Mansour E, Snehanshu S, Bassil N, Kozma S, Ghazzawi I. Hepatitis B care pathway in Jordan: current situation, gaps and recommended actions. Journal of Virus Eradication 2020;6:1-6. [DOI: 10.1016/s2055-6640(20)30004-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 515 |
Hwan YJ, Shin J, Jin YJ, Lee JW. Comparison of clinical manifestations and outcomes of noncirrhotic and cirrhotic hepatocellular carcinoma patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2020;32:66-73. [PMID: 31268949 DOI: 10.1097/MEG.0000000000001478] [Reference Citation Analysis]
|
| 516 |
Abdel-hady M, Kelly DA. Hepatitis B and C in Children. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65710-0] [Reference Citation Analysis]
|
| 517 |
Fong IW. Major Advances in Hepatitis C Treatment but Not Hepatitis B. Current Trends and Concerns in Infectious Diseases 2020. [DOI: 10.1007/978-3-030-36966-8_5] [Reference Citation Analysis]
|
| 518 |
de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 2020;55:496-514. [PMID: 32185517 DOI: 10.1007/s00535-020-01680-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 519 |
Marrone A, Ciotti M, Rinaldi L, Adinolfi LE, Ghany M. Hepatitis B and C virus infection and risk of haematological malignancies. J Viral Hepat 2020;27:4-12. [PMID: 31325404 DOI: 10.1111/jvh.13183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 520 |
Gabbia D, De Martin S. Specific Medications for Chronic Viral Hepatitis. Liver Diseases 2020. [DOI: 10.1007/978-3-030-24432-3_53] [Reference Citation Analysis]
|
| 521 |
Zheng Z, Liao W, Liu L, Cai S, Zhu H, Yin S. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study. Biomed Pharmacother 2020;122:109698. [PMID: 31918272 DOI: 10.1016/j.biopha.2019.109698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 522 |
Xun Z, Liu C, Yu QQ, Lin JP, Huang JL, Yang TW, Wu WN, Wu SH, Ou QS. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients. Clin Chim Acta 2020;502:120-7. [PMID: 31891671 DOI: 10.1016/j.cca.2019.12.020] [Reference Citation Analysis]
|
| 523 |
Ormaechea MS, Hassan M, Onghanseng N, Park JH, Mahajan S, Al-Kirwi KY, Uludag G, Halim MS, Schlaen A, Sepah YJ, Do DV, Nguyen QD. Safety of systemic therapy for noninfectious uveitis. Expert Opin Drug Saf 2019;18:1219-35. [PMID: 31801415 DOI: 10.1080/14740338.2019.1692810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 524 |
Li G, Lin J, Jiang C, Feng Q, Wen L. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: a bibliometric and visual analysis. J Int Med Res 2020;48:300060519893234. [PMID: 31878813 DOI: 10.1177/0300060519893234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 525 |
Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, Jia J, Tian Q, Aggarwal R, Muljono DH, Omata M, Ooka Y, Han KH, Lee HW, Jafri W, Butt AS, Chong CH, Lim SG, Pwu RF, Chen DS. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5:167-228. [PMID: 31852635 DOI: 10.1016/s2468-1253(19)30342-5] [Cited by in Crossref: 162] [Cited by in F6Publishing: 179] [Article Influence: 40.5] [Reference Citation Analysis]
|
| 526 |
Wang L, Zhu M, Cao L, Yao M, Lu Y, Wen X, Zhang Y, Ning J, Long H, Zhu Y, Hu G, Dang S, Fu Q, Chen L, Zhang X, Zhao J, Gao Z, Nan Y, Lu F. Liver Stiffness Measurement Can Reflect the Active Liver Necroinflammation in Population with Chronic Liver Disease: A Real-world Evidence Study. J Clin Transl Hepatol 2019;7:313-21. [PMID: 31915600 DOI: 10.14218/JCTH.2019.00040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 527 |
Tadrous M, Knowles S, Ruddock B, Oh P, Mamdani MM, Juurlink DN, Gomes T. Comprehensive Drug-Class Review Framework for improved evidence-based drug policy and formulary modernization. Int J Technol Assess Health Care 2020;36:12-9. [PMID: 31796132 DOI: 10.1017/S0266462319000746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 528 |
Graf C, Mondorf A, Knop V, Peiffer KH, Dietz J, Friess J, Wedemeyer H, Buggisch P, Mauss S, Berg T, Rausch M, Sprinzl M, Klinker H, Hinrichsen H, Bronowicki JP, Haag S, Hüppe D, Lutz T, Poynard T, Zeuzem S, Friedrich-Rust M, Sarrazin C, Vermehren J. Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. J Clin Med 2019;8:E2101. [PMID: 31810183 DOI: 10.3390/jcm8122101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 529 |
Hu Y, Ye YZ, Ye LJ, Wang XH, Yu H. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China. World J Pediatr 2019;15:595-600. [PMID: 31487005 DOI: 10.1007/s12519-019-00303-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 530 |
Wang H, Wang J, Huang R, Xia J, Zuo L, Yan X, Yang Y, Wu C. Red blood cell distribution width for predicting significant liver inflammation in patients with autoimmune hepatitis. Eur J Gastroenterol Hepatol 2019;31:1527-32. [PMID: 31107736 DOI: 10.1097/MEG.0000000000001447] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 531 |
Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45. [PMID: 31222626 DOI: 10.1007/s40257-019-00457-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 532 |
Macías-díaz JE, Ahmed N, Rafiq M. Analysis and Nonstandard Numerical Design of a Discrete Three-Dimensional Hepatitis B Epidemic Model. Mathematics 2019;7:1157. [DOI: 10.3390/math7121157] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 533 |
Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, Tang H. Hepatitis B Virus Infection: Overview. Adv Exp Med Biol 2020;1179:1-16. [PMID: 31741331 DOI: 10.1007/978-981-13-9151-4_1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 534 |
Oropeza CE, Tarnow G, Sridhar A, Taha TY, Shalaby RE, McLachlan A. The Regulation of HBV Transcription and Replication. Adv Exp Med Biol 2020;1179:39-69. [PMID: 31741333 DOI: 10.1007/978-981-13-9151-4_3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 535 |
Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 536 |
Gu Y, Chen L, Lian Y, Gu L, Chen Y, Bi Y, Huang Z, Huang Y, Hu B, Huang Y. Serum HBV pregenomic RNA is correlated with Th1/Th2 immunity in treatment-naïve chronic hepatitis B patients. J Med Virol 2020;92:317-28. [PMID: 31642539 DOI: 10.1002/jmv.25612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 537 |
Shen S, Wong GL, Kuang Z, van Campenhout MJH, Fan R, Wong VW, Yip TC, Chi H, Liang X, Hu X, Lin W, Wu Y, Liu X, Boonstra A, Hou J, Sun J, Chan HL. Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. J Med Virol 2020;92:1206-13. [PMID: 31724212 DOI: 10.1002/jmv.25628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 538 |
Abravanel F, Lhomme S, Trémeaux P, Migueres M, Harter A, Haslé C, Bruel P, Alric L, Métivier S, Raymond S, Izopet J. Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA. Diagn Microbiol Infect Dis 2020;96:114946. [PMID: 31771903 DOI: 10.1016/j.diagmicrobio.2019.114946] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 539 |
Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, Zhang J, Wong C, Wong C, Trinh H. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study. J Infect Dis 2019;219:10-8. [PMID: 29982737 DOI: 10.1093/infdis/jiy391] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 540 |
Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology 2019. [PMID: 31713892 DOI: 10.1002/hep.31030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 541 |
Gao F, Zhang WT, Lin YY, Wang WM, Xu N, Bai GQ. Early Start Of Tenofovir Treatment Achieves Better Viral Suppression In Pregnant Women With A High HBV Viral Load: A Real-World Prospective Study. Infect Drug Resist 2019;12:3475-84. [PMID: 31807036 DOI: 10.2147/IDR.S228982] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 542 |
Kong Z, Liang N, Yang GL, Zhang Z, Liu Y, Li J, Liu X, Liang S, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B. Cochrane Database Syst Rev 2019;2019. [PMID: 31697415 DOI: 10.1002/14651858.CD013090.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 543 |
Hepatitis B Care Pathway in the United Arab Emirates: Current Situation, Gaps, and Actions. EMJ Hepatol 2019. [DOI: 10.33590/emjhepatol/19-00061] [Reference Citation Analysis]
|
| 544 |
Al Zaabi M, Al Quraishi H, Al Rifai A, Abdelaziz M, Mansour E, Snehanshu S, Bassil N, Kozma S, Taha M. Hepatitis B Care Pathway in the United Arab Emirates: Current Situation, Gaps, and Actions. EMJ Hepatol 2019. [DOI: 10.33590/emjhepatol/10313909] [Reference Citation Analysis]
|
| 545 |
Kilonzo SB, Gunda D, Ning Q, Han M. Where Hepatitis B and Hepatitis E Meet: Epidemiological and Clinical Aspects. Hepat Mon 2019;19. [DOI: 10.5812/hepatmon.93840] [Reference Citation Analysis]
|
| 546 |
Smalls DJ, Kiger RE, Norris LB, Bennett CL, Love BL. Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies. Pharmacotherapy 2019;39:1190-203. [PMID: 31596963 DOI: 10.1002/phar.2340] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 547 |
Goyal A, Liao LE, Perelson AS. Within-host mathematical models of hepatitis B virus infection: Past, present, and future. Curr Opin Syst Biol 2019;18:27-35. [PMID: 31930181 DOI: 10.1016/j.coisb.2019.10.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 548 |
Xiong F, Bao X, Gu N, Guo J, Wang J, Ma Y, Yu L, Gao Y, Tan B, Lu J. The combination therapy of Peginterferonα and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk. Infect Genet Evol 2020;78:104101. [PMID: 31689542 DOI: 10.1016/j.meegid.2019.104101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 549 |
O'Neil CR, Congly SE, Rose MS, Lee SS, Borman MA, Charlton CL, Osiowy C, Swain MG, Burak KW, Coffin CS. Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers. Ann Hepatol 2018;17:232-41. [PMID: 31097238 DOI: 10.5604/01.3001.0010.8640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 550 |
Hung TH, Tsai CC, Lee HF. Population-based study of Entecavir and long-term mortality in chronic hepatitis B-related decompensated liver cirrhosis. Clin Res Hepatol Gastroenterol 2019;43:694-9. [PMID: 30922728 DOI: 10.1016/j.clinre.2019.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 551 |
Soriano V, Aguilera A, Gonzalez R, Gomez-Gallego F, Barea L, Treviño M, Corral O. Occult hepatitis B and HIV infection. Eur J Gastroenterol Hepatol 2019;31:1403-7. [PMID: 30969194 DOI: 10.1097/MEG.0000000000001417] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 552 |
Liu K, Choi J, Le A, Yip TC, Wong VW, Chan SL, Chan HL, Nguyen MH, Lim YS, Wong GL. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther 2019;50:1037-48. [PMID: 31524304 DOI: 10.1111/apt.15499] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 553 |
Kaneko S, Kurosaki M, Tamaki N, Itakura J, Hayashi T, Kirino S, Osawa L, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Yasui Y, Tsuchiya K, Nakanishi H, Takahashi Y, Watanabe M, Izumi N. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. J Gastroenterol Hepatol 2019;34:2004-10. [PMID: 31017689 DOI: 10.1111/jgh.14686] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 554 |
Shin J, Yu JH, Jin YJ, Chae MH, Yoon CH, Lee JW. Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience. Medicine (Baltimore) 2019;98:e18020. [PMID: 31764818 DOI: 10.1097/MD.0000000000018020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 555 |
Yao X, Li Z, Gong X, Fu X, Xiao X, He M, Huang B, Xu Z. Total saponins extracted from Abrus cantoniensis Hance suppress hepatitis B virus replication in vitro and in rAAV8-1.3HBV transfected mice. J Ethnopharmacol 2020;249:112366. [PMID: 31678415 DOI: 10.1016/j.jep.2019.112366] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 556 |
Yazie TD, Tebeje MG. An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia. BMC Infect Dis 2019;19:917. [PMID: 31664923 DOI: 10.1186/s12879-019-4486-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 557 |
Wang YH, Liao J, Zhang DM, Wu DB, Tao YC, Wang ML, Chen EQ, Tang H. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir. J Med Virol 2020;92:302-8. [PMID: 31609007 DOI: 10.1002/jmv.25608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 558 |
Moore MS, Bocour A, Winters A. Surveillance-Based Estimate of the Prevalence of Chronic Hepatitis B Virus Infection, New York City, 2016. Public Health Rep 2019;134:695-702. [PMID: 31647883 DOI: 10.1177/0033354919882962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 559 |
Huang M, Zhong J, Lu C, Deng F, Li L, Nong Y, Liang L, Qin H, Deng Y. Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy. Pharmgenomics Pers Med 2019;12:297-303. [PMID: 31695474 DOI: 10.2147/PGPM.S224256] [Reference Citation Analysis]
|
| 560 |
Gil-García AI, Madejón A, Francisco-Recuero I, López-López A, Villafranca E, Romero M, García A, Olveira A, Mena R, Larrubia JR, García-Samaniego J. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment. World J Gastroenterol 2019; 25(38): 5883-5896 [PMID: 31636479 DOI: 10.3748/wjg.v25.i38.5883] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 561 |
Chen W, Lin C, Gong L, Chen J, Liang Y, Zeng P, Diao H. Comprehensive Analysis of the mRNA-lncRNA Co-expression Profile and ceRNA Networks Patterns in Chronic Hepatitis B. Curr Genomics 2019;20:231-45. [PMID: 32030083 DOI: 10.2174/1389202920666190820122126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 562 |
Wei MT, Henry L, Nguyen MH. Nonliver Comorbidities in Patients With Chronic Hepatitis B. Clin Liver Dis (Hoboken) 2019;14:126-30. [PMID: 31632664 DOI: 10.1002/cld.829] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 563 |
Yang JQ, Zeng R, Cao JM, Wu CQ, Chen TW, Li R, Zhang XM, Ou J, Li HJ, Mu QW. Predicting gastro-oesophageal variceal bleeding in hepatitis B-related cirrhosis by CT radiomics signature. Clin Radiol 2019;74:976.e1-9. [PMID: 31604574 DOI: 10.1016/j.crad.2019.08.028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 564 |
Ma TL, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS One 2019;14:e0222221. [PMID: 31584951 DOI: 10.1371/journal.pone.0222221] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 565 |
Dessordi R, Santana RC, Navarro AM. Influence of antiretroviral therapy on bone metabolism of patients with chronic hepatitis B: a review. Rev Soc Bras Med Trop 2019;52:e20180441. [PMID: 31596347 DOI: 10.1590/0037-8682-0441-2018] [Reference Citation Analysis]
|
| 566 |
Wang J, Shen T, Wang Q, Zhang T, Li L, Wang Y, Fang Y. The long-term efficacy of cytokine-induced killer cellular therapy for hepatocellular carcinoma: a meta-analysis. Immunotherapy 2019;11:1325-35. [PMID: 31578914 DOI: 10.2217/imt-2019-0079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 567 |
Mizutani T, Matsuoka S, Kikuta D, Hayama J, Nagai S, Matsumoto N, Nakamura H, Nirei K, Kanda T, Moriyama M, Miura K, Takei M, Sugitani M. Successful Management of a Patient with Multiple Nucleos(t)ide Analogue-Resistant Hepatitis B Virus and Diffuse Large B Cell Lymphoma Using Tenofovir Disoproxil Fumarate: A Case Report. Nichidai Igaku Zasshi 2019;78:295-300. [DOI: 10.4264/numa.78.5_295] [Reference Citation Analysis]
|
| 568 |
Liu J, Wang J, Yan T, Du D, Qi C, Cao F, Yao N, Yang Y, He Y, Tian Z, Ren D, Zhu L, Chen T, Zhao Y. Efficacy and safety of telbivudine and tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: A real-life practice. J Viral Hepat 2019;26:1170-7. [PMID: 31177596 DOI: 10.1111/jvh.13156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 569 |
Shah ND, Ventura-Cots M, Abraldes JG, Alboraie M, Alfadhli A, Argemi J, Badia-Aranda E, Arús-Soler E, Barritt AS 4th, Bessone F, Biryukova M, Carrilho FJ, Fernández MC, Dorta Guiridi Z, El Kassas M, Eng-Kiong T, Queiroz Farias A, George J, Gui W, Thurairajah PH, Hsiang JC, Husić-Selimovic A, Isakov V, Karoney M, Kim W, Kluwe J, Kochhar R, Dhaka N, Costa PM, Nabeshima Pharm MA, Ono SK, Reis D, Rodil A, Domech CR, Sáez-Royuela F, Scheurich C, Siow W, Sivac-Burina N, Dos Santos Traquino ES, Some F, Spreckic S, Tan S, Vorobioff J, Wandera A, Wu P, Yacoub M, Yang L, Yu Y, Zahiragic N, Zhang C, Cortez-Pinto H, Bataller R. Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. Clin Gastroenterol Hepatol 2019;17:2320-2329.e12. [PMID: 30708110 DOI: 10.1016/j.cgh.2019.01.026] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 570 |
Lee LY, Lee GH, Mattar C, Saw S, Aw M. Maternal HBeAg positivity and viremia associated with umbilical cord blood hepatitis B viremia. Pediatr Neonatol 2019;60:517-22. [PMID: 30683599 DOI: 10.1016/j.pedneo.2019.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 571 |
Choi R, Oh Y, Park S, Lee SG, Lee EH. Understanding the patient population and test utilization for hepatitis B virus testing. J Clin Lab Anal 2019;33:e22987. [PMID: 31568619 DOI: 10.1002/jcla.22987] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 572 |
Wu Y, Wang X, Lin X, Shen C, Chen X. Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance. J Microbiol Immunol Infect 2021;54:238-44. [PMID: 31784245 DOI: 10.1016/j.jmii.2019.09.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 573 |
Höner Zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GEG, Gineste P, Nitcheu J, Crabé S, Stepien S, Manns MP, Trépo C, Wedemeyer H, Cornberg M. Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients. J Infect Dis 2018;218:1480-4. [PMID: 29893893 DOI: 10.1093/infdis/jiy350] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 574 |
Oliveira MS, Silva RPM, Valle SDCND, Souza RM, Figueiredo EN, Taminato M, Fram DS. Hepatitis B and Delta: clinical aspects of patients in the Brazilian Western Amazonia. Rev Bras Enferm 2019;72:1265-70. [PMID: 31531650 DOI: 10.1590/0034-7167-2018-0100] [Reference Citation Analysis]
|
| 575 |
van Bömmel F, van Bömmel A, Krauel A, Wat C, Pavlovic V, Yang L, Deichsel D, Berg T, Böhm S. Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. J Infect Dis 2018;218:1066-74. [PMID: 29741634 DOI: 10.1093/infdis/jiy270] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 576 |
Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity 2019;50:907-23. [PMID: 30995506 DOI: 10.1016/j.immuni.2019.03.025] [Cited by in Crossref: 456] [Cited by in F6Publishing: 472] [Article Influence: 114.0] [Reference Citation Analysis]
|
| 577 |
Peiffer KH, Kuhnhenn L, Jiang B, Mondorf A, Vermehren J, Knop V, Susser S, Walter D, Dietz J, Carra G, Finkelmeier F, Zeuzem S, Sarrazin C, Hildt E. Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients. J Infect Dis 2018;218:114-23. [PMID: 29528436 DOI: 10.1093/infdis/jiy119] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 578 |
Bloom K, Kaldine H, Cathomen T, Mussolino C, Ely A, Arbuthnot P. Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. BMC Infect Dis. 2019;19:802. [PMID: 31510934 DOI: 10.1186/s12879-019-4436-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 579 |
Park JH, Choi J, Jun DW, Han SW, Yeo YH, Nguyen MH. Low Alanine Aminotransferase Cut-Off for Predicting Liver Outcomes; A Nationwide Population-Based Longitudinal Cohort Study. J Clin Med 2019;8:E1445. [PMID: 31514449 DOI: 10.3390/jcm8091445] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 580 |
Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019; 25(33): 4985-4998 [PMID: 31543688 DOI: 10.3748/wjg.v25.i33.4985] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 581 |
Li G, Zhou Y, Sze DM, Liu C, Zhang Q, Wang Z, Yu H, Chan G, Wu Z, Su S, Hu Y. Active Ingredients and Action Mechanisms of Yi Guan Jian Decoction in Chronic Hepatitis B Patients with Liver Fibrosis. Evid Based Complement Alternat Med 2019;2019:2408126. [PMID: 31565062 DOI: 10.1155/2019/2408126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 582 |
Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, Khalili H, Chung RT, Ludvigsson JF. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Ann Intern Med 2019;171:318-27. [PMID: 31426090 DOI: 10.7326/M18-2753] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 16.3] [Reference Citation Analysis]
|
| 583 |
Tafesh ZH, Brown RS. Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. Curr Hepatology Rep 2019;18:363-369. [DOI: 10.1007/s11901-019-00483-z] [Reference Citation Analysis]
|
| 584 |
Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. Liver Int 2019;39:1624-30. [PMID: 31050379 DOI: 10.1111/liv.14129] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 585 |
Kumar R, Teo PSE, Tan WB, Choi X, Chia PY, Lee HL, Tan C, Chang JP, Krishnamoorthy TL, Tan HK, Goh GB, Wang YT, Xin X, Chow WC. A randomised clinical trial of the safety, cost effectiveness and patient experience of nurse‐led telemonitoring of chronic hepatitis B patients. GastroHep 2019;1:249-255. [DOI: 10.1002/ygh2.365] [Reference Citation Analysis]
|
| 586 |
Chen YH, Lu SN, Wang JH, Hung CH, Hu TH, Chen CH. Pre-S/Surface and Core Promoter/Precore Mutations in Chronic Hepatitis B Patients with Severe Acute Exacerbation. Dig Dis Sci 2019;64:2563-9. [PMID: 30835025 DOI: 10.1007/s10620-019-05571-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 587 |
Fan Y, Zhou S, Li C, Ma B, Fan L, Jing H. The use of tenofovir and telbivudine combination therapy for immune-tolerant chronic hepatitis B patients awaiting assisted reproduction. Eur J Gastroenterol Hepatol 2019;31:1167-8. [PMID: 31385874 DOI: 10.1097/MEG.0000000000001444] [Reference Citation Analysis]
|
| 588 |
Kim M, Paik J, Golabi P, Jeffers T, Mishra A, Younossi ZM. Resource Utilization and Outcomes of Medicare Recipients With Chronic Hepatitis B in the United States. J Clin Gastroenterol 2019;53:e341-7. [PMID: 30106839 DOI: 10.1097/MCG.0000000000001110] [Reference Citation Analysis]
|
| 589 |
Li M, Kong YY, Wu SS, Zhou JL, Wu XN, Wang L, Su JT, Ou XJ, You H, Xie XQ, Wei ZH, Jia JD. Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China. J Dig Dis 2019;20:467-75. [PMID: 31231938 DOI: 10.1111/1751-2980.12794] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 590 |
Liu J, Li T, Zhang L, Xu A. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review. Hepatology 2019;70:1045-55. [PMID: 30561829 DOI: 10.1002/hep.30474] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 17.5] [Reference Citation Analysis]
|
| 591 |
Huang YJ, Yang SS, Yeh HZ, Chang CS, Peng YC. Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B. PLoS One 2019;14:e0221958. [PMID: 31469875 DOI: 10.1371/journal.pone.0221958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 592 |
Xu J, Tao LL, Ma LX. Efficacy and safety of telbivudine to prevent mother-to-child transmission of hepatitis B virus in middle- and late-stage pregnancy with high viral loads. J Med Virol 2019;91:2153-7. [PMID: 31397488 DOI: 10.1002/jmv.25566] [Reference Citation Analysis]
|
| 593 |
Kong Z, Liang N, Yang GL, Zhang Z, Liu Y, Yang Y, Liu YX, Wang QG, Zhang F, Zhang HY, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Acupuncture for chronic hepatitis B. Cochrane Database Syst Rev 2019;8:CD013107. [PMID: 31436846 DOI: 10.1002/14651858.CD013107.pub2] [Reference Citation Analysis]
|
| 594 |
Wortmann N, Höner Zu Siederdissen C, Cornberg M. [Chronic hepatitis B and D (delta) : Current and future treatments]. Internist (Berl) 2018;59:519-27. [PMID: 29761292 DOI: 10.1007/s00108-018-0432-3] [Reference Citation Analysis]
|
| 595 |
Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev 2019;8:207. [PMID: 31426837 DOI: 10.1186/s13643-019-1126-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 596 |
Li T, Li J, Yang Y, Han Y, Wu D, Xiao T, Wang Y, Liu T, Zhao Y, Li Y, Dai Z, Fu X. Synthesis, pharmacological evaluation, and mechanistic study of adefovir mixed phosphonate derivatives bearing cholic acid and l-amino acid moieties for the treatment of HBV. Bioorg Med Chem 2019;27:3707-21. [PMID: 31301948 DOI: 10.1016/j.bmc.2019.07.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 597 |
Zhang Z, Wang C, Liu Z, Zou G, Li J, Lu M. Host Genetic Determinants of Hepatitis B Virus Infection. Front Genet. 2019;10:696. [PMID: 31475028 DOI: 10.3389/fgene.2019.00696] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 598 |
Yeh ML, Huang CF, Huang CI, Dai CY, Lin IH, Liang PC, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chen JJ, Yu ML, Chuang WL. Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. PLoS One 2019;14:e0220663. [PMID: 31393964 DOI: 10.1371/journal.pone.0220663] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 599 |
Ma T, Lee LY, Aw MM, Lee GH. Cost-effectiveness analysis of antiviral treatment for pregnant women with high viral load to prevent hepatitis B virus vertical transmission. Singapore Med J 2020;61:24-7. [PMID: 31388686 DOI: 10.11622/smedj.2019092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 600 |
Liu Y, Jia M, Wu S, Jiang W, Feng Y. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis. Int J Infect Dis 2019;86:201-7. [PMID: 31394205 DOI: 10.1016/j.ijid.2019.07.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 601 |
Nayagam S, Thursz M. Strategies for Global Elimination of Chronic HBV Infection: 2019 Update. Curr Hepatology Rep 2019;18:300-9. [DOI: 10.1007/s11901-019-00478-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 602 |
Liang RY, Xu JH, Si CW, Wang S, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Yu YY. A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48. Medicine (Baltimore) 2019;98:e16778. [PMID: 31415381 DOI: 10.1097/MD.0000000000016778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 603 |
Ahn SH, Kim W, Jung YK, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Yim HJ, Lee KS, Lim YS, Lee WS, Park NH, Jin SY, Kim KH, Choi W, Han KH. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2019;17:1850-1859.e4. [PMID: 30448598 DOI: 10.1016/j.cgh.2018.11.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 604 |
Koh C, Da BL, Glenn JS. HBV/HDV Coinfection: A Challenge for Therapeutics. Clin Liver Dis 2019;23:557-72. [PMID: 31266627 DOI: 10.1016/j.cld.2019.04.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 605 |
Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology. Clin Liver Dis 2019;23:487-92. [PMID: 31266622 DOI: 10.1016/j.cld.2019.04.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 606 |
Shiels MS, Engels EA, Yanik EL, McGlynn KA, Pfeiffer RM, O'Brien TR. Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013. Cancer 2019;125:2621-30. [PMID: 30980394 DOI: 10.1002/cncr.32129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 607 |
Hu Y, Ye Y, Ye L, Wang X, Yu H. Efficacy and safety of interferon alpha therapy in children with chronic hepatitis B: A long-term follow-up cohort study from China. Medicine (Baltimore) 2019;98:e16683. [PMID: 31393369 DOI: 10.1097/MD.0000000000016683] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 608 |
Vittal A, Ghany MG. WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective. Clin Liver Dis 2019;23:417-32. [PMID: 31266617 DOI: 10.1016/j.cld.2019.04.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 609 |
Abdelaal R, Yanny B, El Kabany M. HBV/HCV Coinfection in the Era of HCV-DAAs. Clin Liver Dis 2019;23:463-72. [PMID: 31266620 DOI: 10.1016/j.cld.2019.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 610 |
Zhang W, Gong H, Su Z, Zhang X, Cao S. Risk factors associated with hepatic osteopathy in HBV related cirrhosis measured by liver stiffness: An Observational study. Medicine (Baltimore) 2019;98:e16628. [PMID: 31374030 DOI: 10.1097/MD.0000000000016628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 611 |
Bzowej NH, Tran TT, Li R, Belle SH, Smith CI, Khalili M, Chung R, Tsai N, Terrault N; Hepatitis B Research Network (HBRN). Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study. Am J Gastroenterol 2019;114:1283-91. [PMID: 31082876 DOI: 10.14309/ajg.0000000000000221] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 612 |
Wu YL, Shen CL, Chen XY. Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. World J Clin Cases 2019; 7(14): 1784-1794 [PMID: 31417924 DOI: 10.12998/wjcc.v7.i14.1784] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 613 |
Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7-17. [PMID: 31347138 DOI: 10.1007/s15010-019-01345-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 18.3] [Reference Citation Analysis]
|
| 614 |
Toy M, Hutton DW, So S. Economic Analyses to Inform and Support Health Policy for Chronic Hepatitis B Treatment. Curr Hepatology Rep 2019;18:357-62. [DOI: 10.1007/s11901-019-00482-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 615 |
Li TY, Yang Y, Zhou G, Tu ZK. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World J Gastroenterol 2019; 25(27): 3527-3537 [PMID: 31367154 DOI: 10.3748/wjg.v25.i27.3527] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 616 |
Xie L, Liao G, Chen H, Xia M, Huang X, Fan R, Peng J, Zhang X, Liu H. Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B. BMC Infect Dis 2019;19:640. [PMID: 31324231 DOI: 10.1186/s12879-019-4261-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 617 |
Fedonin GG, Fantin YS, Favorov AV, Shipulin GA, Neverov AD. VirGenA: a reference-based assembler for variable viral genomes. Brief Bioinform 2019;20:15-25. [PMID: 28968771 DOI: 10.1093/bib/bbx079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 618 |
Toy M, Hutton DW, So S. Population Health And Economic Impacts Of Reaching Chronic Hepatitis B Diagnosis And Treatment Targets In The US. Health Aff (Millwood) 2018;37:1033-40. [PMID: 29985701 DOI: 10.1377/hlthaff.2018.0035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 619 |
Sagnelli C, Pisaturo M, Calò F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol 2019; 25(26): 3299-3312 [PMID: 31341357 DOI: 10.3748/wjg.v25.i26.3299] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 620 |
Han LF, Zheng JM, Zheng LQ, Gao HB, Chen LX, Xu QL, Chai YH, Zhang X, Pan C, Yao LF. Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation. BMC Infect Dis 2019;19:614. [PMID: 31299917 DOI: 10.1186/s12879-019-4250-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 621 |
Cai M, Hao Y, Zhong J, Yao W, Cao X, Gu G, Qin G. Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study. Can J Gastroenterol Hepatol 2019;2019:9046260. [PMID: 31380321 DOI: 10.1155/2019/9046260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 622 |
Nishida T, Matsubara T, Yakushijin T, Inada M. Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers. Hepatol Int 2019;13:407-15. [PMID: 31290069 DOI: 10.1007/s12072-019-09966-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 623 |
Lawandi A, Cheng MP, Lee TC. Hepatitis B testing practices at a tertiary care centre and their associated costs: A retrospective analysis. PLoS One 2019;14:e0219347. [PMID: 31283801 DOI: 10.1371/journal.pone.0219347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 624 |
Park HS, Choe WH, Han HS, Yu MH, Kim YJ, Jung SI, Kim JH, Kwon SY. Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients: Pilot study. World J Gastroenterol 2019; 25(25): 3256-3267 [PMID: 31333316 DOI: 10.3748/wjg.v25.i25.3256] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 625 |
Li N, Ma WT, Pang M, Fan QL, Hua JL. The Commensal Microbiota and Viral Infection: A Comprehensive Review. Front Immunol. 2019;10:1551. [PMID: 31333675 DOI: 10.3389/fimmu.2019.01551] [Cited by in Crossref: 134] [Cited by in F6Publishing: 145] [Article Influence: 33.5] [Reference Citation Analysis]
|
| 626 |
Wilson P, Parr JB, Jhaveri R, Meshnick SR. Call to Action: Prevention of Mother-to-Child Transmission of Hepatitis B in Africa. J Infect Dis 2018;217:1180-3. [PMID: 29351639 DOI: 10.1093/infdis/jiy028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 627 |
Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell TC, Laccabue D, Alfieri A, Brillo F, Fisicaro P, Acerbi G, Pedrazzi G, Andreone P, Cursaro C, Margotti M, Santoro R, Piazzolla V, Brunetto MR, Coco B, Cavallone D, Zhao Y, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Massetto B, Fung S, Ahn SH, Ma X, Mangia A, Ferrari C. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. Gastroenterology 2019;157:227-241.e7. [PMID: 30930022 DOI: 10.1053/j.gastro.2019.03.044] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 17.8] [Reference Citation Analysis]
|
| 628 |
Xie Y, Yi W, Zhang L, Lu Y, Hao HX, Gao YJ, Ran CP, Lu HH, Chen QQ, Shen G, Wu SL, Chang M, Ping-Hu L, Liu RY, Sun L, Wan G, Li MH. Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels. J Viral Hepat 2019;26 Suppl 1:42-9. [PMID: 31380591 DOI: 10.1111/jvh.13163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 629 |
Lim SG, Agcaoili J, De Souza NNA, Chan E. Therapeutic vaccination for chronic hepatitis B: A systematic review and meta-analysis. J Viral Hepat 2019;26:803-17. [PMID: 30801899 DOI: 10.1111/jvh.13085] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 630 |
Li MH, Yi W, Zhang L, Lu Y, Lu HH, Shen G, Wu SL, Hao HX, Gao YJ, Chang M, Liu RY, Hu LP, Cao WH, Chen QQ, Li JN, Wan G, Xie Y. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat 2019;26 Suppl 1:32-41. [PMID: 31380582 DOI: 10.1111/jvh.13151] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 631 |
Zhou L, Li X, Huang X, Chen L, Gu L, Huang Y. Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B. J Viral Hepat 2019;26:795-802. [PMID: 30578715 DOI: 10.1111/jvh.13055] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 632 |
Choi GH, Kim GA, Choi J, Han S, Lim YS. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther 2019;50:215-26. [PMID: 31135074 DOI: 10.1111/apt.15311] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 633 |
Fan H, Lin L, Jia S, Xie M, Luo C, Tan X, Ying R, Guan Y, Li F. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B. J Viral Hepat 2019;26 Suppl 1:77-84. [PMID: 31380586 DOI: 10.1111/jvh.13165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 634 |
Zhang S, Sang X, Hou D, Chen J, Gu H, Zhang Y, Li J, Yang D, Zhu H, Yang X, Wang F, Zhang C, Chen X, Zen K, Zhang C, Hong Z. Plant-derived RNAi therapeutics: A strategic inhibitor of HBsAg. Biomaterials 2019;210:83-93. [DOI: 10.1016/j.biomaterials.2019.04.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 635 |
Wu ZX, Chen FS, Zhou XL, Huang Q, Zhang SA, Wu HC, Cai LR, Zeng ZY, Li YH, Li DL. Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study. Eur J Gastroenterol Hepatol 2019;31:832-5. [PMID: 30601336 DOI: 10.1097/MEG.0000000000001345] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 636 |
Zhang Q, Li G, Yu Y, Qiu C, Zheng J, Zhang H, Zhang M, Song Z, Yang Y, Du X, Hong J, Lu J, Li N, Tang Q, Xu L, Wang X, Huang Y, Zhang J, Chen Z, Zhang W. Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naïve chronic hepatitis B patients. J Viral Hepat 2019;26 Suppl 1:59-68. [PMID: 31380588 DOI: 10.1111/jvh.13153] [Reference Citation Analysis]
|
| 637 |
Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, Jung MC, Schott E, Fülöp B, Schlosser B, Berg T, van Bömmel F. Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. Eur J Gastroenterol Hepatol 2019;31:845-52. [PMID: 30789375 DOI: 10.1097/MEG.0000000000001351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 638 |
Sripongpun P, Tangkijvanich P, Chotiyaputta W, Charatcharoenwitthaya P, Chaiteerakij R, Treeprasertsuk S, Bunchorntavakul C, Sobhonslidsuk A, Leerapun A, Khemnark S, Poovorawan K, Siramolpiwat S, Chirapongsathorn S, Pan-Ngum W, Soonthornworasiri N, Sukeepaisarnjaroen W; THASL study group. Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis 4 scores for hepatic fibrosis assessment compared with transient elastography in chronic hepatitis C patients. JGH Open 2020;4:69-74. [PMID: 32055700 DOI: 10.1002/jgh3.12219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 639 |
Liang N, Kong Z, Lu CL, Ma SS, Li YQ, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B. Cochrane Database Syst Rev 2019;6:CD013106. [PMID: 31232459 DOI: 10.1002/14651858.CD013106.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 640 |
Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxf) 2019;7:231-45. [PMID: 32477569 DOI: 10.1093/gastro/goz023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 641 |
Mechtler A, Ahmed NH, Wheeler JA, Gonzalez-Estrada A. Oral desensitization to entecavir: An 11-step protocol. Ann Allergy Asthma Immunol 2019;123:312-3. [PMID: 31238101 DOI: 10.1016/j.anai.2019.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 642 |
Aretzweiler G, Leuchter S, García-Álvarez M, Simon C, Marins E, Paxinos E, Canchola J, Delgado R, Frontzek A. Analytical performance of four molecular platforms used for HIV-1, HBV and HCV viral load determinations. Expert Rev Mol Diagn 2019;19:941-9. [PMID: 31159598 DOI: 10.1080/14737159.2019.1624162] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 643 |
Chi X, Xiao H, Shi M, Cai G, Xie Y, Jiang J, Tian G, Wu S, Zhang C, Zhao P, Chen J. Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience. BMC Gastroenterol 2019;19:88. [PMID: 31196030 DOI: 10.1186/s12876-019-1005-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 644 |
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 124] [Article Influence: 28.3] [Reference Citation Analysis]
|
| 645 |
Lv LL, Yang YX, Shi TD. Effect of haptoglobin on the treatment of chronic hepatitis B with interferon. Exp Ther Med 2019;18:1417-25. [PMID: 31316628 DOI: 10.3892/etm.2019.7661] [Reference Citation Analysis]
|
| 646 |
Zhou Y, Yan R, Ru GQ, Yu LL, Yao J, Wang H. Pegylated-interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non-cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open-label pilot trial. Hepatol Int. 2019;13:422-430. [PMID: 31172416 DOI: 10.1007/s12072-019-09957-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 647 |
Wu D, Wang P, Han M, Chen Y, Chen X, Xia Q, Yan W, Wan X, Zhu C, Xie Q, Jiang J, Wei L, Tan D, Dou X, Yu Y, Hou J, Luo X, Ning Q. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol Int. 2019;13:573-586. [PMID: 31172415 DOI: 10.1007/s12072-019-09956-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 648 |
Sung PS, Park DJ, Kim JH, Han JW, Lee EB, Lee GW, Nam HC, Jang JW, Bae SH, Choi JY, Shin EC, Park SH, Yoon SK. Ex vivo Detection and Characterization of Hepatitis B Virus-Specific CD8+ T Cells in Patients Considered Immune Tolerant. Front Immunol 2019;10:1319. [PMID: 31244857 DOI: 10.3389/fimmu.2019.01319] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 649 |
Cheung KW, Seto MTY, So PL, Wong D, Mak ASL, Lau WL, Wang W, Kan ASY, Lee CP, Ng EHY. Optimal timing of hepatitis B virus DNA quantification and clinical predictors for higher viral load during pregnancy. Acta Obstet Gynecol Scand 2019;98:1301-6. [PMID: 31021394 DOI: 10.1111/aogs.13631] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 650 |
Park ES, Lee AR, Kim DH, Lee JH, Yoo JJ, Ahn SH, Sim H, Park S, Kang HS, Won J, Ha YN, Shin GC, Kwon SY, Park YK, Choi BS, Lee YB, Jeong N, An Y, Ju YS, Yu SJ, Chae HB, Yu KS, Kim YJ, Yoon JH, Zoulim F, Kim KH. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol 2019;70:1093-102. [PMID: 30794889 DOI: 10.1016/j.jhep.2019.02.006] [Cited by in Crossref: 94] [Cited by in F6Publishing: 93] [Article Influence: 23.5] [Reference Citation Analysis]
|
| 651 |
El-Raziky ME, Fouad HM, Abd Elkhalak NS, Ghobrial CM, El-Karaksy HM. Paediatric chronic hepatitis B virus infection: are children too tolerant to treat? Acta Paediatr 2019;108:1144-50. [PMID: 30362178 DOI: 10.1111/apa.14626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 652 |
Dusheiko G, Lemoine M. An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans. J Hepatol 2019;70:1046-8. [PMID: 31103095 DOI: 10.1016/j.jhep.2019.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 653 |
Feld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network. Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. Hepatology 2019;69:2338-48. [PMID: 30549279 DOI: 10.1002/hep.30417] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 654 |
Rogan SC, Beigi RH. Treatment of Viral Infections During Pregnancy. Clin Perinatol 2019;46:235-56. [PMID: 31010558 DOI: 10.1016/j.clp.2019.02.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 655 |
Yoon EL, Yim HJ. Updated Treatment of Chronic Hepatitis B. Korean J Med 2019;94:252-262. [DOI: 10.3904/kjm.2019.94.3.252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 656 |
Kranidioti H, Manolakopoulos S, Kontos G, Breen MS, Kourikou A, Deutsch M, Quesada-Del-Bosque ME, Martinez-Nunez RT, Naiyer MM, Woelk CH, Sanchez-Elsner T, Hadziyannis E, Papatheodoridis G, Khakoo SI. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:697-709. [PMID: 30702196 DOI: 10.1111/jvh.13068] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 657 |
Martin P. Immune-Tolerant Hepatitis B: Maybe a Misnomer but Still Hard to Treat. Hepatology 2019;69:2315-7. [PMID: 30964209 DOI: 10.1002/hep.30654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 658 |
Wang Y, Liang J, Sheng W, Tien F, Chen C, Tien H. Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemia. Leukemia Research 2019;81:95-7. [DOI: 10.1016/j.leukres.2019.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 659 |
Fujii T, Kawasoe K, Ohta A, Nitta K. A case of entecavir-induced Fanconi syndrome. CEN Case Rep 2019;8:256-60. [PMID: 31154657 DOI: 10.1007/s13730-019-00404-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 660 |
Seto WK, Chan TS, Hwang YY, Mak LY, Wong DK, Fung J, Liu KS, Cheung KS, Lai CL, Kwong YL, Yuen MF. Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. Clin Gastroenterol Hepatol 2019;17:1410-2. [PMID: 30243760 DOI: 10.1016/j.cgh.2018.09.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 661 |
Aberra H, Desalegn H, Berhe N, Mekasha B, Medhin G, Gundersen SG, Johannessen A. The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. J Hepatol 2019;70:1065-71. [PMID: 30929749 DOI: 10.1016/j.jhep.2019.01.037] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 662 |
Yenilmez E, Cetinkaya RA. Are there optimal alanine aminotransferase and HBV DNA thresholds for discriminating HBeAg-positive chronic infection from chronic hepatitis? An evaluation of 215 young and male cases. Saudi Med J 2019;40:131-9. [PMID: 30723857 DOI: 10.15537/smj.2019.2.23934] [Reference Citation Analysis]
|
| 663 |
Chen YM, Chen HH, Huang WN, Chen YH, Hsieh TY, Yang SS, Lan JL, Chen DY. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. Int J Rheum Dis 2019;22:1145-51. [PMID: 31117160 DOI: 10.1111/1756-185X.13582] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 664 |
Wang L, He T, Wan B, Wang X, Zhang L. Orexin A ameliorates HBV X protein-induced cytotoxicity and inflammatory response in human hepatocytes. Artificial Cells, Nanomedicine, and Biotechnology 2019;47:2003-9. [DOI: 10.1080/21691401.2019.1614014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 665 |
Doyle J, Raggatt M, Slavin M, Mclachlan S, Strasser SI, Sasadeusz JJ, Howell J, Hajkowicz K, Nandurkar H, Johnston A, Bak N, Thompson AJ. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Medical Journal of Australia 2019;210:462-8. [DOI: 10.5694/mja2.50160] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 666 |
Min IS, Lee CH, Shin IS, Lee NE, Son HS, Kim SB, Seo SY, Kim SH, Kim SW, Lee SO, Lee ST, Kim IH. Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate. Gut Liver 2019;13:93-103. [PMID: 30400723 DOI: 10.5009/gnl18183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 667 |
Wu Y, Wen J, Xiao W, Zhang B. Pregenomic RNA: How to assist the management of chronic hepatitis B? Rev Med Virol 2019;29:e2051. [PMID: 31074177 DOI: 10.1002/rmv.2051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 668 |
Inoue T, Tanaka Y. The Role of Hepatitis B Core-Related Antigen. Genes (Basel) 2019;10:E357. [PMID: 31075974 DOI: 10.3390/genes10050357] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 669 |
Luo J, You X, Chong Y, Wu Y, Gong J, Jie Y, Li X, Xi S, Zhang Z, Zhang Y, Xie D, Li Z, Li X. Efficacy of long-term treatment with tenofovir in Chinese nucleos(t)ide-naïve chronic hepatitis B patients regardless of baseline viral load. Exp Ther Med 2019;18:260-8. [PMID: 31258661 DOI: 10.3892/etm.2019.7547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 670 |
Ngongondo M, Miyahara S, Hughes MD, Sun X, Bisson GP, Gupta A, Kumwenda J, Lavenberg JA, Torres TS, Nyirenda M, Kidonge KK, Hosseinipour MC; AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. J Acquir Immune Defic Syndr 2018;78:54-61. [PMID: 29406428 DOI: 10.1097/QAI.0000000000001641] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 671 |
Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, Wu CY. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. JAMA Intern Med 2019;179:633-40. [PMID: 30882847 DOI: 10.1001/jamainternmed.2018.8342] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 23.3] [Reference Citation Analysis]
|
| 672 |
Yu K, Du Z, Li Q, Cheng Q, Huang C, Shi G, Li N. Comparison of non-invasive models for predicting liver damage in chronic hepatitis B patients. Gastroenterología y Hepatología (English Edition) 2019;42:281-288. [DOI: 10.1016/j.gastre.2018.12.001] [Reference Citation Analysis]
|
| 673 |
Ito H, Kanbe A, Hara A, Ishikawa T. Induction of humoral and cellular immune response to HBV vaccine can be up-regulated by STING ligand. Virology 2019;531:233-9. [PMID: 30928701 DOI: 10.1016/j.virol.2019.03.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 674 |
Fong TL, Lee BT, Tien A, Chang M, Lim C, Ahn A, Bae HS. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. J Viral Hepat 2019;26:561-7. [PMID: 30576085 DOI: 10.1111/jvh.13053] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 675 |
Ma K, Berger D, Reau N. Liver Diseases During Pregnancy. Clin Liver Dis 2019;23:345-61. [PMID: 30947881 DOI: 10.1016/j.cld.2018.12.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 676 |
Fontaine H, Alric L, Labreuche J, Legendre B, Louvet A, Antoine C, Legendre CM, Hazzan M, Kamar N, Dharancy S, Pol S, Duhamel A, Mathurin P. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. J Hepatol 2019;70:831-8. [PMID: 30879789 DOI: 10.1016/j.jhep.2018.12.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 677 |
Lei JH, Peng F, Chen Z, Xiao XQ. Is HBV viral load at admission associated with development of acute-on-chronic liver failure in patients with acute decompensation of chronic hepatitis B related cirrhosis? BMC Infect Dis 2019;19:363. [PMID: 31039732 DOI: 10.1186/s12879-019-3988-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 678 |
Arandjelovic P, Doerflinger M, Pellegrini M. Current and emerging therapies to combat persistent intracellular pathogens. Curr Opin Pharmacol 2019;48:33-9. [PMID: 31051429 DOI: 10.1016/j.coph.2019.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 679 |
Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Treeprasertsuk S, Tanwandee T, Charatcharoenwitthaya P, Thongsawat S, Leerapun A, Piratvisuth T, Boonsirichan R, Bunchorntavakul C, Pattanasirigool C, Pornthisarn B, Tuntipanichteerakul S, Sripariwuth E, Jeamsripong W, Sanpajit T, Poovorawan Y, Komolmit P. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study. Asian Pac J Cancer Prev 2019;20:1257-64. [PMID: 31030503 DOI: 10.31557/APJCP.2019.20.4.1257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 680 |
Han Z, Zhang Y, Bai X, Yin Y, Xu C, Hou H. Mother-to-child transmission of hepatitis B virus after amniocentesis: A retrospective matched cohort study. Prenat Diagn 2019;39:431-40. [PMID: 30916399 DOI: 10.1002/pd.5452] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 681 |
Khalighinejad P, Alavian SM, Fesharaki MG, Jalilianhasanpour R. Lamivudine's efficacy and safety in preventing mother-to-child transmission of hepatitis B: A meta-analysis. Turk J Gastroenterol. 2019;30:66-74. [PMID: 30475212 DOI: 10.5152/tjg.2018.18148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 682 |
Koksal AR, Alkim H, Boga S, Iyisoy MS, Sen I, Tekin Neijmann S, Alkim C. Value of Cystatin C-Based e-GFR Measurements to Predict Long-Term Tenofovir Nephrotoxicity in Patients With Hepatitis B. Am J Ther. 2019;26:e25-e31. [PMID: 27753647 DOI: 10.1097/mjt.0000000000000518] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 683 |
Zheng C, Yan H, Zeng J, Cai S, Wu X. Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B. Infect Drug Resist. 2019;12:845-854. [PMID: 31114265 DOI: 10.2147/idr.s195144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 684 |
Sasagawa Y, Yamada H, Morizane M, Deguchi M, Shirakawa T, Morioka I, Tanimura K. Hepatitis B virus infection: Prevention of mother-to-child transmission and exacerbation during pregnancy. J Infect Chemother 2019;25:621-5. [PMID: 30982723 DOI: 10.1016/j.jiac.2019.03.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 685 |
Paccoud O, Surgers L, Lacombe K. [Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach]. Rev Med Interne 2019;40:590-8. [PMID: 30982550 DOI: 10.1016/j.revmed.2019.03.333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 686 |
Guo R, Xie Y, Yang J, Lu H, Ye P, Jin L, Lin W. Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment. Sci Rep 2019;9:5916. [PMID: 30976044 DOI: 10.1038/s41598-019-42421-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 687 |
Sonneveld MJ, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Liaw YF, Hansen BE, Choi H, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Knegt RJ, Janssen HLA. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. Lancet Gastroenterol Hepatol 2019;4:538-44. [PMID: 30975477 DOI: 10.1016/S2468-1253(19)30087-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 688 |
Cocker F, Chien Yee K, Palmer AJ, de Graaff B. Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide. Aust N Z J Public Health 2019;43:267-73. [PMID: 30958629 DOI: 10.1111/1753-6405.12889] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 689 |
Patel PD, Nair S, Jadhav N, Patange A, D. M. P, Botre A. ASSESSMENT OF CASES OF ACUTE VIRAL HEPATITIS IN CORRELATION WITH LIVER PROFILE. jemds 2019;8:1124-1127. [DOI: 10.14260/jemds/2019/249] [Reference Citation Analysis]
|
| 690 |
Song JE, Lee CH, Kim BS. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. Korean J Intern Med. 2019;34:802-810. [PMID: 30959583 DOI: 10.3904/kjim.2019.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 691 |
Fang J, Zhuge L, Rao H, Huang S, Jin L, Li J. Increased Levels of miR-155 are Related to Higher T-Cell Activation in the Peripheral Blood of Patients with Chronic Hepatitis B. Genet Test Mol Biomarkers 2019;23:118-23. [PMID: 30735455 DOI: 10.1089/gtmb.2018.0092] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 692 |
Liang N, Kong Z, Ma SS, Lu CL, Yang M, Feng LD, Shen C, Diao RH, Cui LJ, Lu XY, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B. Cochrane Database Syst Rev 2019;4:CD013089. [PMID: 30941748 DOI: 10.1002/14651858.CD013089.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 693 |
Yuen MF, Gane EJ, Kim DJ, Weilert F, Yuen Chan HL, Lalezari J, Hwang SG, Nguyen T, Flores O, Hartman G, Liaw S, Lenz O, Kakuda TN, Talloen W, Schwabe C, Klumpp K, Brown N. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. Gastroenterology 2019;156:1392-1403.e7. [PMID: 30625297 DOI: 10.1053/j.gastro.2018.12.023] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 22.8] [Reference Citation Analysis]
|
| 694 |
Zeng J, Zheng C, Li H. Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy. Medicine (Baltimore) 2019;98:e15092. [PMID: 30946367 DOI: 10.1097/MD.0000000000015092] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 695 |
Liu S, Zhou B, Valdes JD, Sun J, Guo H. Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology 2019;69:1816-27. [PMID: 30362148 DOI: 10.1002/hep.30325] [Cited by in Crossref: 103] [Cited by in F6Publishing: 105] [Article Influence: 25.8] [Reference Citation Analysis]
|
| 696 |
Wan YM, Li YH, Xu ZY, Wu HM, Xu Y, Wu XN, Yang JH. Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C. J Clin Gastroenterol 2019;53:e171-7. [PMID: 29659382 DOI: 10.1097/MCG.0000000000001038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 697 |
Nguyen VH, Le AK, Trinh HN, Chung M, Johnson T, Wong C, Wong C, Zhang J, Li J, Levitt BS, Nguyen HA, Nguyen KK, Henry L, Cheung R, Nguyen MH. Poor Adherence to Guidelines for Treatment of Chronic Hepatitis B Virus Infection at Primary Care and Referral Practices. Clin Gastroenterol Hepatol 2019;17:957-967.e7. [PMID: 30326298 DOI: 10.1016/j.cgh.2018.10.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 698 |
Vu V, Trinh S, Le A, Johnson T, Hoang J, Jeong D, Henry L, Barnett S, Cheung R, Nguyen MH. Hepatitis B and renal function: A matched study comparing non-hepatitis B, untreated, treated and cirrhotic hepatitis patients. Liver Int 2019;39:655-66. [PMID: 30460749 DOI: 10.1111/liv.14009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 699 |
Cloherty G, Butler E, Kuhns M. Serum Hepatitis B Virus RNA as a Potential Diagnostic Biomarker During Chronic Hepatitis B Virus Infection. Clin Liver Dis (Hoboken) 2019;13:90-2. [PMID: 30988945 DOI: 10.1002/cld.774] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 700 |
Han K, Cremer J, Elston R, Oliver S, Baptiste-Brown S, Chen S, Gardiner D, Davies M, Saunders J, Hamatake R, Losos J, Leivers M, Hood S, van der Berg F, Paff M, Ritter JM, Theodore D. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects. Clin Pharmacol Drug Dev. 2019;8:790-801. [PMID: 30861337 DOI: 10.1002/cpdd.670] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 701 |
Iida-Ueno A, Enomoto M, Kozuka R, Tamori A, Kawada N. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial. J Med Virol 2019;91:1295-300. [PMID: 30815880 DOI: 10.1002/jmv.25442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 702 |
Tillmann HL, Samuel G. Current state-of-the-art pharmacotherapy for the management of hepatitis B infection. Expert Opin Pharmacother 2019;20:873-85. [PMID: 30857443 DOI: 10.1080/14656566.2019.1583744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 703 |
Park DW, Lee YJ, Chang W, Park JH, Lee KH, Kim YH, Kang NK, Chung JW, Jang HY, Ahn S, Kim H, Jeong SH, Kim JW, Jang ES. Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease. PLoS One 2019;14:e0212771. [PMID: 30856201 DOI: 10.1371/journal.pone.0212771] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 704 |
Ababneh NA, Sallam M, Kaddomi D, Attili AM, Bsisu I, Khamees N, Khatib A, Mahafzah A. Patterns of hepatitis B virus S gene escape mutants and reverse transcriptase mutations among genotype D isolates in Jordan. PeerJ 2019;7:e6583. [PMID: 30867996 DOI: 10.7717/peerj.6583] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 705 |
Kumar R, Teo EK, How CH, Wong TY, Ang TL. A practical clinical approach to liver fibrosis. Singapore Med J 2018;59:628-33. [PMID: 30631885 DOI: 10.11622/smedj.2018145] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 706 |
Gu Y, Lian Y, Gu L, Chen L, Li X, Zhou L, Huang Y, Wang J, Huang Y. Correlations between cytokines produced by T cells and clinical-virological characteristics in untreated chronic hepatitis B patients. BMC Infect Dis 2019;19:216. [PMID: 30832595 DOI: 10.1186/s12879-019-3853-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 707 |
Chan HLY. Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. J Gastroenterol Hepatol 2019;34:501-6. [PMID: 30402981 DOI: 10.1111/jgh.14534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 708 |
Viganò M, Loglio A, Labanca S, Zaltron S, Castelli F, Andreone P, Messina V, Ganga R, Coppola N, Marrone A, Russello M, Marzano A, Tucci A, Taliani G, Fasano M, Fagiuoli S, Villa E, Bronte F, Santantonio T, Brancaccio G, Occhipinti V, Facchetti F, Grossi G, Rumi M, Lampertico P. Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. Liver Int 2019;39:484-93. [PMID: 30525275 DOI: 10.1111/liv.14017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 709 |
Yip TC, Wong GL, Chan HL, Tse YK, Lam KL, Lui GC, Wong VW. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol 2019;70:361-70. [PMID: 30367899 DOI: 10.1016/j.jhep.2018.10.014] [Cited by in Crossref: 124] [Cited by in F6Publishing: 124] [Article Influence: 31.0] [Reference Citation Analysis]
|
| 710 |
Tian Y, James Ou JH. Hepatitis B Virus-Specific T Cells as a Biomarker for Discontinuation of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Hepatology 2019;69:1342-4. [PMID: 30168616 DOI: 10.1002/hep.30243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 711 |
Lee LY, Chan SM, Ong C, M Aw M, Wong F, Saw S, Lee GH, Thoon KC, Phua KB. Comparing monovalent and combination hepatitis B vaccine outcomes in children delivered by mothers with chronic hepatitis B. J Paediatr Child Health 2019;55:327-32. [PMID: 30161273 DOI: 10.1111/jpc.14194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 712 |
Xu M, Zhou Z, Xu R, Zhang H, Lin N, Zhong Y. Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis. World J Surg Oncol 2019;17:45. [PMID: 30823932 DOI: 10.1186/s12957-019-1577-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 713 |
Abara WE, Collier MG, Moorman A, Bixler D, Jones J, Annambhotla P, Bowman J, Levi ME, Brooks JT, Basavaraju SV. Characteristics of deceased solid organ donors and screening results for hepatitis B, C, and human immunodeficiency viruses — United States, 2010–2017. Am J Transplant 2019;19:939-47. [DOI: 10.1111/ajt.15284] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 714 |
Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. Sci Rep 2019;9:2508. [PMID: 30792468 DOI: 10.1038/s41598-019-39043-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 715 |
Yao M, Wang L, You H, Wang J, Liao H, Yang D, Liu S, Xu Q, Chen X, Jia J, Zhao J, Lu F. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B. Clin Chim Acta 2019;493:92-7. [PMID: 30796901 DOI: 10.1016/j.cca.2019.02.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 716 |
Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Lancet Gastroenterol Hepatol. 2019;4:296-304. [PMID: 30795958 DOI: 10.1016/s2468-1253(19)30015-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 717 |
Wu S, Tu R, Liang X. Patchy echogenicity of the liver in patients with chronic hepatitis B does not indicate poorer elasticity. Ultrasonography 2019;38:327-35. [PMID: 31302950 DOI: 10.14366/usg.18071] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 718 |
Yu K, Du Z, Li Q, Cheng Q, Huang C, Shi G, Li N. Comparison of non-invasive models for predicting liver damage in chronic hepatitis B patients. Gastroenterol Hepatol 2019;42:281-8. [PMID: 30772087 DOI: 10.1016/j.gastrohep.2018.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 719 |
Al Mahtab M, Mf Akbar S, Begum M, Islam MA, Rahim MA, M Noor-E-Alam S, Alam MA, A Khondaker F, L Moben A, Mohsena M, Khan MSI, Huq MZ, Munshi S, Hoque A, Haque SA. Stem Cell Therapy for Cirrhosis of Liver in Bangladesh: Specific Design Compatible for Developing Country. Euroasian J Hepatogastroenterol 2018;8:121-5. [PMID: 30828553 DOI: 10.5005/jp-journals-10018-1277] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 720 |
Suzuki F, Hosaka T, Suzuki Y, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan. J Gastroenterol 2019;54:182-93. [PMID: 30136216 DOI: 10.1007/s00535-018-1502-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 721 |
Liu WP, Xiao XB, Xue M, Wang GQ, Wang XP, Song YQ, Zhu J. Prophylactic Use of Entecavir for Lymphoma Patients With Past Hepatitis B Virus Infection: A Randomized Controlled Trial. Clinical Lymphoma Myeloma and Leukemia 2019;19:103-8. [DOI: 10.1016/j.clml.2018.11.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 722 |
Suárez E, Buti M, Rodríguez M, Prieto M, Pascasio-Acevedo JM, Casanovas T, Crespo J, Tapiador JAR, Gómez-Rodríguez R, Figueruela B, Diago M, Morillas RM, Zozaya JM, Calleja JL, Casado M, Molina E, Fuentes J, Simón MA. Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients. Eur J Gastroenterol Hepatol 2019;31:267-71. [PMID: 30576297 DOI: 10.1097/MEG.0000000000001289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 723 |
Morillas RM, López Sisamón D. Reactivation of hepatitis B associated with immunosuppressants and chemotherapy. Natural history, risk factors and recommendations for prevention. Medicina Clínica (English Edition) 2019;152:107-114. [DOI: 10.1016/j.medcle.2018.12.006] [Reference Citation Analysis]
|
| 724 |
Hsu HY, Chang MH. Hepatitis B Virus Infection and the Progress toward its Elimination. J Pediatr 2019;205:12-20. [PMID: 30244984 DOI: 10.1016/j.jpeds.2018.08.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 725 |
Liem KS, van Campenhout MJH, Xie Q, Brouwer WP, Chi H, Qi X, Chen L, Tabak F, Hansen BE, Janssen HLA. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2019;49:448-56. [PMID: 30689258 DOI: 10.1111/apt.15098] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 726 |
He L, Xia Z, Shen J, Zhang X, Peng W, Li C, Wen T. The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection. Medicine (Baltimore) 2019;98:e14386. [PMID: 30732177 DOI: 10.1097/MD.0000000000014386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 727 |
Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol 2019;4:135-84. [PMID: 30647010 DOI: 10.1016/S2468-1253(18)30270-X] [Cited by in Crossref: 286] [Cited by in F6Publishing: 294] [Article Influence: 71.5] [Reference Citation Analysis]
|
| 728 |
Morillas RM, López Sisamón D. Reactivación de la hepatitis B asociada a agentes inmunodepresores y a quimioterapia. Historia natural, factores de riesgo y recomendaciones para prevenirla. Medicina Clínica 2019;152:107-14. [DOI: 10.1016/j.medcli.2018.08.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 729 |
Fernández G, L Sanchez A, Jerez E, E Anillo L, Freyre F, A Aguiar J, Leon Y, Cinza Z, A Diaz P, Figueroa N, Muzio V, G Nieto G, Lobaina Y, Aguilar A, Penton E, C Aguilar J. Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac. Euroasian J Hepatogastroenterol 2018;8:133-9. [PMID: 30828555 DOI: 10.5005/jp-journals-10018-1279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 730 |
Chen Y, Yang S, Chen D. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. Journal of Microbiology, Immunology and Infection 2019;52:1-8. [DOI: 10.1016/j.jmii.2017.10.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 731 |
Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH, Peng CY. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. J Gastroenterol Hepatol 2019;34:442-9. [PMID: 29968933 DOI: 10.1111/jgh.14372] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 732 |
Zhou YH. Insufficient Evidence to Diagnose Intrauterine Transmission of Hepatitis B Virus. J Clin Gastroenterol 2019;53:157. [PMID: 30439764 DOI: 10.1097/MCG.0000000000001155] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 733 |
Drößler L, Lehmann C, Töpelt K, Nierhoff D, Vehreschild JJ, Rybniker J, Hallek M, Fischer J, Stormberg V, Fätkenheuer G, Wieland U, Jung N. HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation? Infection 2019;47:293-300. [PMID: 30689161 DOI: 10.1007/s15010-019-01271-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 734 |
Abara WE, Collier MG, Moorman A, Bixler D, Jones J, Annambhotla P, Bowman J, Levi ME, Brooks JT, Basavaraju SV. Characteristics of Deceased Solid Organ Donors and Screening Results for Hepatitis B, C, and Human Immunodeficiency Viruses - United States, 2010-2017. MMWR Morb Mortal Wkly Rep 2019;68:61-6. [PMID: 30677008 DOI: 10.15585/mmwr.mm6803a2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 735 |
Cheung KW, Seto MTY, Wong D, Mak ASL, So PL, Lau WL, Wang W, Kan ASY, Lee CP, Ng EHY. Pattern and predictors of medical care received by hepatitis B carriers during pregnancy and after delivery. Public Health 2019;168:36-42. [PMID: 30685596 DOI: 10.1016/j.puhe.2018.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 736 |
Nsokolo B, Kanunga A, Sinkala E, Zyambo K, Kumwenda D, Chama D, Muyinda G, Vinikoor M, Ijaz S, Tedder R, Elmdaah AKA, Jones M, Chiluba C, Mudenda V, Goldin RD, Foster G, Kelly P. Stage of disease in hepatitis B virus infection in Zambian adults is associated with large cell change but not well defined using classic biomarkers. Trans R Soc Trop Med Hyg 2017;111:425-32. [PMID: 29378031 DOI: 10.1093/trstmh/trx077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 737 |
Chung SW, Chang Y, Lee HY, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients? Gastroenterol Res Pract 2018;2018:6948235. [PMID: 30647735 DOI: 10.1155/2018/6948235] [Reference Citation Analysis]
|
| 738 |
Zhang YR, Wu DM, Liu XC, Zhou N, Cao CC, Liu WH, Wang CX, Wang H. Multimodal therapy and twenty years of valid management of a patient with chronic hepatitis B in a less developed Western Region in China---case report and review of the literature. BMC Infect Dis 2019;19:49. [PMID: 30642253 DOI: 10.1186/s12879-019-3673-4] [Reference Citation Analysis]
|
| 739 |
Wu X, Shi Y, Zhou J, Sun Y, Piao H, Jiang W, Ma A, Chen Y, Xu M, Xie W, Cheng J, Xie S, Shang J, Cheng J, Xie Q, Ding H, Zhang X, Bai L, Zhang M, Wang B, Chen S, Ma H, Ou X, Jia J, You H. Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. Expert Opin Biol Ther 2018;18:61-9. [PMID: 30063860 DOI: 10.1080/14712598.2018.1451511] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 740 |
Kwong AJ, Chang MS, Tuomala RE, Riley LE, Robinson JN, Mutinga ML, Andersson KL, Brown RS Jr, Oken E, Ukomadu C, Rutherford AE. Peripartum Care for Mothers Diagnosed with Hepatitis B During Pregnancy: A Survey of Provider Practices. Matern Child Health J 2018;22:1345-51. [PMID: 29512054 DOI: 10.1007/s10995-018-2515-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 741 |
Barros MMO, Ronchini KROM, Soares RLS. HEPATITIS B AND C IN PREGNANT WOMEN ATTENDED BY A PRENATAL PROGRAM IN AN UNIVERSITARY HOSPITAL IN RIO DE JANEIRO, BRAZIL: RETROSPECTIVE STUDY OF SEROPREVALENCE SCREENING. Arq Gastroenterol 2018;55:267-73. [PMID: 30540090 DOI: 10.1590/S0004-2803.201800000-68] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 742 |
Singh US, Mulamoottil VA, Chu CK. Synthesis of an Anti-hepatitis B Agent, 2'-Fluoro-6'-methylene-carbocyclic Adenosine (FMCA) and Its Phosphoramidate (FMCAP). J Org Chem 2019;84:752-9. [PMID: 30589264 DOI: 10.1021/acs.joc.8b02599] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 743 |
Tavakolpour S, Darvishi M, Sali S. Tenofovir Alafenamide: A New Drug With Various Ambiguous Aspects in Treatment of Chronic Hepatitis B Infection. Arch Clin Infect Dis 2019;In Press. [DOI: 10.5812/archcid.65343] [Reference Citation Analysis]
|
| 744 |
Mostafa A, Elsisi GH. A cost-effectiveness analysis of the use of safety-engineered syringes in reducing HBV, HCV, and HIV burden in Egypt. Expert Rev Med Devices 2019;16:155-63. [PMID: 30571154 DOI: 10.1080/17434440.2019.1561267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 745 |
Ho CH, Chen SH, Tsai HW, Wu IC, Chang TT. Fully galactosyl-fucosyl-bisected IgG1 reduces anti-HBV efficacy and liver histological improvement. Antiviral Res 2019;163:1-10. [PMID: 30611775 DOI: 10.1016/j.antiviral.2018.12.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 746 |
Lei P, Shen G, Wang F, Ning Q, Ren H, Yan W, Wu D. Immunological Features of AECHB. Acute Exacerbation of Chronic Hepatitis B 2019. [DOI: 10.1007/978-94-024-1606-0_5] [Reference Citation Analysis]
|
| 747 |
Sharifian A, Ashtari S, Hatami B, Mohebbi SR, Naderi N. Risk factors of transmission and natural history of chronic hepatitis B infection in Iranian patients. Gastroenterol Hepatol Bed Bench 2019;12:S149-55. [PMID: 32099616] [Reference Citation Analysis]
|
| 748 |
Perez-alamino R. Hepatitis Arthritis: HBV and HCV. Infections and the Rheumatic Diseases 2019. [DOI: 10.1007/978-3-030-23311-2_10] [Reference Citation Analysis]
|
| 749 |
Meurer L, Post A. Chronic Hepatitis B. Liver Disease 2019. [DOI: 10.1007/978-3-319-98506-0_6] [Reference Citation Analysis]
|
| 750 |
Sawinski D, Blumberg EA. Infection in Renal Transplant Recipients. Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier; 2019. pp. 621-638.e6. [DOI: 10.1016/b978-0-323-52978-5.00040-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 751 |
Kwo PY, John N. Chronic Hepatitis. Diagnosis of Liver Disease 2019. [DOI: 10.1007/978-981-13-6806-6_5] [Reference Citation Analysis]
|
| 752 |
Cai D, Pan C, Yu W, Dang S, Li J, Wu S, Jiang N, Wang M, Zhang Z, Lin F, Xin S, Yang Y, Shen B, Ren H. Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials. Medicine (Baltimore) 2019;98:e13983. [PMID: 30608440 DOI: 10.1097/MD.0000000000013983] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 753 |
Lee CK, Jonas MM. Viral Hepatitis B: Management in Children. Viral Hepatitis in Children 2019. [DOI: 10.1007/978-981-13-0050-9_10] [Reference Citation Analysis]
|
| 754 |
Ghufran A. Viral Hepatitis: Hepatitis B, D, and E Viruses. Gastrointestinal and Liver Disorders in Women’s Health 2019. [DOI: 10.1007/978-3-030-25626-5_17] [Reference Citation Analysis]
|
| 755 |
Rosenthal E, Baden R. Hepatitis B: The Western Perspective. Clinical Epidemiology of Chronic Liver Diseases 2019. [DOI: 10.1007/978-3-319-94355-8_10] [Reference Citation Analysis]
|
| 756 |
Indolfi G, D’antiga L. Chronic Viral Hepatitis. Pediatric Hepatology and Liver Transplantation 2019. [DOI: 10.1007/978-3-319-96400-3_9] [Reference Citation Analysis]
|
| 757 |
Aljumah AA, Babatin M, Hashim A, Abaalkhail F, Bassil N, Safwat M, Sanai FM. Hepatitis B care pathway in Saudi Arabia: Current situation, gaps and actions. Saudi J Gastroenterol 2019;25:73-80. [PMID: 30720000 DOI: 10.4103/sjg.SJG_421_18] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 758 |
Su P, Shih C. Emerging New Therapies for Viral Hepatitis. Viral Hepatitis in Children 2019. [DOI: 10.1007/978-981-13-0050-9_16] [Reference Citation Analysis]
|
| 759 |
Choudhuri G, Gupta V, Negi TS, Ojha R. Potential Implications of Detecting HBsAg in Asymptomatic People in an Endemic Community Through Medical Camps. J Clin Exp Hepatol 2019;9:43-9. [PMID: 30765938 DOI: 10.1016/j.jceh.2018.02.005] [Reference Citation Analysis]
|
| 760 |
Ashtari S, Sharifian A, Hatami B, Mohebbi SR, Nouri G, Bazdar M, Naderi N. Comparative study on guidelines in determining HBV phases in Iranian patients. Gastroenterol Hepatol Bed Bench 2019;12:S145-8. [PMID: 32099615] [Reference Citation Analysis]
|
| 761 |
Ward JW, Hinman AR. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats. Gastroenterology 2019;156:297-310. [PMID: 30391470 DOI: 10.1053/j.gastro.2018.10.048] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 762 |
Said A, Safdar N, Lucey MR. Liver Disease Among Renal Transplant Recipients. Kidney Transplantation - Principles and Practice 2019. [DOI: 10.1016/b978-0-323-53186-3.00032-2] [Reference Citation Analysis]
|
| 763 |
Chen H. Mother-to-Infant Transmission of Viral Hepatitis. Viral Hepatitis in Children 2019. [DOI: 10.1007/978-981-13-0050-9_4] [Reference Citation Analysis]
|
| 764 |
Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, Hou J, Janssen HLA, Peng J. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. Clin Gastroenterol Hepatol 2019;17:182-191.e1. [PMID: 29902645 DOI: 10.1016/j.cgh.2018.05.047] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 765 |
O'horo JC, Cawcutt KA. Critical Care Viral Infections. Critical Care Nephrology 2019. [DOI: 10.1016/b978-0-323-44942-7.00096-0] [Reference Citation Analysis]
|
| 766 |
Gill US, Kennedy PTF. The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics. J Viral Hepat 2019;26:4-15. [PMID: 30415490 DOI: 10.1111/jvh.13040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 767 |
Wali PD, Suryadevara M. Infectious Hepatitis. Introduction to Clinical Infectious Diseases 2019. [DOI: 10.1007/978-3-319-91080-2_13] [Reference Citation Analysis]
|
| 768 |
Kuo MT, Hu TH, Hung CH, Wang JH, Lu SN, Tsai KL, Chen CH. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther 2019;49:218-28. [PMID: 30484881 DOI: 10.1111/apt.15053] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 769 |
Lian JS, Zhang XL, Lu YF, Chen JY, Zhang YM, Jia HY, Zhang Z, Yang YD. Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety. Int J Med Sci 2019;16:17-22. [PMID: 30662324 DOI: 10.7150/ijms.28700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 770 |
Sandhu DS, Jesudoss R. Treatment of Hepatitis C Virus in Special Populations (HBV Coinfection, Drug Users, and Prisoners). Viral Hepatitis: Chronic Hepatitis C 2019. [DOI: 10.1007/978-3-030-03757-4_6] [Reference Citation Analysis]
|
| 771 |
Chan HLY, Chan FWS, Hui AJ, Li MKK, Chan KH, Wong GLH, Loo CK, Chim AML, Tse CH, Wong VWS. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. J Viral Hepat 2019;26:126-35. [PMID: 30187604 DOI: 10.1111/jvh.13000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 772 |
Chen F, Freyer C, Gong L, Zekry A. Hepatitis B Virus, Hepatitis C Virus, the Microbiome, and Hepatocellular Carcinoma. Gastrointestinal Diseases and their Associated Infections 2019. [DOI: 10.1016/b978-0-323-54843-4.00004-0] [Reference Citation Analysis]
|
| 773 |
van Campenhout MJH, Brouwer WP, Xie Q, Guo S, Chi H, Qi X, Tabak F, Streinu-Cercel A, Wang JY, Zhang NP, Idilman R, Reesink HW, Diculescu M, Simon K, Akdogan M, Mazur W, de Knegt RJ, Verhey E, Hansen BE, Janssen HLA; ARES Study Group. Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up. J Viral Hepat 2019;26:109-17. [PMID: 30187612 DOI: 10.1111/jvh.12997] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 774 |
Aye L, Tran T. Liver Disease and Pregnancy. Liver Disease 2019. [DOI: 10.1007/978-3-319-98506-0_9] [Reference Citation Analysis]
|
| 775 |
Squires RH. Viral Causes of Acute Liver Failure in Children. Viral Hepatitis in Children 2019. [DOI: 10.1007/978-981-13-0050-9_15] [Reference Citation Analysis]
|
| 776 |
O'Brien TR, Yang HI, Groover S, Jeng WJ. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology 2019;156:400-17. [PMID: 30287169 DOI: 10.1053/j.gastro.2018.09.052] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 777 |
Demirtaş CÖ, Özdoğan OC. Convenient chronic hepatitis B candidates for antiviral cessation and retreatment after relapse: When and who? Turk J Gastroenterol 2018;29:720-1. [PMID: 30381278 DOI: 10.5152/tjg.2018.290918] [Reference Citation Analysis]
|
| 778 |
Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open Forum Infect Dis 2019;6:ofy353. [PMID: 30931346 DOI: 10.1093/ofid/ofy353] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 779 |
Guo L, Wang D, Ouyang X, Tang N, Chen X, Zhang Y, Zhu H, Li X. Recent Advances in HBV Reactivation Research. Biomed Res Int. 2018;2018:2931402. [PMID: 30687740 DOI: 10.1155/2018/2931402] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 780 |
